

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAPLUS enhanced with utility model patents from China
NEWS	6	JUL 16	CAPLUS enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAPLUS patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAPLUS enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAPLUS enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAPLUS enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAPLUS coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAPLUS enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS	27	NOV 30	ICSD reloaded with enhancements
NEWS	28	DEC 04	LINPADOCDB now available on STN
NEWS EXPRESS	19	SEPTEMBER 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:32:32 ON 05 DEC 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 17:32:45 ON 05 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 DEC 2007 HIGHEST RN 956696-50-7

DICTIONARY FILE UPDATES: 4 DEC 2007 HIGHEST RN 956696-50-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10527866a.str



```

chain nodes :
11 12 13 14 16 17 18 20
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-17 3-16 6-11 7-12 8-18 11-20 12-13 12-14
ring bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9
exact/norm bonds :
1-2 1-5 1-17 2-3 6-11 8-18 11-20 12-13 12-14
exact bonds :
3-4 3-16 7-12
normalized bonds :
4-5 4-6 5-9 6-7 7-8 8-9
isolated ring systems :
containing 1 :

```

G1:O,N

G2:C,H

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS
12:CLASS 13:CLASS 14:CLASS 16:CLASS 17:CLASS 18:CLASS 20:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,N

G2 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:33:01 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 128 TO ITERATE

100.0% PROCESSED 128 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**


PROJECTED ITERATIONS: 1882 TO 3238

PROJECTED ANSWERS: 784 TO 1736

L2 50 SEA SSS SAM L1

=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(dimethylamino)phenyl]methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-
 MF C24 H31 N7 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-
 MF C16 H21 N5 O3

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full

FULL SEARCH INITIATED 17:38:04 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2867 TO ITERATE

100.0% PROCESSED 2867 ITERATIONS

1359 ANSWERS

SEARCH TIME: 00.00.01

L3 1359 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

175.70

175.91

FILE 'CAPLUS' ENTERED AT 17:38:08 ON 05 DEC 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Dec 2007 VOL 147 ISS 24

FILE LAST UPDATED: 4 Dec 2007 (20071204/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full

L4 30 L3

=> d ibib abs hitstr tot

ACCESSION NUMBER: 2007:385265 CAPLUS

DOCUMENT NUMBER: 146:379968

TITLE: Preparation of 1H-pyrazolo[3,4-b]pyridines as phosphodiesterase, especially PDE4B, inhibitors for treatment of inflammatory and/or allergic diseases

INVENTOR(S): Edlin, Christopher David; Holman, Stuart; Jones, Paul; Spencer, Keeling; Suzanne Elaine; Lindvall, Mika; Kristian Mitchell, Charlotte Jane; Trivedi, Naimisha

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 263pp.

CODEN: P1XK02

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007036733	A1	20070405	WO 2006-GB3626	20060929
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2005-721597P P 20050929


OTHER SOURCE(S): MARPAT 146:379968

GI



RN 932113-96-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]amino]-1-ethyl-6-methyl-, ethyl ester (CA INDEX NAME)



RN 932114-15-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-6-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)


AB Title compds. I [R1 = fluoro/alkyl, CH₂CH₂OH; R2 = H, Me, Et, n-Pr, i-Pr, n-Bu, fluoroalkyl, cyclopropyl, etc.; R3 = (un)substituted cycloalkyl, mono-unsatd. cycloalkenyl, heterocyclyl, bicycyl with provisos; Rb = H, Me; Ra = Rb, Et; when Rb = Me, then Ra = Me and R2 = H; R4 = H, Me, Et, n-Pr, COMe, CO-fluoroalkyl; provided that when R4 = COMe or CO-fluoroalkyl, then R5 = CH₂-Ar; R5 = CO(CH₂)_nAr, CO-fluoroalkyl, SO₂-alkyl, CH₂Ar, etc.; n = 0-2; Ar = 1-methyl-pyrazol-5-yl, 2-trifluoromethyl-1,3-thiazol-5-yl, (un)substituted Ph, pyridin-4-yl, thiophen-2-yl, 1H-imidazol-4-yl, etc.; or R4 and R5 taken together are (CH₂)_p, CO-(CH₂)_p, etc.; p = 4-6; p' = 3-5; or NR4R5 = 1-oxo-2,3-dihydro-1H-indol-2-yl, 6-oxo-4,5-dihydro-6H-pyrrolo[3,4-d][1,2,3]thiadiazol-5-yl; 4-oxo-5,6-dihydro-4H-furo[2,3-c]pyrrol-5-yl, etc.; and salts thereof] were prepared as selective phosphodiesterase 4 (PDE4), especially PDE4B, inhibitors. The invention also provides for the

use of I for the treatment and/or prophylaxis of an inflammatory and/or allergic disease, such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, allergic rhinitis, psoriasis, or atopic dermatitis. Thus, acylation of amine II (preparation given) with 5-chlorovaleryl chloride, and cyclization in DMF in the presence of NaH gave pyrazolopyridine III. Selected I inhibited PDE4B with pIC₅₀ in the range of about 10.0 to about 11.0. Pharmaceutical compns. containing I are described.

IT 865713-74-2P, Ethyl 1,6-diethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 932113-95-6P, Ethyl 4-[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]amino]-1,6-diethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 932113-96-7P, Ethyl 4-[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]amino]-1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 932114-15-3P, Ethyl 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-6-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate


RN 865713-74-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1,6-diethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)



RN 932113-95-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]amino]-1,6-diethyl-, ethyl ester (CA INDEX NAME)



IT 675112-01-3, Ethyl 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675114-55-3, Ethyl 1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate


RN 675112-01-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)



RN 675114-55-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 2007:385004 CAPLUS
DOCUMENT NUMBER: 146:401968
TITLE: Preparation of N-[[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl]-3-methyl-5-isoxazolecarboxamide as a phosphodiesterase IV (PDE4) inhibitor.
INVENTOR(S): Christensen, Siegfried Benjamin, IV; Holman, Stuart; Keeling, Suzanne Elaine; Sayani, Amaryn Pyarali
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 96pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007036734	A1	20070405	WO 2006-GB3627	20060929
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BV, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p>				
PRIORITY APPLN. INFO.: US 2005-721597P P 20050929				
OTHER SOURCE(S): MARPAT 146:401968				




AB N-[[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl]-3-methyl-5-isoxazolecarboxamide (I) was prepared. Thus, 3-methyl-5-isoxazolecarboxylic acid was stirred 40 min. with (COCl)₂ and cat. DMF in CH₂Cl₂; the resulting solution was added dropwise to a solution of 5-aminomethyl-1,6-diethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine in MeCN; diisopropylethylamine was added and the mixture was stirred 15 h to give I. I inhibited PDE4B with pIC₅₀ = 9.8.

IT 675112-01-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of)
diethyltetrahydropyran-4-ylaminopyrazolo[3,4-b]pyridin-5-ylmethylisoxazole-3-carboxamide as a PDE4 inhibitor)
RN 675112-01-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-ylamino)-], ethyl ester (CA INDEX NAME)




IT 865713-74-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of)
diethyltetrahydropyran-4-ylaminopyrazolo[3,4-b]pyridin-5-ylmethylisoxazole-3-carboxamide as a PDE4 inhibitor)
RN 865713-74-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1,6-diethyl-4-[(tetrahydro-2H-pyran-4-ylamino)-], ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 2007:330210 CAPLUS
DOCUMENT NUMBER: 146:337882
TITLE: Preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase IV inhibitors
INVENTOR(S): Palle, Venakta P.; Balachandran, Sarala; Gupta, Nidhi; Khairnar, Vinayak Vasantrao; Ramaiah, Raghu; Ray, Abhijit; Dastidar, Sunanda Ghose
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 37pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007031838	A1	20070322	WO 2006-1B2494	20060911
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BV, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p>				
PRIORITY APPLN. INFO.: IN 2005-DE2522 A 20050916				
OTHER SOURCE(S): MARPAT 146:337882				




AB Title compds. [I: P = atoms to form a 6-membered ring containing 1-3 double bonds; M = atoms to form a 5-membered ring containing 1-2 double bonds; X1, X2 = C; X3 = N; R1 = H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl, etc.; R2 = H, alkyl, halo, cyano, NO₂, amino, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, etc.; R3 = (substituted) amino, acylamino; R4 = substituted dihydroisoxazolyl], were prepared. Thus, a stirred mixture of Me methacrylate and 4-cyclopropylamino-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxaldehyde oxime (preparation given) in THF was treated with aqueous NaOCl over 5 min followed by stirring for 4 h to give 513 Me 3-[4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]-5-methyl-4,5-dihydroisoxazole-5-carboxylate.
IT 675112-13-7P 675112-25-1P 929625-95-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


L4 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (prepn. of pyrazolopyridines as phosphodiesterase IV inhibitors)
 RN 675112-13-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopropylamino)-1-ethyl-, ethyl ester (CA INDEX NAME)



RN 675112-25-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopropylamino)-1-ethyl- (CA INDEX NAME)



RN 929625-95-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopropylamino)-1-ethyl-N-methoxy-N-methyl- (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:328286 CAPLUS
 DOCUMENT NUMBER: 146:358837
 TITLE: Preparation spiroisoxazolylopyrazolopyridinamines as phosphodiesterase IV inhibitors
 INVENTOR(S): Palle, Venkata P.; Balachandran, Sarala; Gupta, Nidhi; Khairnar, Vinayak Vasantrao; Ramaiah, Raghu; Ray, Abhijit; Destidar, Sunanda G.
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
 SOURCE: PCT Int. Appl., 29pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007031977	A2	20070322	WO 2006-1853349	20060918
WO 2007031977	A3	20070607		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: IN 2005-DE2521 A 20050916
 OTHER SOURCE(S): MARPAT 146:358837
 G1




AB Title compds. [I: P = atoms to complete a 6-membered ring containing 1-3 double bonds; M = atoms to complete a 5-membered ring containing 1-2 double bonds; X1, X2 = C; X3-X5 = N; R1 = H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, aralkenyl, heterocyclyl, heteroaryl, etc.; R2 = H, alkyl, halo, cyano, NO2, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, (substituted) (CH2)nOH, SH, NH2, etc.; n = 0-2; R3 = (substituted) amino; R4 = spiroisoxazolylo], were prepared Thus, a mixture of methylenecyclohexane and 4-cyclopropylamino-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxaldehyde oxime (preparation given) in THF was treated with aqueous NaOCl over 5 min. followed by stirring for 4 h to give 21.6% N-cyclopropyl-1-ethyl-5-(1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine. I inhibited PDE IV with X30 values of 0.15-10 μ M.
 IT 675112-13-7P 675112-25-1P 929625-95-6P


L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. spiroisoxazolylopyrazolopyridinamines as phosphodiesterase IV inhibitors)
 RN 675112-13-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopropylamino)-1-ethyl-, ethyl ester (CA INDEX NAME)




RN 675112-25-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopropylamino)-1-ethyl- (CA INDEX NAME)



RN 929625-95-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopropylamino)-1-ethyl-N-methoxy-N-methyl- (CA INDEX NAME)



L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:1166559 CAPLUS
 DOCUMENT NUMBER: 143:60074
 TITLE: New pyrazolo[3,4-b]pyridones as selective A1 adenosine receptor antagonists: synthesis, biological evaluation and molecular modeling studies. [Erratum to document cited in CA143:248327]
 AUTHOR(S): Fossa, Paola; Pestarino, Marco; Menozzi, Giulia; Mosti, Luisa; Schenone, Silvia; Ranise, Angelo; Bondavalli, Francesco; Trincavelli, Letizia M.; Lucacchini, Antonio; Martini, Claudia
 CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Genova, Genoa, 16132, Italy
 SOURCE: Organic & Biomolecular Chemistry (2005), 3(20), 3826
 CODEN: OBCRAK; ISSN: 1477-0520
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB On page 2265, Table 2, the second structure in the heading (the scaffold of compds. 17 to 24), the NHR group was incorrectly positioned (position 3 of the imidazo-quinoxaline group); it should be in position 4. The corrected structure is given.
 IT 383911-67-9
 RI: PRP (Properties)
 (mol. modeling and QSAR of imidazopyrimidines, imidazoloquinoxalines, triazoloquinoxalines, imidazoquinolines and pyrazolopyridines (Erratum))
 RN 383911-67-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclopropylamino)-, ethyl ester (CA INDEX NAME)




L4 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 2005:1117957 CAPLUS
 DOCUMENT NUMBER: 144:36283
 TITLE: Synthesis and 3D QSAR of New Pyrazolo[3,4-b]pyridines: Potent and Selective Inhibitors of A1 Adenosine Receptors
 AUTHOR(S): Manetti, Fabrizio; Schenone, Silvia; Bondavalli, Francesco; Brullo, Chiara; Bruno, Olga; Ranise, Angelo; Mosti, Luisa; Menozzi, Giulia; Fossa, Paola; Trincavelli, Maria Letizia; Martini, Claudia; Martinelli, Adriano; Tintori, Cristina; Botta, Maurizio
 CORPORATE SOURCE: Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Siena, I-53100, Italy
 SOURCE: Journal of Medicinal Chemistry (2005), 48(23), 7172-7185
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 144:36283

AB A number of 4-(amino)pyrazolo[3,4-b]pyridine-5-carboxylic acid esters were synthesized and evaluated for their binding affinity at the A1, A2A, and A3 adenosine receptors (AR), in bovine cortical membranes, as well as for their affinity toward human A1AR (hA1AR) (A1 purinoceptor antagonists). Some of the new compounds were characterized by a high affinity and selectivity toward the A1 receptor subtype, showing a significant improvement in comparison with other pyrazolo-pyridines previously reported in the literature. In particular two compounds, both of them bearing a (p-methoxyphenyl)ethylamino side chain presented Ki values of 6 and 7 nM, resp. To rationalize the relationship between structure and affinity of the novel compounds, a 3D QSAR model was also generated starting from compounds belonging to different classes of known A1AR antagonists.


IT 871038-26-5P 871038-42-5P 871038-48-1P
 871038-59-4P 871038-64-1P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of (amino)pyrazolo[3,4-b]pyridine-5-carboxylic acid ester derivs. and study of their activity as selective inhibitors of A1 adenosine receptors study of their 3D QSAR)

RN 871038-26-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclopropylamino)-, methyl ester (CA INDEX NAME)




RN 871038-42-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclopropylamino)-, propyl ester (CA INDEX NAME)

L4 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




IT 383911-67-9
 RI: BSU (Biological study, unclassified); BIOL (Biological study)
 (study of affinity of (amino)pyrazolo[3,4-b]pyridine-5-carboxylic acid ester derivs. and their analogs toward A1 adenosine receptors and study of their 3D QSAR)

RN 383911-67-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclopropylamino)-, ethyl ester (CA INDEX NAME)




REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 871038-48-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclopropylamino)-, 1-methylethyl ester (CA INDEX NAME)



RN 871038-59-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclopropylamino)-, butyl ester (CA INDEX NAME)



RN 871038-64-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclopropylamino)-, 1-methylpropyl ester (CA INDEX NAME)

L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2005:1042249 CAPLUS
 DOCUMENT NUMBER: 143:347166
 TITLE: Preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors
 INVENTOR(S): Cook, Caroline Mary; Dowle, Michael Dennis; Edlin, Christopher David; Johnson, Martin Redpath; Jones, Paul Spencer; Lindvall, Mika Kristian; Trivedi, Naimisha; Redgrave, Alison Judith
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 142 pp.
 CODEN: PFXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090354	A1	20050929	WO 2005-GB987	20050315
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SE, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, IE, MR, NE, SN, TD, TG				
EP 1740590	A1	20070110	EP 2005-718039	20050315
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, IE, JP 2007529486	T	20071025	JP 2007-503404	20050315
PRIORITY APPL. INFO.:			GB 2004-5893	A 20040316
			GB 2005-5214	A 20050314
			WO 2005-GB987	W 20050315

OTHER SOURCE(S): MARPAT 143:347166
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compounds I [R1 = alkyl, fluoroalkyl, CH2CH2OH; R2 = H, Me, fluoroalkyl; R3 = (un)substituted 4-(aminocarbonyl)cyclohexyl, N-aminocarbonylpiperidinyl, N-aminocarbonylpyrrolidinyl; R4 = H; R5 = II-V (wherein one or two of A, B, D, E and F = N, and the remaining of A-F are CH, CR6; R6 = halo, alkyl, fluoroalkyl, etc.; n = 0-2; G = O, S, NR9; R9 = H, alkyl, fluoroalkyl; none, one, two or three of J, L, M and Q = N, and the remaining of J-Q = CH, CR6; r = 0-2; n = 1-2)] that are inhibitors of phosphodiesterase type IV (PDE4) useful in the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, allergic rhinitis, psoriasis or atopic dermatitis in a mammal such as a human, were prepared and formulated. Thus, amidation of the corresponding acid (preparation given) with 2,4-dimethylbenzylamine afforded VI which showed pIC50 of 9.1-9.2 (± about 0.5) against PDE4B. Preps. of the


L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2007 ACS on STM (Continued)
pharmaceutical compns. (including micronization example) comprising the
compds. I were described.

IT 865713-86-6P 865713-87-7P 865718-02-1P
865718-03-2P 865718-04-3P 865718-05-4P
865718-06-5P 865718-07-6P 865718-08-7P
865718-09-8P 865718-10-1P 865718-11-2P
865718-12-3P 865718-13-4P 865718-14-5P
865718-15-6P 865718-16-7P 865718-17-8P
865718-18-9P 865718-19-0P 865718-20-3P
865718-21-4P 865718-22-5P 865718-23-6P
865718-24-7P 865718-25-8P 865718-26-9P
865718-27-0P 865718-28-1P 865718-29-2P
865718-30-5P 865718-31-6P 865718-32-7P
865718-33-8P 865718-34-9P 865718-35-0P
865718-36-1P 865718-38-3P 865718-39-4P
865718-40-7P 865718-41-8P 865718-42-9P
865718-43-0P 865718-44-1P 865718-45-2P
865718-46-3P 865718-47-4P 865718-48-5P
865718-49-6P 865718-50-9P 865718-51-0P
865718-52-1P 865718-53-2P 865718-54-3P
865718-55-4P 865718-56-5P 865718-57-6P
865718-58-7P 865718-59-8P 865718-60-1P
865718-61-2P 865718-62-3P 865718-63-4P
865718-64-5P 865718-65-6P 865718-66-7P
865718-67-8P 865718-68-9P 865718-69-0P
865718-70-3P 865718-71-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)


(Preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase type 4
(PDE4) inhibitors for treating inflammatory and allergic diseases)

RN 865713-86-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-
piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl- (CA INDEX
NAME)




RN 865713-87-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-
piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-,
monohydrochloride (9C1) (CA INDEX NAME)

L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2007 ACS on STM (Continued)




RN 865718-04-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-
(aminocarbonyl)cyclohexyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-
(CA INDEX NAME)




RN 865718-05-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-
(aminocarbonyl)cyclohexyl]amino]-N-[(2,4-dimethylphenyl)methyl]-1-ethyl-
(CA INDEX NAME)

L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2007 ACS on STM (Continued)




● HC1

RN 865718-02-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-
piperidinyl]amino]-N-[(2,4-dimethylphenyl)methyl]-1-ethyl- (CA INDEX
NAME)




RN 865718-03-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-
piperidinyl]amino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)

L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2007 ACS on STM (Continued)




RN 865718-06-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-
(aminocarbonyl)cyclohexyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-
(CA INDEX NAME)

Relative stereochemistry.




RN 865718-07-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[trans-4-
(aminocarbonyl)cyclohexyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-
(CA INDEX NAME)


Relative stereochemistry.




RN 865718-08-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(2,4-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-09-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(4-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 865718-10-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(4-hydroxyphenyl)methyl]- (CA INDEX NAME)




RN 865718-11-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 865718-12-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(2-(methylsulfonyl)phenyl)methyl]- (CA INDEX NAME)




RN 865718-13-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(3-hydroxyphenyl)methyl]- (CA INDEX NAME)




RN 865718-14-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(2,3-dichlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-15-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(2,3-dimethylphenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-16-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(1,1'-biphenyl)-2-ylmethyl]-1-ethyl- (CA INDEX NAME)




RN 865718-17-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(4-chloro-2-fluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-18-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(2,3-dihydro-5-benzofuranyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-19-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(4-(difluoromethoxy)phenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-20-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(4-chloro-2-methylphenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-21-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-22-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(4-(methylsulfonyl)phenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-23-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(4-(trifluoromethyl)[1,1'-biphenyl]-2-yl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-24-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(4-chlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-25-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(1,1'-biphenyl)-4-ylmethyl]-1-ethyl- (CA INDEX NAME)




RN 865718-26-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(4'-ethoxy[1,1'-biphenyl]-4-yl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-27-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(1,1'-biphenyl)-3-ylmethyl]-1-ethyl- (CA INDEX NAME)




RN 865718-28-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methyl]- (CA INDEX NAME)




RN 865718-29-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(3'-methyl[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)




RN 865718-30-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(3'-methoxy[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)




RN 865718-31-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-32-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-33-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(4'-methyl[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)




RN 865718-34-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(4'-methoxy[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)




RN 865718-35-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[2-(3-furanyl)phenyl]methyl]- (CA INDEX NAME)




RN 865718-36-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[2-(6-methoxy-3-pyridinyl)phenyl]methyl]- (CA INDEX NAME)




RN 865718-38-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[2-(3-thienyl)phenyl]methyl]- (CA INDEX NAME)




RN 865718-39-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[2-(4-methyl-3-thienyl)phenyl]methyl]- (CA INDEX NAME)




RN 865718-40-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(5-methyl[1,1'-biphenyl]-2-yl)methyl]- (CA INDEX NAME)




RN 865718-41-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[4-methyl-2-(3-thienyl)phenyl]methyl]- (CA INDEX NAME)



RN 865718-42-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[[2-(3-furanyl)-4-methylphenyl]methyl]- (CA INDEX NAME)




RN 865718-43-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3'-chloro-5-methyl[1,1'-biphenyl]-2-yl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-44-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(2,4-dimethylphenyl)methyl]-1-ethyl- (CA INDEX NAME)

Relative stereochemistry.




RN 865718-45-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[trans-4-(aminocarbonyl)cyclohexyl]amino]-N-[(2,4-dimethylphenyl)methyl]-1-ethyl- (CA INDEX NAME)

Relative stereochemistry.




RN 865718-46-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-N-[(4-methoxyphenyl)methyl]-1-ethyl- (CA INDEX NAME)


Relative stereochemistry.




RN 865718-47-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(4-methylsulfonyl)phenyl]methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-48-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(2,3-dimethylphenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-49-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[[1,1'-biphenyl]-2-ylmethyl]-1-ethyl- (CA INDEX NAME)




RN 865718-50-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(4-chloro-2-fluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-51-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(2,3-dichlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-52-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(2-methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 865718-53-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(4-chlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-54-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 865718-55-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(1,1'-biphenyl)-4-ylmethyl]-1-ethyl- (CA INDEX NAME)




RN 865718-56-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(4-hydroxyphenyl)methyl]- (CA INDEX NAME)




RN 865718-57-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 865718-58-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(2,4-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-59-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(4-(difluoromethoxy)phenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-60-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(2,3-dihydro-5-benzofuranyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-61-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(1,1'-biphenyl)-3-ylmethyl]-1-ethyl- (CA INDEX NAME)




RN 865718-62-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(4-fluorophenyl)methyl]- (CA INDEX NAME)




RN 865718-63-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(4-chloro-2-methylphenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-64-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-65-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[[2,3-dichloro-6-(hydroxymethyl)phenyl]methyl]-1-ethyl- (CA INDEX NAME)



RN 865718-66-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[[5,6,7,8-tetrahydro-1-naphthalenyl]methyl]- (CA INDEX NAME)




RN 865718-67-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[(3,4-dimethoxyphenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 865718-68-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[[2,4-dimethylphenyl]methyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 865718-69-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[[3,4-dimethylphenyl]methyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 865718-70-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[[2,4-dimethylphenyl]methyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 865718-71-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[[3,4-dimethylphenyl]methyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




IT 856563-14-9P 856563-15-0P 856563-16-1P
856563-17-2P 856563-25-2P 856563-26-3P
856563-27-4P 856563-28-5P 856563-41-2P
856563-42-3P 856563-43-4P 856563-44-5P
856563-45-6P 856563-46-7P 856563-47-8P
856563-48-9P 856563-56-9P 865718-73-6P
865718-74-7P


Re: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase type 4

inhibitors for treating inflammatory and allergic diseases)

RN 856563-14-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[4-(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]amino]-1-ethyl-, ethyl ester (CA INDEX NAME)




RN 856563-15-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-(4-piperidinylamino)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 856563-16-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-, ethyl ester (CA INDEX NAME)




RN 856563-17-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-, ethyl ester (CA INDEX NAME)




RN 856563-25-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-, ethyl ester (CA INDEX NAME)

Relative stereochemistry.




RN 856563-26-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-, ethyl ester (CA INDEX NAME)

Relative stereochemistry.




RN 856563-27-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-, ethyl ester (CA INDEX NAME)

Relative stereochemistry.



RN 856563-28-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-, ethyl ester (CA INDEX NAME)


Relative stereochemistry.



RN 856563-41-2 CAPLUS


L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-42-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 856563-43-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 856563-44-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(3R)-3-pyrrolidinylamino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



Absolute stereochemistry.




● HCl

RN 856563-45-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(3S)-1-(aminocarbonyl)-3-pyrrolidinylamino]-1-ethyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 865718-73-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinylamino]-N-[(2-bromophenyl)methyl]-1-ethyl- (CA INDEX NAME)



RN 865718-74-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinylamino]-N-[(2-bromo-4-methylphenyl)methyl]-1-ethyl- (CA INDEX NAME)


RN 856563-46-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(3R)-1-(aminocarbonyl)-3-pyrrolidinylamino]-1-ethyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-47-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(3R)-1-(aminocarbonyl)-3-pyrrolidinylamino]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-48-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(3R)-1-(aminocarbonyl)-3-pyrrolidinylamino]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 856563-56-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinylamino]-1-ethyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:1042248 CAPLUS

DOCUMENT NUMBER: 143:347165

TITLE: Preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase type 4 (PDE4) inhibitors
 INVENTOR(S): Coe, Diane Mary; Cook, Caroline Mary; Cooper, Anthony William James; Edlin, Christopher David; Hamblin, Julie Nicole; Johnson, Martin Redpath; Jones, Paul Spencer; Lindvall, Mika Kristian; Mitchell, Charlotte Jane; Redgrave, Alison Judith; Robinson, John Edward

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 114 pp.

CODEN: PIXXD2




DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090353	A1	20050929	WO 2005-GB976	20050315
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1735315	A1	20061227	EP 2005-718029	20050315
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2007529484	T	20071025	JP 2007-503401	20050315
US 2007167485	A1	20070719	US 2006-598944	20060915
PRIORITY APPLN. INFO.: GB 2004-5937 A 20040316				
WO 2005-GB976 W 20050315				
OTHER SOURCE(S): CASREACT 143:347165; MARPAT 143:347165				
GI				




AB The title compds. I [R1 = Et, Pr, iso-Pr, fluoroalkyl, CH2CH2OH; R2 = H, Me, Et, etc.; NR3 = NHCR3aR3bCR3cR3dR3e (wherein R3a = Me, Et; R3b, R3c, R3d = H, Me, Et; R3e = H, Me; with provisions); R5 = alkyl, (un)substituted cycloalkyl, (CH2)ncycloalkyl, etc.], useful as inhibitors of phosphodiesterase type IV (PDE4), and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis or allergic rhinitis, were prepared and formulated. Thus, amidation of the acid (15)-II (preparation given) with 2-ethylbutylamine afforded (15)-III which showed PDE4B inhibitory activity with pIC50 of 8.1 (± about 0.5).

IT 675114-51-9P
 R1: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase type 4 (PDE4) inhibitors for treating inflammatory and allergic diseases)

RN 675114-51-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)



IT 675112-33-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase type 4 (PDE4) inhibitors for treating inflammatory and allergic diseases)

RN 675112-33-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:1042247 CAPLUS

DOCUMENT NUMBER: 143:347164

TITLE: Preparation of 4-[(1-(aminocarbonyl)-4-piperidinyl)amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide as a PDE4 inhibitor

INVENTOR(S): Christensen, Siegfried Benjamin, IV; Cook, Caroline Mary; Edlin, Christopher David; Johnson, Martin Redpath; Jones, Paul Spencer; Lindvall, Mika Kristian; Sayani, Amyr Pyarali; Trivedi, Nainisha; Trotter, Lionel

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 90 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090352	A1	20050929	WO 2005-EP3038	20050315
V: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005223351	A1	20050929	AU 2005-223351	20050315
CA 2559629	A1	20050929	CA 2005-2559629	20050315
EP 1735314	A1	20061227	EP 2005-716291	20050315
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
BR 2005008843	A	20070828	BR 2005-8843	20050315
JP 2007529464	T	20071025	JP 2007-503306	20050315
MX 2006PA10486	A	20061208	MX 2006-PA10486	20060914
IN 2006KN2753	A	20070601	IN 2006-KN2753	20060920
NO 2006004450	A	20061114	NO 2006-4450	20061002
PRIORITY APPLN. INFO.: GB 2004-5893 A 20040316				
WO 2005-5214 A 20050314				
WO 2005-EP3038 W 20050315				
OTHER SOURCE(S): CASREACT 143:347164; MARPAT 143:347164				
GI				



AB The invention provides 4-[[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (I) or a salt thereof which is useful as an inhibitor of phosphodiesterase type IV (PDE4), for example in the treatment and/or prophylaxis of an inflammatory and/or allergic disease, cognitive impairment or depression in a mammal. E.g., a multi-step synthesis of I, starting from 5-amino-1-ethylpyrazole and di-Et ethoxymethylenemalonate, was given. The compound I was tested in various tests (data given). In particular, the invention provides the use of the compound I or its pharmaceutically acceptable salt in the treatment and/or prophylaxis of atopic dermatitis in a mammal, for example by external topical administration to the mammal such as a human. Pharmaceutical compns. containing said compound or salt,

in particular suitable for external topical administration, are also provided and claimed.

IT 865713-86-6P 865713-87-7P 865713-89-9P
865713-90-2P 865713-91-3P 865713-92-4P
865713-93-5P 865713-94-6P 865713-95-7P
865713-96-8P 865713-97-9P


RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[3,4-b]pyridine derivative as phosphodiesterase type 4

(PDE4) inhibitor for treating inflammatory and allergic diseases)


RN 865713-86-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl- (CA INDEX NAME)



RN 865713-87-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 865713-89-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


RN 865713-90-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, sulfate (1:1) (CA INDEX NAME)

CH 1

CRN 865713-86-6

CHF C24 H31 N7 O2



CH 2

CRN 7664-93-9

CHF H2 O4 S




RN 865713-91-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, mononitrate (9CI) (CA INDEX NAME)

CH 1

CRN 865713-86-6

CHF C24 H31 N7 O2



CH 2

CRN 7697-37-2

CHF H N O3




RN 865713-92-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, phosphate (1:1) (CA INDEX NAME)

CH 1

CRN 865713-86-6

CHF C24 H31 N7 O2




CM 2

CRN 7664-38-2
CHF H3 O4 P

RN 865713-93-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 865713-86-6
CHF C24 H31 N7 O2

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 865713-86-6
CHF C24 H31 N7 O2

CM 2

CRN 75-75-2
CHF C H4 O3 S


RN 865713-96-8 CAPLUS

CN Ethanesulfonic acid, compd. with 4-[[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 865713-86-6
CHF C24 H31 N7 O2


CM 2

CRN 104-15-4
CHF C7 H8 O3 S

RN 865713-94-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-, monobenzenesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 865713-86-6
CHF C24 H31 N7 O2


CM 2

CRN 98-11-3
CHF C6 H6 O3 S

RN 865713-95-7 CAPLUS



CM 2


CRN 594-45-6
CHF C2 H6 O3 S

RN 865713-97-9 CAPLUS

CN Naphthalenesulfonic acid, compd. with 4-[[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 865713-86-6
CHF C24 H31 N7 O2



CN 2

CRN 25155-19-5
 CNF C10 H8 O3 S
 CCI IDS

D1-SO₃H

IT 856563-14-9P 856563-15-OP 856563-16-1P

856563-17-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrazolo[3,4-b]pyridine derivative as phosphodiesterase

type 4

(PDE4) inhibitor for treating inflammatory and allergic diseases)


RN 856563-14-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]amino]-1-ethyl-, ethyl ester (CA
 INDEX NAME)



RN 856563-15-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(4-piperidinylamino)-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 856563-16-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-, ethyl ester (CA INDEX NAME)



RN 856563-17-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl- (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:1042245 CAPLUS
 DOCUMENT NUMBER: 143:347163

TITLE: Preparation of pyrazolo[3,4-b]pyridines as
 phosphodiesterase type 4 (PDE4) inhibitors
 INVENTOR(S): Allen, David George; Coe, Diane Mary; Cook, Caroline
 Mary; Dowle, Michael Dennis; Edlin, Christopher David;
 Hamblin, Julie Nicole; Johnson, Martin Redpath; Jones,
 Paul Spencer; Lindvall, Mika Kristian; Mitchell,
 Charlotte Jane; Redgrave, Alison Judith; Trivedi,
 Naimisha

PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090348	A1	20050929	WO 2005-GB983	20050315
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1751151	A1	20070214	EP 2005-718036	20050315
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2007529485	T	20071025	JP 2007-503402	20050315
PRIORITY APPLN. INFO.:			GB 2004-5933	A 20040316
			WO 2005-GB983	W 20050315
OTHER SOURCE(S):			CASREACT 143:347163; MARPAT 143:347163	
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I (W = Ar, CR4R5Ar, II, III (wherein Ar = IV, V; m = 1-2); R1 = alkyl, fluoroalkyl or CH₂CH₂OH; R2 = alkyl, cycloalkyl or (CH₂)_ncycloalkyl (n = 1-2); R3 = (un)substituted cycloalkyl, mono-unsatd. cycloalkenyl, heterocyclyl, etc.; R4, R5 = H, Me, Et, cyclopropyl, etc.; A, B, D, E, F = CR₆, N or nitrogen-oxide (with provisions); R6 = H, halo, alkyl, etc.; G = O, S, NR₉ (R₉ = H, alkyl, fluoroalkyl); J, L, M, Q = CR₇, C, N (with provisions); R7 = H, halo, alkyl, etc.; useful as inhibitors of phosphodiesterase type IV (PDE4), and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis or allergic rhinitis, were prepared and formulated. E.g., a multi-step synthesis of VI, starting from di-Et malonate and cyclopropylcarbonyl chloride, was given. All of the exemplified compds. I showed PDE4 inhibitory activities in the range of pIC₅₀ = about 7 (± about 0.5) to

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


IT 865713-37-7P 865713-38-8P 865713-39-9P
865713-40-2P 865713-41-3P 865713-42-4P
865713-43-5P 865713-44-6P 865713-45-7P
865713-46-8P 865713-54-8P 865713-55-9P
865713-56-0P 865713-57-1P

RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase type 4 inhibitors for treating inflammatory and allergic diseases)


RN 865713-37-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-6-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 865713-38-8 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-methoxyphenyl)methyl]-6-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 865713-39-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-chloro-2-methylphenyl)methyl]-1-ethyl-6-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 865713-43-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1,6-diethyl-N-[(4-methoxyphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 865713-44-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethylphenyl)methyl]-1,6-diethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 865713-45-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,3-dihydro-1H-inden-2-yl)-1,6-diethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 865713-40-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethylphenyl)methyl]-1-ethyl-6-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 865713-41-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-6-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 865713-42-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1,6-diethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 865713-46-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)propyl]-1,6-diethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-54-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 6-(cyclopropylmethyl)-1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-55-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 6-(cyclopropylmethyl)-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 865713-56-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 6-(cyclopropylmethyl)-N-[(2,3-dihydro-1H-inden-2-yl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-] (CA INDEX NAME)




RN 865713-57-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-6-(cyclopropylmethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




IT 865713-73-1P 865713-74-2P 865713-76-4P
865713-79-7P 865713-80-0P 865713-82-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 865713-79-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-6-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 865713-80-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1,6-diethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 865713-82-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 6-(cyclopropylmethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(prepn. of pyrazolo[3,4-b]pyridines as phosphodiesterase type 4 (PDE4) inhibitors for treating inflammatory and allergic diseases)


RN 865713-73-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-6-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)



RN 865713-74-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1,6-diethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)




RN 865713-76-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 6-(cyclopropylmethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)



L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L4 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:603702 CAPLUS
 DOCUMENT NUMBER: 143:248327
 TITLE: New pyrazolo[3,4-b]pyridones as selective A1 adenosine receptor antagonists: Synthesis, biological evaluation and molecular modeling studies
 AUTHOR(S): Fossa, Paolo; Pastarino, Marco; Menozzi, Giulia; Mosti, Luisa; Schenone, Silvia; Ranise, Angelo; Bondavalli, Francesco; Trincavelli, M. Letizia; Lucacchini, Antonio; Martini, Claudia
 CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Università degli Studi di Genova, Genova, 16132, Italy
 SOURCE: Organic & Biomolecular Chemistry (2005), 3(12), 2262-2270
 CODEN: OBCRAK; ISSN: 1477-0520
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:248327
 GI




AB A series of Et 4-amino-1-(2-chloro-2-phenylethyl)-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridine-5-carboxylates, e.g., I, has been synthesized as potential A1 adenosine receptor (A1 AR) ligands. Binding affinities of the compds. were determined for adenosine A1, A2A and A3 receptors. Two of the compds. showed good affinity (K_i = 299 nM and 517 nM) and selectivity towards A1 AR, whereas some showed good affinity for A2A AR (K_i = 290 nM), higher than towards A1 AR (K_i = 1000 nM). The only arylamino derivative of the series displayed high affinity (K_i = 4.6 nM) and selectivity for A3 AR. Mol. modeling and 3D-QSAR (CoMFA) studies carried out on the most active compds. gave further support to the pharmacol. results.
 IT 383911-67-9
 RL: PRP (Properties)
 (mol. modeling and QSAR of imidazopyrimidines, imidazoquinoxalines, triazoloquinolines, imidazoquinolines and pyrazolopyridines)
 RM 383911-67-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclopropylamino)-, ethyl ester (CA INDEX NAME)

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:570893 CAPLUS
 DOCUMENT NUMBER: 143:97353
 TITLE: Preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase, especially PDE4B, inhibitors for treatment of inflammatory and/or allergic diseases
 INVENTOR(S): Allen, David George; Cos, Diane Mary; Cook, Caroline Mary; Doble, Michael Dennis; Edlin, Christopher David; Hamblin, Julie Nicole; Johnson, Martin Redpath; Jones, Paul Spencer; Lindvall, Mika Kristian; Mitchell, Charlotte Jane; Redgrave, Alison Judith; Robinson, John Edward; Trivedi, Naimisha
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 295 pp.
 CODEN: PIKX02
 PATENT: Patent
 DOCUMENT TYPE: English
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058892	A1	20050630	WO 2004-EP14490	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004056823	A1	20040708	WO 2003-EP314867	20031219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004299277	A1	20050630	AU 2004-299277	20041217
CA 2557004	A1	20050630	CA 2004-2557004	20041217
EP 1737857	A1	20070103	EP 2004-804089	20041217
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
CN 1914205	A	20070214	CN 2004-80041657	20041217
JP 2007514704	T	20070607	JP 2006-544380	20041217
US 2007111995	A1	20070517	US 2006-596561	20060616
NO 2006003340	A	20060912	NO 2006-3340	20060718
PRIORITY APPL. INFO.:				
			WO 2003-EP314867	A 20031219
			GB 2004-5899	A 20040316
			GB 2004-5936	A 20040316
			GB 2004-6754	A 20040325
			GB 2002-30045	A 20021223
			GB 2002-30165	A 20021224
			GB 2003-7998	A 20030407

L4 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 WO 2003-EP14867 A 20031219
 WO 2004-EP14490 W 20041217
 OTHER SOURCE(S): MARPAT 143:97353
 GI




III

AB Title compds. I [wherein Ar = (un)substituted Ph, naphthyl, indanyl, pyridinyl, etc. with proviso: R1 = fluoro/alkyl, CH2CH2OH; R2 = H, Me, fluoroalkyl; R3 = (un)substituted cycloalkyl, monounsaturated, cycloalkenyl, bicyclic, heterocyclic; R4 = H, Me, Et, Pr, i-Pr, fluoroalkyl, cyclopropyl, etc.; R5 = H, fluoro/alkyl, (un)substituted cyclo/alkyl, Ph, etc.] provided that at least one of R4 and R5 is not H; and salts thereof] were prepared as selective phosphodiesterase 4 (PDE4), especially PDE4B, inhibitors. The invention also provides for the use of I for the treatment and/or prophylaxis of an inflammatory and/or allergic disease, such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, allergic rhinitis or atopic dermatitis. Eight biol. methods are given. For example, coupling of acid II with 2-phenyl-2-propanamine gave title compound III. Selected I inhibited PDE4B with IC50 in the range of. I are in particle size-reduced form (DC50 value of about 0.5 to about 10 µ) when used in inhalant compns.
 IT 856560-57-1P, 1-Ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-63-9P, N-[1-(3,5-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses) (PDE4B inhibitor; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)
 RM 856560-57-1 CAPLUS

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-63-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




IT 856558-90-2P, N-[1-(4-Chlorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856558-91-3P, 1-Ethyl-N-[1-[4-(ethyloxy)phenyl]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856559-00-7P, N-[1-(4-Chlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-99-1P, 1-Ethyl-N-[1-[4-[(1-methylethyl)oxy]phenyl]ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856561-56-3P, 1-Ethyl-4-[(3-hydroxycyclohexyl)amino]-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 RI: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (PDE4B inhibitor; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)
 RN 856558-90-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-1-

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 856561-56-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(3-hydroxycyclohexyl)amino]-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.




IT 856561-70-1P 856561-71-2P 856561-72-3P
 856561-73-4P 856561-74-5P 856561-75-6P
 RI: PAC (Pharmacological activity); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (PDE4B inhibitor; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)
 RN 856561-70-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-, (+)- (CA INDEX NAME)

Rotation (+).


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856558-91-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-ethoxyphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-00-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856560-99-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-[4-(1-methylethoxy)phenyl]ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 856561-71-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 856561-72-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-[4-(1-methylethoxy)phenyl]ethyl]-4-[(4-oxocyclohexyl)amino]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 856561-73-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-[4-(1-methylethoxy)phenyl]ethyl]-4-[(4-oxocyclohexyl)amino]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 856561-74-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 856561-75-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-, (-)- (CA INDEX NAME)

Rotation (-).




IT 856561-62-1P 856561-63-2P 856561-64-3P
856561-65-4P 856561-66-5P 856561-67-6P
856561-69-8P 856561-77-8P 856561-79-9P
1-Ethyl-4-[(1S,3R)-3-hydroxycyclohexyl]amino]-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide




RN 856561-65-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, (-)- (CA INDEX NAME)

Rotation (-).



RN 856561-66-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-ethoxyphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 856561-67-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-ethoxyphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, (-)- (CA INDEX NAME)

Rotation (-).


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
856561-79-0P, 1-Ethyl-4-[(1R,3S)-3-hydroxycyclohexyl]amino]-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PDE4B inhibitor; prepn. of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)
RN 856561-62-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 856561-63-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, (-)- (CA INDEX NAME)

Rotation (-).




RN 856561-64-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, (+)- (CA INDEX NAME)

Rotation (+).




RN 856561-69-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(1S)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856561-77-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(1S)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856561-78-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(1S,3R)-3-hydroxycyclohexyl]amino]-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-79-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(1R,3S)-3-hydroxycyclohexyl]amino-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 856560-51-5P, N-[1-(4-chlorophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-52-6P, N-[1-(4-chlorophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-55-9P, 1-Ethyl-N-[1-(4-ethoxyphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-56-0P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-(4-propyloxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-58-2P, 1-Ethyl-N-[(1R)-2-hydroxy-1-phenylethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-59-3P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-phenylpropyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-61-7P, 1-Ethyl-N-[1-(4-(1-methylethyl)phenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-64-0P, 1-Ethyl-N-[(1R)-1-(4-(methyloxy)phenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-65-1P, 1-Ethyl-N-[1-(4-fluorophenyl)propyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-66-2P, N-[1-(2,3-dichlorophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-67-3P, 1-Ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-4-[(4-

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-ethoxyphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 856560-56-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-(4-propoxyphenyl)ethyl]- (CA INDEX NAME)



RN 856560-58-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-2-hydroxy-1-phenylethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856560-68-4P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-(1-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-69-5P, N-[(1R)-1-(4-Bromophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-79-7P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[(1R)-1-phenylpropyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-80-0P, 1-Ethyl-N-[(1R)-1-(3-methyloxyphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-89-9P, 1-Ethyl-N-[1-(3-hydroxyphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-91-3P, N-[1-(2,3-Dichlorophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (PDE4B inhibitor; preph. of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)


RN 856560-51-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-52-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-55-9 CAPLUS

RN 856560-59-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-(1-phenylpropyl)- (CA INDEX NAME)



RN 856560-61-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methoxyphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-64-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methoxyphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-65-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-66-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dichlorophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-67-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-80-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-methoxyphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 856560-89-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-hydroxyphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 856560-91-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dichlorophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-68-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-(1-phenylethyl)- (CA INDEX NAME)




RN 856560-69-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856560-79-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 720705-46-4P, 1-Ethyl-N-[(1R)-2-hydroxy-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
720705-47-5P, 1-Ethyl-N-[(1S)-2-hydroxy-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
720705-50-0P, 1-Ethyl-N-[(1S,2R)-2-hydroxy-1-phenylpropyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-81-1P, 1-Ethyl-N-[(1R)-1-phenylpropyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-82-2P, 1-Ethyl-N-[(1-methyl-1-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-83-3P, 1-Ethyl-N-[(1-methylsulfonyl)phenyl]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-84-4P, N-(Diphenylmethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-85-5P, 1-Ethyl-N-[(1-(3-pyridinyl)ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-86-6P, 1-Ethyl-N-[(1S)-1-phenylpropyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-87-7P, 1-Ethyl-N-[(1S)-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-88-8P, 1-Ethyl-N-[(1R)-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-89-9P, 1-Ethyl-N-[(1-methyl-1-(4-pyridinyl)ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-90-0P, 1-Ethyl-N-[(1-methyl-1-(4-pyridinyl)ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-91-1P, 1-Ethyl-N-[(1-methyl-1-(4-pyridinyl)ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-92-4P, 1-Ethyl-N-[(1-methyl-1-(4-pyridinyl)ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-93-5P, 1-Ethyl-N-[(1-methyl-1-(4-pyridinyl)ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-94-6P, N-[2-(Dimethylamino)-1-phenylethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-95-7P, 1-Ethyl-N-[(1-phenyl-2-(1-pyrrolidinyl)ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-96-8P, 1-Ethyl-N-[(1-hydroxymethyl)-1-phenylpropyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-97-9P, 1-Ethyl-N-[(1-(4-(propyloxy)phenyl)ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856558-98-0P, Methyl 3-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-yl]carbonyl]amino]-3-phenylpropanoate
856558-99-1P, 1-Ethyl-N-[(1-(4-fluorophenyl)ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
856559-01-8P, Ethyl [[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-yl]carbonyl]amino] (phenyl)acetate
856559-02-9P, 1-Ethyl-N-[(1R)-1-[(3-methoxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-03-OP,
1-Ethyl-N-[(1S)-2-(methyloxy)-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-04-1P,
N-[(1R)-2-Amino-2-oxo-1-phenylethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-05-2P,
1-Ethyl-N-[(1R)-1-(4-nitrophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-06-3P,
1-Ethyl-N-[(1R)-2-(methyloxy)-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-07-4P,
1-Ethyl-N-(2-hydroxy-1,1-diphenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-08-5P,
N-[(1-3-Cyanophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-09-6P,
N-[Cyanophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-10-9P,
N-[Cyclopropyl(4-(methyloxy)phenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-11-0P,
1-Ethyl-N-[(1-1-naphthalenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-12-1P,
N-[(1,2-Diphenylethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-13-2P,
1-Ethyl-N-[(1-4-(methyloxy)phenyl)butyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-14-3P,
1-Ethyl-N-[(1R)-1-(4-naphthalenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-15-4P,
1-Ethyl-N-[(1S)-1-(1-naphthalenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-16-5P,
N-[(1-Aminocarbonyl)-1-phenylpropyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-17-6P,
1-Ethyl-N-(1-phenylcyclopentyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-18-7P,
1-Ethyl-N-(4-phenyltetrahydro-2H-pyran-4-yl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-19-8P,
1-Ethyl-N-(1-phenylcyclopropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-20-1P,
N-[(1-4-(Cyclohexyloxy)-3-methylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-21-2P,
N-[(1-3-(Cyclohexyloxy)-4-methylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-22-3P,
1-Ethyl-N-[(1-2,3-Dichlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-23-4P,
N-[(1-4-(Cyclohexyloxy)-3-hydroxyphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-24-5P,
N-[(1-4-(Cyclopentyl)phenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-25-6P,
1-Ethyl-N-[(1-4-methylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-26-7P,
N-[(1-4-(1,1-dimethyl-1-phenylcycloethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-27-8P,
N-[(1-4-Bromophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-28-9P,
1-Ethyl-N-[(1S)-1-(4-iodophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-29-0P,
N-[(1-4-(Aminooxymethyl)phenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-30-3P,
1-Ethyl-N-[(1-methyl-1-phenylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-31-4P,
N-[(1-1,3-Benzodioxol-5-yl)cyclohexyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
trifluoro-1-[3-(methyloxy)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-82-5P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-4-(methyloxy)phenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-83-6P, 4-(Cyclohexylamino)-1-ethyl-N-[(1R)-1-phenylpropyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-84-7P, 4-(Cyclohexylamino)-N-(diphenylmethyl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-85-8P, 4-(Cyclohexylamino)-1-ethyl-N-[(1R)-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-86-9P, Ethyl [1-[(4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-yl)carbonyl]amino] (phenyl)acetate 856559-87-0P, N-[(1-4-Chlorophenyl)ethyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-88-1P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-methyl-1-phenylethyl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-89-2P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-4-fluorophenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-90-5P, N-[(1-4-Chlorophenyl)propyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-91-6P, 4-(Cyclohexylamino)-N-[(1,2-diphenylethyl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-92-7P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-4-(propyloxy)phenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-93-8P, Methyl 3-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-yl]carbonyl]amino]-3-phenylpropanoate 856559-94-9P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-hydroxymethyl)-1-phenylpropyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-95-0P, 4-(Cyclohexylamino)-1-ethyl-N-[(3-hydroxy-1-phenylpropyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-96-1P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-4-(ethyloxy)phenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-97-2P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-3-hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-98-3P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-phenyl-2-(1-pyrrolidinyl)ethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-99-4P, 4-(Cyclohexylamino)-N-[(2-(dimethylamino)-1-phenylethyl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-00-4P, 4-(Cyclohexylamino)-1-ethyl-N-[(1R)-2-(methyloxy)-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-01-5P, N-[(1R)-2-Amino-2-oxo-1-phenylethyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-02-6P, 4-(Cyclohexylamino)-1-ethyl-N-[(1R)-2-hydroxy-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-03-7P, 4-(Cyclohexylamino)-1-ethyl-N-[(1S)-2-hydroxy-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-04-8P, 4-(Cyclohexylamino)-1-ethyl-N-[(1R)-1-(3-methyloxy)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-05-9P, 4-(Cyclohexylamino)-1-ethyl-N-[(1S)-2-(methyloxy)-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-06-0P, 4-(Cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-nitrophenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-07-1P, 4-(Cyclohexylamino)-1-ethyl-N-[(1S)-1-(1-naphthalenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-08-2P, 4-(Cyclohexylamino)-1-ethyl-N-[(phenyl)(4-phenyl-5-thiazol-2-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-09-3P, N-[Cyanophenyl)methyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-10-6P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-1-naphthalenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-11-7P, 4-(Cyclohexylamino)-1-ethyl-N-[(2-hydroxy-1,1-diphenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-12-8P, 4-(Cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-(methyloxy)phenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-13-9P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-4-

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
856559-32-5P, 1-Ethyl-N-[(1-4-(methyloxy)phenyl)cyclohexyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-33-6P, 1-Ethyl-N-[(1-4-(fluorophenyl)cyclohexyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-34-7P, N-[(1-3-Chlorophenyl)cyclopentyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-35-8P, N-[(1-2-Chlorophenyl)cyclopentyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-36-9P, N-[(1-4-(1,1-Dimethylethyl)phenyl)cyclohexyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-37-0P, 1-Ethyl-N-[(1-4-(1-methylethyl)phenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-38-1P, N-[(1-3,5-Dimethylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-39-2P, 1-Ethyl-N-[(1R)-1-(4-(methyloxy)phenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-40-5P, 1-Ethyl-N-[(1S)-1-(4-(methyloxy)phenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-41-6P, 1-Ethyl-N-[(1-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-42-7P, 1-Ethyl-N-[(1-phenylpentyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-43-8P, 1-Ethyl-N-[(2-methyl-1-phenylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-44-9P, 1-Ethyl-N-[(1-phenylbutyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-45-0P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-(2,2,2-trifluoro-1-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-46-1P, N-[Cyclopropyl(phenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-47-2P, 1-Ethyl-N-[(1-4-fluorophenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-48-3P, N-[(1-2,3-Dichlorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-49-4P, 1-Ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-50-5P, 1-Ethyl-N-[(1-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-51-6P, N-[(1R)-1-(4-Bromophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-52-9P, N-[(1-4-Chlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-53-0P, N-[(1-3,4-Dichlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-54-1P, 856559-55-2P 856559-56-3P 856559-57-4P 856559-58-5P 856559-59-6P 856559-60-9P 856559-61-0P 856559-62-1P 856559-63-2P 856559-64-3P 856559-65-4P 856559-66-5P 856559-67-6P 856559-68-7P 856559-69-8P 856559-70-9P 856559-71-0P 856559-72-3P 856559-73-4P 856559-74-5P 856559-75-6P 856559-76-7P 856559-77-8P 856559-78-9P, N-[(1-2,3-Dihydro-1H-inden-5-yl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-79-0P, 1-Ethyl-N-[(1S,6,7,8-tetrahydro-2-naphthalenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-80-3P, N-[(1-4-Bromophenyl)-2,2,2-trifluoroethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856559-81-4P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(2,2,2-

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
fluorophenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-14-0P, 4-(Cyclohexylamino)-N-[(1-2,3-dichlorophenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-15-1P, 4-(Cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-16-2P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-17-3P, N-[(1R)-1-(4-Bromophenyl)ethyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-18-4P, 4-(Cyclohexylamino)-N-[(1-2,3-dichlorophenyl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-19-5P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-3-(methyloxy)phenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-20-6P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-4-(methyloxy)phenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-21-9P, N-[(1-4-Bromophenyl)propyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-22-0P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-4-(propyloxy)phenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-23-1P, 4-(Cyclohexylamino)-N-[(1-3,5-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-24-2P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-4-methylphenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-25-3P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-4-(1-methylethyl)phenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-26-4P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-2-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-27-5P, 4-(Cyclohexylamino)-N-[(1-4-[(difluoromethyl)oxy]phenyl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-28-6P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-4-(trifluoromethyl)phenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-29-7P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-2-methylphenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-30-0P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-4-(ethyloxy)phenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-31-1P, 4-(Cyclohexylamino)-N-[(1-4-[(difluoromethyl)oxy]phenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-32-2P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-4-(trifluoromethyl)phenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-33-3P, 4-(Cyclohexylamino)-N-[(1-3,4-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-34-4P, 4-(Cyclohexylamino)-N-[(1-2,3-dimethylphenyl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-35-5P, 4-(Cyclohexylamino)-N-[(1-2,4-dimethylphenyl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-36-6P, N-[(1-4-Chloro-2-fluorophenyl)ethyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-37-7P, N-[(1-3-Chloro-4-methylphenyl)ethyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-38-8P, 4-(Cyclohexylamino)-N-[(1-2,3-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-39-9P, 4-(Cyclohexylamino)-N-[(1-2,4-dimethylphenyl)propyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-40-2P, N-[(1-4-Chloro-2-fluorophenyl)propyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-41-3P, N-[(1-3-Chloro-4-methylphenyl)propyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-42-4P, 4-(Cyclohexylamino)-1-ethyl-N-[(1-3-hydroxyphenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-43-5P, N-[(1-4-Chlorophenyl)-2-hydroxyethyl]-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 856560-44-6P, 4-(Cyclohexylamino)-N-[(1-2,3-dihydro-1H-inden-5-yl)ethyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

856560-45-7P, 4-(Cyclohexylamino)-1-ethyl-N-[(1S,6,7,8-tetrahydro-2-naphthalenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-46-8P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(1S)-1-phenylpropyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-47-9P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(1R)-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-48-0P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-(diphenylmethyl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-49-1P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(1S)-1-(4-methylsulfonylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-50-4P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(1R)-1-phenylpropyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-53-7P, 1-Ethyl-N-[(1S)-1-(4-nitrophenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-54-8P, 1-Ethyl-N-[(1R)-1-(4-nitrophenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-60-6P, (2R)-[[(1-Ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl)carbonyl]amino][3-(methyloxy)phenyl]ethanoic acid

856560-62-8P, 1-Ethyl-N-[(1S)-2-(methylphenyl)ethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-70-8P, 1-Ethyl-N-[(1S)-2-hydroxy-1-phenylethyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-71-9P, N-[1-(4-Chlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-72-0P, N-[1-(4-[(Difluoromethyl)oxy]phenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-73-1P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-(4-(trifluoromethyl)phenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-74-2P, 1-Ethyl-N-[(1S)-2-(methylphenyl)propyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-75-3P, 1-Ethyl-N-[(1S)-4-(ethyloxy)phenyl]propyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-76-4P, N-[1-(4-[(Difluoromethyl)oxy]phenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-77-5P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-(4-(trifluoromethyl)phenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-78-6P, N-[1-(3,4-Dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-81-1P, N-[1-(2,3-Dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-82-2P, N-[1-(2,4-Dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-83-3P, N-[1-(4-Chloro-2-fluorophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-84-4P, N-[1-(3-Chloro-4-methylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-85-5P, N-[1-(2,3-Dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-86-6P, N-[1-(2,4-Dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-87-7P, N-[1-(4-Chloro-2-fluorophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-88-8P, N-[1-(3-Chloro-4-methylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-90-2P, 1-Ethyl-N-[(1S)-3-(hydroxyphenyl)propyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-92-4P, 1-Ethyl-N-[(1S)-3-(methyloxy)phenyl]propyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-93-5P, 1-Ethyl-N-[(1S)-4-(methyloxy)phenyl]propyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

856560-94-6P, N-[1-(4-Bromophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-95-7P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-(4-(propyloxy)phenyl)propyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-96-8P, N-[1-(3,5-Dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-97-9P, 1-Ethyl-N-[(1S)-1-(4-methylphenyl)propyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856560-98-0P, 1-Ethyl-N-[(1S)-1-(4-methylphenyl)propyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-00-7P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-(5,6,7,8-tetrahydro-2-naphthalenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-01-8P, N-[1-(4-Bromophenyl)-2,2,2-trifluoroethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-02-9P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[2,2,2-trifluoro-1-[3-(methyloxy)phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-03-0P, 1-Ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[1-(5,6,7,8-tetrahydro-2-naphthalenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-04-1P, 1-Ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[(1S)-2-hydroxy-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-05-2P, N-[1-(2,3-Dihydro-1H-inden-5-yl)ethyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-06-3P, N-[1-(4-Chlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-07-4P, 1-Ethyl-N-[1-(4-(ethyloxy)phenyl)ethyl]-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-08-5P, 1-Ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[1-(4-(propyloxy)phenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-09-6P, 1-Ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-10-9P, 1-Ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[(1R)-2-hydroxy-1-phenylethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-11-0P, 1-Ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[(1-phenylpropyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-12-1P, 1-Ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[1-(4-(1-methylethyl)phenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-13-2P, N-[1-(3,5-Dimethylphenyl)ethyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-14-3P, 1-Ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[(1R)-1-(4-(methyloxy)phenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-15-4P, 1-Ethyl-N-[1-(4-fluorophenyl)propyl]-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

856561-16-5P, N-[1-(2,3-Dichlorophenyl)propyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(PDE4B inhibitor; prepn. of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)

RN 720705-46-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-2-hydroxy-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 720705-47-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-2-hydroxy-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 720705-50-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S,2R)-2-hydroxy-1-phenylpropyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856558-81-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-phenylpropyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 856558-82-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-methyl-1-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-83-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-2-hydroxy-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-84-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(diphenylmethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-85-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-(3-pyridinyl)ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-86-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-1-phenylpropyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856558-87-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 856558-93-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-(3-hydroxyphenyl)ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856558-94-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(dimethylamino)-1-phenylethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-95-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-phenyl-2-(1-pyrrolidinyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-88-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 856558-89-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-methyl-1-(4-pyridinyl)ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-92-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(3-hydroxy-1-phenylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-96-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-(hydroxymethyl)-1-phenylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-97-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-(4-propoxyphenyl)ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856558-98-0 CAPLUS
CN Benzenepropanoic acid, B-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 856558-99-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-(4-fluorophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-01-8 CAPLUS
CN Benzeneacetic acid, α-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 856559-02-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-methoxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-06-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-2-methoxy-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-07-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-hydroxy-1,1-diphenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-08-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-cyanophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-03-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-2-methoxy-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-04-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-2-amino-2-oxo-1-phenylethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-05-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-nitrophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 856559-09-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(cyanophenylmethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-10-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(cyclopropyl(4-methoxyphenyl)methyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-11-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(1-naphthalenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-12-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1,2-diphenylethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]]- (CA INDEX NAME)




RN 856559-13-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-(4-methoxyphenyl)butyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]]- (CA INDEX NAME)




RN 856559-14-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(1-naphthalenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]]- (CA INDEX NAME)


Absolute stereochemistry.




RN 856559-18-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-phenylcyclopentyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]]- (CA INDEX NAME)



RN 856559-19-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-phenylcyclohexyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]]- (CA INDEX NAME)




RN 856559-20-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1-(4-(cyclohexyloxy)-3-methylphenyl)ethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]]- (CA INDEX NAME)




RN 856559-15-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-1-(1-naphthalenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]]- (CA INDEX NAME)


Absolute stereochemistry.




RN 856559-16-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1-(aminocarbonyl)-1-phenylpropyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]]- (CA INDEX NAME)




RN 856559-17-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-phenylcyclopentyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]]- (CA INDEX NAME)




RN 856559-21-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1-[3-(cyclohexyloxy)-4-methoxyphenyl]ethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]]- (CA INDEX NAME)




RN 856559-22-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1-(2,3-dichlorophenyl)ethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]]- (CA INDEX NAME)




RN 856559-23-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1-(4-(cyclohexyloxy)-3-hydroxyphenyl)ethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]]- (CA INDEX NAME)




RN 856559-24-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-(cyclopentylloxy)phenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-25-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-methylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-26-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-(1,1-dimethylethyl)phenyl)cycloheptyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-30-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(1-methyl-1-phenylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-31-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(1,3-benzodioxol-5-yl)cyclohexyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-32-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-methoxyphenyl)cyclohexyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-27-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-bromophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-28-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-1-(4-iodophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 856559-29-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-(aminosulfonyl)phenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-33-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)cyclohexyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-34-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chlorophenyl)cyclopentyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-35-8 CAPLUS


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2-chlorophenyl)cyclopentyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-36-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-(1,1-dimethylethyl)phenyl)cyclohexyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-37-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-(1-methylethyl)phenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 [(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-42-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(1-phenylpentyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-43-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-methyl-1-phenylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-44-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(1-phenylbutyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 856559-38-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-39-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methoxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856559-40-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-1-(4-methoxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 856559-41-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(1-phenylhexyl)-4-

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-45-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-(2,2,2-trifluoro-1-phenylethyl)- (CA INDEX NAME)




RN 856559-46-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(cyclopropylphenylmethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-47-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-48-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,3-dichlorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-49-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-50-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(phenylethyl)]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-54-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-methoxyphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-55-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methoxyphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-56-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-51-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-52-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-53-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3,4-dichlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-57-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-propoxyphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-58-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3,5-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-59-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-60-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-[4-(1-methylphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-61-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(2-methylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-62-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-[4-(difluoromethoxy)phenyl]ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-66-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-[4-(difluoromethoxy)phenyl]propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-67-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(1R)-1-[4-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-68-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-63-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-64-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(2-methylphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-65-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-ethoxyphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-69-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,3-dimethylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-70-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-71-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chloro-2-fluorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-72-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-methylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-73-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,3-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-74-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856559-78-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,3-dihydro-1H-inden-5-yl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-79-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(5,6,7,8-tetrahydro-2-naphthalenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856559-80-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-75-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-76-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-fluorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 856559-77-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-hydroxyphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856559-81-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-hydroxyphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[2,2,2-trifluoro-1-(3-methoxyphenyl)ethyl]- (CA INDEX NAME)




RN 856559-82-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-(methylsulfonyl)phenyl)ethyl]- (CA INDEX NAME)




RN 856559-83-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-84-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-((1R)-1-phenylethyl)-1-ethyl- (CA INDEX NAME)




RN 856559-85-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-((1R)-1-phenylethyl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 856559-86-9 CAPLUS
CN Benzeneacetic acid, alpha-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)




RN 856559-90-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 856559-91-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-(1,2-diphenylethyl)-1-ethyl- (CA INDEX NAME)




RN 856559-92-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-propoxyphenyl)ethyl]- (CA INDEX NAME)




RN 856559-87-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 856559-88-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)




RN 856559-89-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)




RN 856559-93-8 CAPLUS
CN Benzenepropanoic acid, beta-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-, methyl ester (CA INDEX NAME)




RN 856559-94-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(hydroxymethyl)-1-phenylpropyl]- (CA INDEX NAME)




RN 856559-95-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(3-hydroxy-1-phenylpropyl)- (CA INDEX NAME)




RN 856559-96-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(4-ethoxyphenyl)ethyl]-1-ethyl- (CA INDEX NAME)



RN 856559-97-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(3-hydroxyphenyl)ethyl]- (CA INDEX NAME)




RN 856559-98-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 856560-02-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-2-hydroxy-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-03-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1S)-2-hydroxy-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-04-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856559-99-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[2-(dimethylamino)-1-phenylethyl]-1-ethyl- (CA INDEX NAME)




RN 856560-00-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-2-methoxy-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-01-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-2-amino-2-oxo-1-phenylethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-05-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1S)-2-methoxy-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-06-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-nitrophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-07-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1S)-1-(1-naphthalenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 856560-08-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(1-phenyl-2-thiazolyl)methyl- (CA INDEX NAME)




RN 856560-09-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(cyanophenylmethyl)-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)



RN 856560-10-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(1-naphthalenyl)ethyl- (CA INDEX NAME)




RN 856560-14-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(2,3-dichlorophenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856560-15-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-16-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(1-phenylethyl)- (CA INDEX NAME)




RN 856560-11-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(2-hydroxy-1,1-diphenylethyl)- (CA INDEX NAME)




RN 856560-12-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-13-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(1-(4-fluorophenyl)propyl)- (CA INDEX NAME)




RN 856560-17-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)ethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 856560-18-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(2,3-dichlorophenyl)ethyl]-1-ethyl- (CA INDEX NAME)




RN 856560-19-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(3-methoxyphenyl)propyl]- (CA INDEX NAME)




RN 856560-20-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-methoxyphenyl)propyl]- (CA INDEX NAME)




RN 856560-21-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-bromophenyl)propyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 856560-22-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-propoxyphenyl)propyl]- (CA INDEX NAME)




RN 856560-26-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(2-methylphenyl)ethyl]- (CA INDEX NAME)




RN 856560-27-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(4-(difluoromethoxy)phenyl)ethyl]-1-ethyl- (CA INDEX NAME)




RN 856560-28-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-(trifluoromethyl)phenyl)ethyl]- (CA INDEX NAME)




RN 856560-23-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(3,5-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856560-24-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-methylphenyl)propyl]- (CA INDEX NAME)




RN 856560-25-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-(1-methylethyl)phenyl)propyl]- (CA INDEX NAME)




RN 856560-29-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(2-methylphenyl)propyl]- (CA INDEX NAME)




RN 856560-30-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(4-ethoxyphenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856560-31-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(4-(difluoromethoxy)phenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856560-32-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(4-(trifluoromethyl)phenyl)propyl]- (CA INDEX NAME)




RN 856560-33-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856560-34-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(2,3-dimethylphenyl)ethyl]-1-ethyl- (CA INDEX NAME)




RN 856560-38-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(2,3-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856560-39-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856560-40-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)propyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 856560-35-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[1-(2,4-dimethylphenyl)ethyl]-1-ethyl- (CA INDEX NAME)




RN 856560-36-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)ethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 856560-37-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chloro-4-methylphenyl)ethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 856560-41-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chloro-4-methylphenyl)propyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 856560-42-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[1-(3-hydroxyphenyl)propyl]- (CA INDEX NAME)




RN 856560-43-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)-2-hydroxyethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)



RN 856560-44-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-((cyclohexylamino)-N-[1-(2,3-dihydro-1H-inden-5-yl)ethyl]-1-ethyl)- (CA INDEX NAME)




RN 856560-45-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-((cyclohexylamino)-1-ethyl-N-[1-(5,6,7,8-tetrahydro-2-naphthalenyl)ethyl]- (CA INDEX NAME)




RN 856560-46-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-((1-acetyl-4-piperidinyl)amino)-1-ethyl-N-[(1S)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-50-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-((1-acetyl-4-piperidinyl)amino)-1-ethyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-53-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-1-(4-nitrophenyl)ethyl]-4-((4-oxocyclohexyl)amino)- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-54-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-nitrophenyl)ethyl]-4-((4-oxocyclohexyl)amino)- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-47-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-((1-acetyl-4-piperidinyl)amino)-1-ethyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-48-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-((1-acetyl-4-piperidinyl)amino)-N-(diphenylmethyl)-1-ethyl- (CA INDEX NAME)




RN 856560-49-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-((1-acetyl-4-piperidinyl)amino)-1-ethyl-N-[(1S)-1-phenylpropyl]- (CA INDEX NAME)




RN 856560-60-6 CAPLUS
CN Benzeneacetic acid, α-[[[1-ethyl-4-((4-oxocyclohexyl)amino)-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-3-methoxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 856560-62-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-1-(2-methylphenyl)ethyl]-4-((4-oxocyclohexyl)amino)- (CA INDEX NAME)




RN 856560-70-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-2-hydroxy-1-phenylethyl]-4-((4-oxocyclohexyl)amino)- (CA INDEX NAME)


Absolute stereochemistry.



RN 856560-71-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[(4-chlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-72-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[(4-(difluoromethoxy)phenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-73-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[(4-(trifluoromethyl)phenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


RN 856560-76-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[(4-(difluoromethoxy)phenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-77-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[(4-(trifluoromethyl)phenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-78-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[(3,4-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-74-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[(2-methylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-75-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[(4-ethoxyphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 856560-81-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[(2,3-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-82-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-83-3 CAPLUS

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-84-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chloro-4-methylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-85-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chloro-4-methylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-90-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(3-hydroxyphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-92-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(3-methoxyphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 856560-86-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-87-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-88-8 CAPLUS


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 856560-93-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-methoxyphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-94-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-bromophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856560-95-7 CAPLUS


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-(4-propoxyphenyl)propyl]- (CA INDEX NAME)




RN 856560-96-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 856560-97-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-methylphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856561-02-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[2,2,2-trifluoro-1-(3-methoxyphenyl)ethyl]- (CA INDEX NAME)




RN 856561-03-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[1-(5,6,7,8-tetrahydro-2-naphthalenyl)ethyl]- (CA INDEX NAME)


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 856560-98-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-methylethylphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 856561-00-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[1-(5,6,7,8-tetrahydro-2-naphthalenyl)ethyl]- (CA INDEX NAME)




L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 856561-04-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[(1S)-2-hydroxy-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856561-05-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dihydro-1H-inden-5-yl)ethyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]- (CA INDEX NAME)




RN 856561-06-3 CAPLUS


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)-2-hydroxyethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-07-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-ethoxyphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)



RN 856561-08-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(4-propoxyphenyl)ethyl]- (CA INDEX NAME)




RN 856561-12-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(4-(1-methylethyl)phenyl)ethyl]- (CA INDEX NAME)




RN 856561-13-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 856561-09-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-10-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-2-hydroxy-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856561-11-0 CAPLUS

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 856561-14-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-15-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)propyl]-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)



RN 856561-16-5 CAPLUS




L4


L4

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 856645-86-8P, 4-[[4-(Aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-
 ((1R)-1-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 856645-89-1P 856645-92-6P 856645-96-0P,
 4-[[4-(Acetylcyclohexyl)amino]-N-((1R)-1-(2,4-dimethylphenyl)propyl)-1-
 ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 RI: PAC (Pharmacological activity); SPN (Synthetic Preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (PDE4B inhibitor; prepn. of pyrazolo[3,4-b]pyridines as PDE4 inhibitors
 for treatment of inflammatory and/or allergic diseases)
 RN 856561-17-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-
 (hydroxyimino)cyclohexyl]amino]-N-((1R)-1-(4-methylphenyl)ethyl)- (CA
 INDEX NAME)

Absolute stereochemistry.




RN 856561-18-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-
 (hydroxyimino)cyclohexyl]amino]-N-(1-phenylethyl)- (CA INDEX NAME)




RN 856561-19-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-((1R)-1-(4-bromophenyl)ethyl)-
 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 856561-20-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[1-(2,3-dichlorophenyl)ethyl]-
 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-21-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[1-(4-chlorophenyl)propyl]-1-
 ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-22-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[1-(4-chlorophenyl)ethyl]-1-
 ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 856561-23-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-
 (hydroxyimino)cyclohexyl]amino]-N-[[1-(3-methoxyphenyl)propyl]- (CA INDEX
 NAME)




RN 856561-24-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-
 (hydroxyimino)cyclohexyl]amino]-N-[[1-(4-methoxyphenyl)propyl]- (CA INDEX
 NAME)




L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 856561-25-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[1-(4-bromophenyl)propyl]-1-
 ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-26-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-
 (hydroxyimino)cyclohexyl]amino]-N-[[1-(4-propoxyphenyl)propyl]- (CA INDEX
 NAME)





RN 856561-27-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[1-(3,5-dimethylphenyl)propyl]-
 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-28-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(4-methylphenyl)propyl]- (CA INDEX NAME)




RN 856561-29-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(4-(1-methylethyl)phenyl)propyl]- (CA INDEX NAME)




RN 856561-33-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(2-methylphenyl)propyl]- (CA INDEX NAME)




RN 856561-34-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-ethoxyphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)



RN 856561-30-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(2-methylphenyl)ethyl]- (CA INDEX NAME)




RN 856561-31-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[4-(difluoromethoxy)phenyl]ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-32-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(4-(trifluoromethyl)phenyl)ethyl]- (CA INDEX NAME)


RN 856561-35-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-[4-(difluoromethoxy)phenyl]propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)



RN 856561-36-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(4-(trifluoromethyl)phenyl)propyl]- (CA INDEX NAME)




RN 856561-37-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-38-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856561-39-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(1R)-1-(3-methoxyphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856561-40-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 856561-43-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chloro-4-methylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-44-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dimethylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-45-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-41-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-42-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 856561-46-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-47-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chloro-4-methylphenyl)propyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 856561-48-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(3-hydroxyphenyl)ethyl]- (CA INDEX NAME)



RN 856561-49-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(3-hydroxyphenyl)propyl]- (CA INDEX NAME)



RN 856561-50-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-51-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)ethyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-, (+)- (CA INDEX NAME)


Rotation (+).



RN 856561-52-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(4-(1-methylethoxy)phenyl)ethyl]-, (+)- (CA INDEX NAME)

Rotation (+).



RN 856561-53-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(4-(1-methylethoxy)phenyl)ethyl]- (CA INDEX NAME)



RN 856561-54-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[[4-(hydroxyimino)cyclohexyl]amino]-, (+)- (CA INDEX NAME)

Rotation (+).



RN 856561-55-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-1-ethyl-4-[[3-hydroxycyclohexyl]amino]- (CA INDEX NAME)



RN 856561-57-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[[3-hydroxycyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-58-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1S)-1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[[3-hydroxycyclohexyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856561-59-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[[3-hydroxycyclohexyl]amino]- (CA INDEX NAME)




RN 856561-60-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)propyl]-1-ethyl-6-methyl-4-[[tetrahydro-2H-pyran-4-yl]amino]- (CA INDEX NAME)



RN 856561-61-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chlorophenyl)ethyl]-1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 856561-68-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1S)-1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[(4-hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-76-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)ethyl]-1-ethyl-4-[(4-hydroxyimino)cyclohexyl]amino]-, (-) (CA INDEX NAME)


Rotation (-).



RN 856561-82-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 856561-83-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[1-(4-bromophenyl)ethyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856561-84-7 CAPLUS



RN 856561-80-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1S)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 856561-81-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856561-85-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[1-(3-chloro-4-methylphenyl)propyl]-1-ethyl- (CA INDEX NAME)



RN 856561-86-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl- (CA INDEX NAME)



RN 856561-87-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,5-dimethylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-88-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(1R)-1-(2,4,6-trimethylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856561-89-2 CAPLUS


Absolute stereochemistry.



RN 856561-93-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,5-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-94-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(2-ethylphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856561-95-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(1R)-1-(2,4,6-trimethylphenyl)propyl]- (CA INDEX NAME)

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(2-ethylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-90-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-ethylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-91-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-ethylphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-92-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,6-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-96-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-(aminocarbonyl)-4-piperidinyl)amino]-N-[(1R)-1-(2,5-dimethylphenyl)ethyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856561-97-2 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-(aminocarbonyl)-4-piperidinyl)amino]-1-ethyl-N-[(1R)-1-(4-ethylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 856561-98-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(2-ethylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856561-99-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(2,4,6-trimethylphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 856562-00-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 856562-03-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(4-chlorophenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856562-04-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(4-fluorophenyl)propyl]- (CA INDEX NAME)




RN 856562-05-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 856562-01-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(4-chlorophenyl)ethyl]-1-ethyl- (CA INDEX NAME)




RN 856562-02-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 856562-06-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(4-ethylphenyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-07-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(4-(1-methylethyl)phenyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 856562-08-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 856562-09-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(2,6-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-10-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[(1R)-1-(2,5-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 856562-11-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(2,4,6-trimethylphenyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-12-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-N-[(1R)-1-(2,4,6-trimethylphenyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 856562-13-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[1-(4-chlorophenyl)propyl]-1-ethyl- (CA INDEX NAME)




RN 856562-14-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[1-[4-(difluoromethoxy)phenyl]ethyl]-1-ethyl- (CA INDEX NAME)




RN 856562-15-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-N-[1-(4-chlorophenyl)ethyl]-1-ethyl- (CA INDEX NAME)

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 856562-16-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[1-(4-fluorophenyl)propyl]- (CA INDEX NAME)




RN 856562-17-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[cis-4-(aminocarbonyl)cyclohexyl]amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-18-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(cis-4-(aminocarbonyl)cyclohexyl)amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-19-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(cis-4-(aminocarbonyl)cyclohexyl)amino]-1-ethyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-20-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(cis-4-(aminocarbonyl)cyclohexyl)amino]-N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-21-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(trans-4-(aminocarbonyl)cyclohexyl)amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-22-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(trans-4-(aminocarbonyl)cyclohexyl)amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-23-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(trans-4-(aminocarbonyl)cyclohexyl)amino]-1-ethyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-24-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(trans-4-(aminocarbonyl)cyclohexyl)amino]-N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 856562-25-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-26-0 CAPLUS


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[{(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-27-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[{(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-28-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[{(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-29-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[{(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 Absolute stereochemistry.




RN 856562-33-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-3-(aminocarbonyl)cyclobutyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856562-34-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-3-(aminocarbonyl)cyclobutyl]amino]-N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 856562-35-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[trans-4-


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 NAME)

Absolute stereochemistry.




RN 856562-30-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[{(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856562-31-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[{(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856562-32-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[{(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl- (CA INDEX NAME)


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 acetylcyclohexyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-36-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-acetylcyclohexyl]amino]-1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-37-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[[4-(1-hydroxyethyl)cyclohexyl]amino]-, stereoisomer (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-38-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)ethyl]-1-ethyl-4-[(3-hydroxycyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856562-39-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[(1R,3R)-3-hydroxycyclohexyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 856562-40-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[4-(dimethylamino)-1-(3-methylphenyl)-4-oxobutyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856562-41-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-N-[4-(dimethylamino)-1-(3-methylphenyl)-4-oxobutyl]-1-ethyl- (CA INDEX NAME)




RN 856562-42-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methylphenyl)ethyl]-4-(4-piperidinylamino)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



•x HCl


RN 856562-43-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-(4-piperidinylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



• HCl


RN 856564-62-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[1-(4-(1-methylethoxy)phenyl)ethyl]-, (-) (CA INDEX NAME)

Rotation (-).




RN 856564-63-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-fluorophenyl)ethyl]-4-[[4-(hydroxyimino)cyclohexyl]amino]-, (-) (CA INDEX NAME)

Rotation (-).




L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 856564-64-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-N-[1-(4-chlorophenyl)propyl]-1-ethyl- (CA INDEX NAME)

Relative stereochemistry.



RN 856564-65-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-66-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-N-[1-(4-(difluoromethoxy)phenyl)ethyl]-1-ethyl- (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 856564-67-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-N-[1-(4-chlorophenyl)ethyl]-1-ethyl- (CA INDEX NAME)


Relative stereochemistry.



RN 856564-68-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[1-(4-fluorophenyl)propyl]- (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 856564-69-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 856564-70-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(1R)-1-(3,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-71-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 856564-72-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-N-[(1R)-1-(3,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-73-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[(3-hydroxycyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 856564-74-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[(1R)-1-(4-piperidinylamino)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 856645-86-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 856645-89-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
IT 856564-82-4P
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(intermediate; preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)
RN 856564-82-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[(4-(hydroxymethyl)cyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



IT 675112-01-3P, Ethyl 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-03-5P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-05-7P, 1-Ethyl-4-[(3S)-tetrahydrofuran-3-yl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 675112-07-9P 675112-09-1P 675112-11-5P 675112-15-9P, Ethyl 4-[(1,1-dioxidotetrahydrothien-3-yl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-17-1P 675112-19-3P, 1-Ethyl-4-[(3S)-tetrahydrofuran-3-yl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-21-7P 675112-23-9P 675112-25-1P 675112-27-3P 675112-29-5P 675112-33-1P, 1-(n-Propyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-36-4P, 4-(Cyclohexylamino)-1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-38-6P, 1-Ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-54-6P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-56-8P, Ethyl 1-ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-60-4P, 1-Ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-62-6P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-65-9P, 4-(Cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-94-4P, Ethyl 4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-96-6P, Ethyl 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675114-51-9P, Ethyl 1-(n-propyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675114-52-0P, Ethyl 1-(2-hydroxyethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675114-55-3P, Ethyl 1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675114-56-4P, Ethyl 1-ethyl-4-[(4-cyclohexylamino)-1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675114-63-3P, Ethyl 1-ethyl-4-[(4-hydroxycyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675114-64-4P, Ethyl 1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675119-55-8P, Ethyl 1-ethyl-4-[(4-(hydroxymethyl)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 856562-46-4P, 1-Ethyl-4-[(3-hydroxycyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 856563-15-0P, Ethyl 4-[[1-[(1,1-dimethylethyl)oxy]carbonyl]-4-piperidinyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 856563-16-1P, Ethyl 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate hydrochloride 856563-16-1P, Ethyl 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 856563-17-2P, 4-[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 856563-25-2P, Ethyl 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 856563-26-3P, Ethyl 4-[[trans-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 856563-27-4P, 4-[[cis-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 856563-28-5P, 4-[[trans-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 856563-41-2P, Ethyl 4-[[[(3S)-1-[(1,1-dimethylethyl)oxy]carbonyl]-3-pyrrolidinyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 856563-42-3P, Ethyl 4-[[[(3R)-1-[(1,1-dimethylethyl)oxy]carbonyl]-3-pyrrolidinyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 856563-43-4P, Ethyl 1-ethyl-4-[(3S)-pyrrolidin-3-ylamino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate monohydrochloride 856563-44-5P, Ethyl 1-ethyl-4-[(3R)-pyrrolidin-3-ylamino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate monohydrochloride 856563-45-6P, Ethyl 4-[[[(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 856563-46-7P, Ethyl 4-[[[(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 856563-47-8P, 4-[[[(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 856563-48-9P, 4-[[[(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 856563-51-4P, Ethyl 4-[[4-(acetylcyclohexyl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 856563-52-5P, 4-[[4-(Acetylcyclohexyl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 856563-55-8P 856563-56-9P, 4-[[1-[(1,1-Dimethylethyl)oxy]carbonyl]-4-piperidinyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 856563-57-0P, 1,1-Dimethylethyl 4-[[1-ethyl-5-[[[(1R)-1-(4-methylphenyl)ethyl]amino]carbonyl]-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]-1-piperidinecarboxylate 856563-58-1P 856563-63-8P
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prep. of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)
RN 675112-01-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)




RN 675112-03-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675112-05-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(3S)-tetrahydro-3-furanyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 675112-07-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(3R)-tetrahydro-3-furanyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 675112-17-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)




RN 675112-19-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(3S)-tetrahydro-3-furanyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 675112-21-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-thiopyran-4-yl)amino]- (CA INDEX NAME)




RN 675112-09-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-thiopyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)




RN 675112-11-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-3-thienyl)amino]-, ethyl ester (CA INDEX NAME)




RN 675112-15-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-1,1-dioxido-3-thienyl)amino]-, ethyl ester (CA INDEX NAME)




RN 675112-23-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-3-thienyl)amino]- (CA INDEX NAME)




RN 675112-25-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopropylamino)-1-ethyl- (CA INDEX NAME)




RN 675112-27-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-1,1-dioxido-3-thienyl)amino]- (CA INDEX NAME)




RN 675112-29-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]- (CA INDEX NAME)




RN 675112-33-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675112-36-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclohexylamino)-1-ethyl-6-methyl- (CA INDEX NAME)




RN 675112-60-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]- (CA INDEX NAME)




RN 675112-62-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl- (CA INDEX NAME)




RN 675112-65-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 675112-38-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675112-54-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675112-56-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]-, ethyl ester (CA INDEX NAME)




RN 675112-94-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclohexylamino)-1-ethyl-, ethyl ester (CA INDEX NAME)




RN 675112-96-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-, ethyl ester (CA INDEX NAME)




RN 675114-51-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)




RN 675114-52-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-[(2-hydroxyethyl)-(4-((tetrahydro-2H-pyran-4-yl)amino))-ethyl ester (CA INDEX NAME)




RN 675114-55-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-ethyl ester (CA INDEX NAME)




RN 675114-56-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclohexylamino)-1-ethyl-6-methyl-, ethyl ester (CA INDEX NAME)




RN 856562-45-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-ethyl ester (CA INDEX NAME)




RN 856562-46-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(3-hydroxycyclohexyl)amino]-ethyl ester (CA INDEX NAME)




RN 856563-14-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]amino]-1-ethyl-, ethyl ester (CA INDEX NAME)




RN 675114-63-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(4-hydroxycyclohexyl)amino]-ethyl ester (CA INDEX NAME)




RN 675114-64-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(4-oxocyclohexyl)amino]-ethyl ester (CA INDEX NAME)



RN 675119-55-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-ethyl ester (CA INDEX NAME)




RN 856563-15-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 856563-16-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-[(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl-, ethyl ester (CA INDEX NAME)



RN 856563-17-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[[1-(aminocarbonyl)-4-piperidinyl]amino]-1-ethyl]- (CA INDEX NAME)




RN 856563-25-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[[cis-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl]-, ethyl ester (CA INDEX NAME)

Relative stereochemistry.


RN 856563-28-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[[trans-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl]- (CA INDEX NAME)

Relative stereochemistry.





RN 856563-41-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[[(3S)-1-[(1,1-dimethylethoxy)carbonyl]-3-pyrrolidinyl]amino]-1-ethyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-42-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[[(3R)-1-[(1,1-dimethylethoxy)carbonyl]-3-pyrrolidinyl]amino]-1-ethyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-26-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[[trans-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl]-, ethyl ester (CA INDEX NAME)

Relative stereochemistry.




RN 856563-27-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[[cis-4-(aminocarbonyl)cyclohexyl]amino]-1-ethyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 856563-43-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(3S)-3-pyrrolidinyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 856563-44-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(3R)-3-pyrrolidinyl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 856563-45-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[[(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-1-ethyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-46-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[[(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-1-ethyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-47-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[[(3S)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-48-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[[(3R)-1-(aminocarbonyl)-3-pyrrolidinyl]amino]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-56-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]amino]-1-ethyl- (CA INDEX NAME)




RN 856563-57-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-ethyl-5-[[[(1R)-1-(4-methylphenyl)ethyl]amino]carbonyl]-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 856563-58-1 CAPLUS



RN 856563-51-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[[(4-acetylcyclohexyl)amino]-1-ethyl-, ethyl ester (CA INDEX NAME)




RN 856563-52-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[[(4-acetylcyclohexyl)amino]-1-ethyl- (CA INDEX NAME)



RN 856563-55-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(3-hydroxycyclohexyl)amino]-, ethyl ester (CA INDEX NAME)


CN 1-Piperidinecarboxylic acid, 4-[[[5-[[[(1R)-1-(2,4-dimethylphenyl)propyl]amino]carbonyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 856563-63-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[[[(3R)-tetrahydro-3-furanyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.




IT 856564-26-6P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PUR (Purification or recovery); PYP (Physical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)

RN 856564-26-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[[(1R)-1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



IT 856564-14-2P
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PUR (Purification or recovery); PYP (Physical process); SPW (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROOC (Process); USES (Uses)
 (preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)
 RN 856564-14-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




IT	856564-18-6P	856564-19-7P	856564-20-0P	
	856564-21-1P	856564-22-2P	856564-23-3P	
	856564-24-4P	856564-25-5P	856564-27-7P	
	856564-28-8P	856564-29-9P	856564-30-2P	
	856564-31-3P	856564-32-4P	856564-33-5P	
	856564-34-6P	856564-35-7P	856564-36-8P	
	856564-37-9P	856564-38-0P	856564-39-1P	
	856564-40-4P			
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)			
RN	856564-18-6	CAPLUS		
CN	1H-pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-[4-(difluoromethoxy)phenyl]ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)			




RN 856564-22-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-[4-(difluoromethoxy)phenyl]propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA
INDEX NAME)

Absolute stereochemistry.




RN 856564-23-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[(1R)-1-[4-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-24-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-19-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(4-cyclohexyl)amino]-N-[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-20-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(2-methylphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-21-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-ethoxyphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-25-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,3-dimethylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-27-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-({(1R)-1-(4-chloro-2-fluorophenyl)ethyl}-1-ethyl-4-({(4-oxocyclohexyl)amino)- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-28-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-methylphenyl)ethyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-29-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,3-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-30-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-31-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 856564-35-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methoxyphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-36-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-37-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-propoxyphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-32-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-methylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-33-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-hydroxyphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-34-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-methoxyphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-38-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3,5-dimethylphenyl)propyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-39-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methylphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856564-40-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(4-methylethylphenyl)propyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



IT 856563-69-4P 856563-70-7P 856563-71-8P
 856563-72-9P 856563-73-0P 856563-74-1P
 856563-75-2P 856563-76-3P 856563-77-4P
 856563-78-5P 856563-79-6P 856563-80-9P
 856563-81-0P 856563-82-1P 856563-83-2P
 856563-84-3P 856563-85-4P 856563-86-5P
 856563-87-6P 856563-88-7P 856563-89-8P
 856563-90-1P 856563-91-2P 856563-92-3P
 856563-93-4P 856563-94-5P 856563-95-6P
 856563-96-7P 856563-97-8P 856563-98-9P
 856563-99-0P 856564-00-6P 856564-01-7P
 856564-02-8P 856564-03-9P 856564-04-0P
 856564-05-1P 856564-06-2P 856564-07-3P
 856564-08-4P 856564-09-5P 856564-10-8P
 856564-11-9P 856564-12-0P 856564-13-1P
 856564-15-3P 856564-16-4P 856564-17-5P
 856564-41-5P 856564-42-6P 856564-43-7P
 856564-44-8P 856564-45-9P 856564-46-0P
 856564-47-1P 856564-48-2P 856564-49-3P
 856564-50-6P 856564-51-7P 856564-52-8P
 856564-53-9P 856564-54-0P 856564-55-1P
 856564-56-2P 856564-57-3P 856564-58-4P
 856564-59-5P 856564-60-8P 856564-61-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic diseases)

RN 856563-69-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(3-methoxyphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-70-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-methoxyphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-71-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)propyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-72-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-propoxyphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-73-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(3,5-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-74-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-methylphenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-75-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-(1-methylethyl)phenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-76-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(2-methylphenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-77-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(4-(difluoromethoxy)phenyl)ethyl]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 856563-78-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(4-(trifluoromethyl)phenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-79-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(2-methylphenyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-80-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(4-ethoxyphenyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-81-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(4-(difluoromethoxy)phenyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-85-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(2,4-dimethylphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-86-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chloro-2-fluorophenyl)ethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-87-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-methylphenyl)ethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-82-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-[4-(trifluoromethyl)phenyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-83-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(3,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-84-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(2,3-dimethylphenyl)ethyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-88-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(2,3-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-89-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-90-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chloro-2-fluorophenyl)propyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-91-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-methylphenyl)propyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-92-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1R)-1-(3-hydroxyphenyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856563-93-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1S)-1-(4-chlorophenyl)-2-hydroxyethyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 856563-94-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(3-methoxyphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856563-95-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-methoxyphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856563-96-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-bromophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856563-97-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-propoxyphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856563-98-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,5-dimethylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856563-99-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-methylphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-00-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-(1-methylethyl)phenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-01-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(2-methylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-02-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-(difluoromethoxy)phenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 856564-03-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(1-ethoxy-4-(trifluoromethyl)phenyl)ethyl]- (CA INDEX NAME)




RN 856564-04-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(2-methylphenyl)propyl]-4-[(1-ethoxy-4-(trifluoromethyl)phenyl)ethyl]- (CA INDEX NAME)




RN 856564-05-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-ethoxyphenyl)propyl]-1-ethyl-4-[(1-ethoxy-4-(trifluoromethyl)phenyl)ethyl]- (CA INDEX NAME)




RN 856564-09-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dimethylphenyl)ethyl]-1-ethyl-4-[(1-ethoxy-4-(trifluoromethyl)phenyl)ethyl]- (CA INDEX NAME)




RN 856564-10-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,4-dimethylphenyl)ethyl]-1-ethyl-4-[(1-ethoxy-4-(trifluoromethyl)phenyl)ethyl]- (CA INDEX NAME)




RN 856564-11-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)ethyl]-1-ethyl-4-[(1-ethoxy-4-(trifluoromethyl)phenyl)ethyl]- (CA INDEX NAME)




RN 856564-06-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-(difluoromethoxy)phenyl)propyl]-1-ethyl-4-[(1-ethoxy-4-(trifluoromethyl)phenyl)ethyl]- (CA INDEX NAME)




RN 856564-07-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(1-ethoxy-4-(trifluoromethyl)phenyl)propyl]- (CA INDEX NAME)




RN 856564-08-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,4-dimethylphenyl)propyl]-1-ethyl-4-[(1-ethoxy-4-(trifluoromethyl)phenyl)ethyl]- (CA INDEX NAME)




RN 856564-12-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3-chloro-4-methylphenyl)ethyl]-1-ethyl-4-[(1-ethoxy-4-(trifluoromethyl)phenyl)ethyl]- (CA INDEX NAME)




RN 856564-13-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(2,3-dimethylphenyl)propyl]-1-ethyl-4-[(1-ethoxy-4-(trifluoromethyl)phenyl)ethyl]- (CA INDEX NAME)




RN 856564-15-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl-4-[(1-ethoxy-4-(trifluoromethyl)phenyl)ethyl]- (CA INDEX NAME)



RN 856564-16-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-fluorophenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-methylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (CA INDEX NAME)




RN 856564-17-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-chloro-4-methylphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-methylphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (CA INDEX NAME)




RN 856564-41-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-(3-hydroxyphenyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-methoxyphenyl)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-45-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3,5-dimethylphenyl)propyl]-1-ethyl-4-[(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-methoxyphenyl)propyl]-1-ethyl-4-[(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-46-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[(1R)-1-(4-methylphenyl)propyl]-1-ethyl-4-[(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-methylphenyl)propyl]-1-ethyl-4-[(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-47-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[(1R)-1-(4-(1-methylethyl)phenyl)propyl]-1-ethyl-4-[(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-(1-methylethyl)phenyl)propyl]-1-ethyl-4-[(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (CA INDEX NAME)




RN 856564-42-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[(1R)-1-(4-methoxyphenyl)propyl]-1-ethyl-4-[(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-methoxyphenyl)propyl]-1-ethyl-4-[(hydroxyimino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (CA INDEX NAME)

Absolute stereochemistry.



RN 856564-43-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)propyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[(1R)-1-(4-propoxyphenyl)propyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-bromophenyl)propyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (CA INDEX NAME)


Absolute stereochemistry.



RN 856564-44-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[(1R)-1-(4-propoxyphenyl)propyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-propoxyphenyl)propyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 856564-48-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-(difluoromethyl)phenyl)ethyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[(1R)-1-(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-(difluoromethyl)phenyl)ethyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-49-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[(1R)-1-(4-(trifluoromethyl)phenyl)ethyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-(trifluoromethyl)phenyl)ethyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-50-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[(1R)-1-(2-methylphenyl)propyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2-methylphenyl)propyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (CA INDEX NAME)




RN 856564-51-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-ethoxyphenyl)propyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-52-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-(difluoromethoxy)phenyl)propyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-53-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[(1R)-1-(4-(trifluoromethyl)phenyl)propyl]- (CA INDEX NAME)




RN 856564-57-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,3-dimethylphenyl)propyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-58-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,4-dimethylphenyl)propyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-59-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chloro-2-fluorophenyl)propyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]- (CA INDEX NAME)




RN 856564-54-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(2,3-dimethylphenyl)ethyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-55-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(4-chloro-2-fluorophenyl)ethyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 856564-56-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-methylphenyl)ethyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]- (CA INDEX NAME)




RN 856564-60-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-1-(3-chloro-4-methylphenyl)propyl]-1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 856564-61-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-(hydroxyimino)cyclohexyl)amino]-N-[(1R)-1-(3-hydroxyphenyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:160835 CAPLUS
DOCUMENT NUMBER: 142:254632
TITLE: Methods for treating neurodegenerative diseases by inhibiting phosphodiesterase 4 activity using compounds in pyrazolopyridine family
INVENTOR(S): Schweighoffer, Fabien; Guillet, Philippe
PATENT ASSIGNEE(S): Exonhit Therapeutics Sa, Fr.
SOURCE: U.S. Pat. Appl. Publ., 37 pp., Cont.-in-part of U.S. Ser. No. 486,639.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005043319	A1	20050224	US 2004-857455	20040601
FR 2828693	A1	20030221	FR 2001-10819	20010814
FR 2828693	B1	20040618		
US 2003064374	A1	20030403	US 2001-983754	20011025
US 6855736	B2	20050215		
WO 2003016563	A2	20030227	WO 2002-FR2861	20020813
WO 2003016563	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG				
US 2004219552	A1	20041104	US 2004-486639	20040212
PRIORITY APPLN. INFO.:				
			FR 2001-10819	A 20010814
			US 2001-983754	A2 20011025
			WO 2002-FR2861	W 20020813
			US 2004-486639	A2 20040212

AB The present invention relates to new methods for the detection, characterization and/or treatment (or management) of neurodegenerative diseases, particularly amyotrophic lateral sclerosis. In particular, the invention describes the role of PDE4B in these diseases and its use as a therapeutic, diagnostic or exptl. target. Specifically, the method for the treatment of respiratory disorders associated with ALS, comprises administering to a subject in need of such treatment a compound that inhibits PDE4, preferably a compound that selectively inhibits PDE4. The compound is an antisense nucleic acid, capable of inhibiting transcription of the PDE4B gene or translation of the corresponding messenger. The compound is also chosen from among the compds. in the pyrazolopyridine family, particularly etazolate, and the compds. in the family of xanthine deriva., particularly pentoxifylline.


IT 383911-67-9 383911-73-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for treating neurodegenerative diseases by inhibiting phosphodiesterase 4 activity using compds. in pyrazolopyridine family)

RN 383911-67-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclopropylamino)-, ethyl ester (CA INDEX NAME)



RN 383911-73-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(phenylamino)-, ethyl ester (CA INDEX NAME)



2005:588 CAPLUS
DOCUMENT NUMBER: 142:86671
TITLE: Methods and compositions for the treatment of cognitive deficiencies with ligands for the benzodiazepine peripheral receptor
INVENTOR(S): Schweighoffer, Fabien; Desire, Laurent; Resink, Annelies
PATENT ASSIGNEE(S): Exonhit Therapeutics S. A., Fr.
SOURCE: Fr. Demande, 34 pp.
CODEN: FROXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2856595	A1	20041231	FR 2003-7824	20030627
AU 2004251466	A1	20050106	AU 2004-251466	20040625
CA 2528284	A1	20050106	CA 2004-2528284	20040625
WO 2005000302	A1	20050106	WO 2004-FR1630	20040625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1638559	A1	20060329	EP 2004-767477	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1812786	A	20060802	CN 2004-8001848	20040625
JP 2007520427	T	20070726	JP 2006-516332	20040625
IN 20050N05464	A	20070817	IN 2005-DN5464	20051128
US 2006142326	A1	20060629	US 2005-560774	20051214
PRIORITY APPLN. INFO.:				
			FR 2003-7824	A 20030627
			WO 2004-FR1630	W 20040625

AB The present invention relates to methods to improve, increase or facilitate the cognitive ability of subjects afflicted with neurodegenerative disorders. The invention more particularly involves ligands for the benzodiazepine peripheral receptor, preferably ligands of the pyrazolopyridine family, for the improvement of cognitive abilities in subjects afflicted with neurodegenerative disorders, particularly those with Alzheimer's disease.


IT 383911-67-9 383911-73-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment of cognitive deficiencies with ligands for benzodiazepine peripheral receptor)

RN 383911-67-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclopropylamino)-, ethyl ester (CA INDEX NAME)



RN 383911-73-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(phenylamino)-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:934227 CAPLUS
 DOCUMENT NUMBER: 141:388737
 TITLE: Phosphodiesterase 4B gene mutations in diagnosis of brain disorders and PDE4B inhibitors for treatment of brain disorders
 INVENTOR(S): Ait, Ikhlef Ali; Resink, Annelies; Schweighoffer, Fabien
 PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 983,754.
 SOURCE: CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004219552	A1	20041104	US 2004-486639	20040212
FR 2828693	A1	20030221	FR 2001-10819	20010814
FR 2828693	B1	20040618		
US 2003064374	A1	20030403	US 2001-983754	20011025
US 6855736	B2	20050215		
WO 2003016563	A2	20030227	WO 2002-FR2861	20020813
WO 2003016563	A3	20040401		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GR, GU, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GM, GG, GW, HN, HR, HU, IL, IN, JP, KE, KG, KH, KI, KM, KN, KR, KZ, KY, KZ, LA, LB, LC, LI, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SZ, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

US 2005043319 A1 20050224 US 2004-857455 20040601
 PRIORITY APPLN. INFO.: FR 2001-10819 A 20010814
 US 2001-983754 A2 20011025
 WO 2002-FR2861 W 20020813
 US 2004-486639 A2 20040212


AB The invention describes the role of phosphodiesterase 4B (PDE4B) in neurodegenerative diseases and its use as a therapeutic or diagnostic target. Thus, antisense nucleic acids, pyrazolopyridines, and xanthine derivs. may be used to inhibit PDE4B and treat these diseases. Primers and probes for detecting mutations in PDE4B nucleic acids may be used in diagnosis of such diseases. Thus, PDE4B was demonstrated to be involved in excitotoxicity, especially in an ALS model, and inhibitors of PDE4B (etazolate and pentoxifylline) were shown to preserve neuronal viability during stress linked to excitotoxicity.

IT 383911-67-9 383911-73-7
 RI: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (phosphodiesterase 4B gene mutations in diagnosis of brain disorders and PDE4B inhibitors for treatment of brain disorders)

RN 383911-67-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclopropylamino)-, ethyl ester (CA INDEX NAME)




RN 383911-73-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(phenylamino)-, ethyl ester (CA INDEX NAME)



L4 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:911948 CAPLUS
 DOCUMENT NUMBER: 142:48492
 TITLE: Discovery of new orally active phosphodiesterase (PDE4) inhibitors
 AUTHOR(S): Ochiai, Hiroshi; Ishida, Akiharu; Ohtani, Tazumi; Kusumi, Kensuke; Kishikawa, Katuya; Yamamoto, Susumu; Takeda, Hiroshi; Obata, Takaaki; Nakai, Hisao; Toda, Masaaki
 CORPORATE SOURCE: Minase Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, 618-8585, Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (2004), 52(9), 1098-1104
 CODEN: CPBTAL; ISSN: 0009-2363
 PUBLISHER: Pharmaceutical Society of Japan
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:48492
 AB A series of 4-anilino-pyrazolopyridine derivs. were synthesized and biol. evaluated as inhibitors of phosphodiesterase (PDE4). Chemical modification of 3, a structurally new chemical lead that was found in our inhouse library, was focused on 1- and 3-substituents. Full details of the discovery of a new orally active chemical lead 5 are presented. Structure-activity relationship data, pharmacol. evaluation, and the subtype selectivity study are also presented.

IT 389058-31-5P, 4-[(3-methoxyphenyl)amino]-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 RI: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and activity of PDE4 inhibitors)

RN 389058-31-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(3-methoxyphenyl)amino]-1-methyl- (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 2004:680001 CAPLUS
DOCUMENT NUMBER: 141:200206
TITLE: Methods and compositions for the treatment of ocular degenerative diseases with phosphodiesterase 4B inhibitors binding to the benzodiazepine receptor
INVENTOR(S): Schwaighoffer, Fabien; Resink, Annelies; Desire, Laurent
PATENT ASSIGNEE(S): Exonhit Therapeutics S.A., Fr.
SOURCE: Fr. Demande, 68 pp.
CODEN: FR00BL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2851247	A1	20040820	FR 2003-2021	20030219
FR 2851247	B1	20070629		
AU 2004212736	A1	20040902	AU 2004-212736	20040218
CA 2516266	A1	20040902	CA 2004-2516266	20040218
WO 2004073711	A2	20040902	WO 2004-FR366	20040218
WO 2004073711	A3	20050414		
V:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BV, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1594498	A2	20051116	EP 2004-712083	20040218
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006520753	T	20060914	JP 2006-502151	20040218
US 2006241062	A1	20061026	US 2005-541503	20050707
PRIORITY APPLN. INFO.:			FR 2003-2021	A 20030219
			WO 2004-FR366	W 20040218


AB The present invention relates to the field of biol., genetics and medicine. It describes new methods for the detection, characterization and/or treatment of neurodegenerative diseases. The invention also includes methods for screening compds. involved in those pathologies. The invention further involved compds., genes, cells, plasmids or compns. to be used in the aforementioned methods. The invention particularly involves the characterization of the roles mediated by phosphodiesterase 4B and the peripheral benzodiazepine receptor in degenerative diseases, and described their use as therapeutic, diagnostic or exptl. targets and markers for these disorders.

IT 383911-73-7 741680-79-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for treatment of ocular degenerative diseases with phosphodiesterase 4B inhibitors binding to the benzodiazepine receptor)
RN 383911-73-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(phenylamino)-, ethyl ester (CA INDEX NAME)

L4 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



RN 741680-79-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclobutylamino)-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN
ACCESSION NUMBER: 2004:550957 CAPLUS
DOCUMENT NUMBER: 141:106464
TITLE: Preparation of pyrazolo[3,4-b]pyridine derivatives for use in pharmaceutical compositions as phosphodiesterase inhibitors
INVENTOR(S): Allen, David George; Coe, Diane Mary; Cook, Caroline Mary; Cooper, Anthony William James; Dowle, Michael Dennis; Edlin, Christopher David; Hamblin, Julie Nicole; Johnson, Martin Redpath; Jones, Paul Spencer; Lindvall, Mika Kristian; Mitchell, Charlotte Jane; Redgrave, Alison Judith
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 244 pp.
CODEN: P1XXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056823	A1	20040708	WO 2003-EP14867	20031219
V:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2511340	A1	20040708	CA 2003-251340	20031219
AU 2003293999	A1	20040714	AU 2003-293999	20031219
EP 1581532	A1	20051005	EP 2003-789413	20031219
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003017645	A	20051206	BR 2003-17645	20031219
JP 1751042	A	20060322	CN 2003-80109835	20031219
CN 2006513258	T	20060420	JP 2005-502565	20031219
AU 2004299277	A1	20050630	AU 2004-299277	20041217
CA 2557004	A1	20050630	CA 2004-2557004	20041217
WO 2005058892	A1	20050630	WO 2004-EP14490	20041217
V:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BV, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1737857	CH	20070103	EP 2004-804089	20041217
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HU, LV			
CN 1914205	A	20070214	CN 2004-80041657	20041217
JP 2007514704	T	20070607	JP 2006-544380	20041217
IN 2005KN01207	A	20070713	IN 2005-KN1207	20050622

L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MX 2005PA06923	A	20050818	MX 2005-PA6923	20050623
NO 200503600	A	20050822	NO 2005-3600	20050722
US 2006252790	A1	20061109	US 2006-540371	20060221
US 2007111995	A1	20070517	US 2006-596561	20060616
IN 2006KN01988	A	20070518	IN 2006-KN1988	20060714
NO 2006003340	A	20060912	NO 2006-3340	20060718
PRIORITY APPLN. INFO.:			GB 2002-30045	A 20021223
			GB 2002-30165	A 20021224
			GB 2003-7998	A 20030407
			WO 2003-EP14867	W 20031219
			WO 2003-EP314867	A 20031219
			GB 2004-5899	A 20040316
			GB 2004-5936	A 20040316
			GB 2004-6754	A 20040325
			WO 2004-EP14490	W 20041217


OTHER SOURCE(S): MARPAT 141:106464
GI



AB Pyrazolo[3,4-b]pyridine derivs., such as I [R = heterocyclyl; R1 = (CH2)2OH, alkyl, fluoroalkyl; R2 = H, Me, fluoroalkyl; R3 = alkyl, (un)substituted-Ph, cycloalkyl, heterocyclyl, etc.; R3a = H, alkyl], were prepared for therapeutic uses as inhibitors of phosphodiesterase, particularly phosphodiesterase IV (PDE4). These pyrazolo[3,4-b]pyridines were claimed for use in the treatment and/or prophylaxis of cognitive impairment and inflammatory and/or allergic diseases, such as chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis. Thus, pyrazolo[3,4-b]pyridine derivative II was prepared via a cyclocondensation reaction of hydrazide III using POCl3 in MeCN. The prepared pyrazolo[3,4-b]pyridine were assayed for PDE4 inhibitory activity, and systems for delivery of these PDE4 inhibitors were discussed.


IT 675112-01-3P, Ethyl 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-03-5P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-33-1P, 1-Propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-38-6P, 1-Ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-

L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-92-2P, Ethyl
 4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
 675112-96-6P, Ethyl 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-1H-
 pyrazolo[3,4-b]pyridine-5-carboxylate 675113-15-2P,
 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675114-51-9P, Ethyl 1-propyl-4-[(tetrahydro-2H-pyran-
 4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675114-55-3P
 . Ethyl 1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxylate 675114-78-0P,
 1-Ethyl-N-(2-hydroxy-1-methylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675114-79-1P, Methyl
 (2S)-2-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-
 b]pyridin-5-yl]carbonyl]amino]-3-hydroxypropanoate 720705-32-8P
 720705-33-9P 720705-34-0P 720705-35-1P
 720705-36-2P 720705-37-3P 720705-42-0P
 720705-43-1P 720705-44-2P 720705-45-3P
 720705-46-4P 720705-47-5P 720705-48-6P
 720705-49-7P 720705-50-0P 720705-51-1P
 720705-52-2P 720705-53-3P 720705-57-7P
 720705-58-8P 720705-59-9P 720705-60-2P
 720705-61-3P 720705-62-4P 720705-63-5P
 720705-64-6P 720705-65-7P 720705-66-8P
 720705-67-9P 720705-68-0P 720705-69-1P
 720705-70-4P 720705-71-5P 720705-72-6P
 720705-73-7P 720705-74-8P 720705-75-9P
 720705-78-2P 720705-79-3P 720705-80-6P
 720705-81-7P 720705-82-8P 720705-83-9P
 720705-84-0P 720705-85-1P 720705-86-2P
 720705-87-3P 720705-88-4P 720705-89-5P
 720705-90-8P 720705-91-9P 720705-92-0P
 720705-93-1P 720705-94-2P 720705-95-3P
 720705-96-4P 720705-97-5P 720705-98-6P
 720705-99-7P 720706-00-3P 720706-01-4P
 720706-02-5P 720706-03-6P 720706-04-7P
 720706-19-4P
 RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of pyrazolo[3,4-b]pyridine derivs. for use in pharmaceutical
 compns. as phosphodiesterase inhibitors)
 RN 675112-01-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-
 pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)




RN 675112-03-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-
 pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)


L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 675112-96-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(1-acetyl-4-
 piperidinyl)amino]-1-ethyl-, ethyl ester (CA INDEX NAME)




RN 675113-15-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-
 4-yl)amino]- (CA INDEX NAME)




RN 675114-51-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-propyl-4-[(tetrahydro-2H-
 pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)


L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 pyran-4-yl)amino]- (CA INDEX NAME)



RN 675112-33-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-propyl-4-[(tetrahydro-2H-
 pyran-4-yl)amino]- (CA INDEX NAME)




RN 675112-38-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-6-methyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675112-92-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopentylamino)-1-ethyl-
 , ethyl ester (CA INDEX NAME)


L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 675114-55-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-6-methyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)




RN 675114-78-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-hydroxy-1-
 methylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-79-1 CAPLUS
 CN L-Serine, N-[(1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-
 b]pyridin-5-yl)carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.




RN 720705-32-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopentylamino)-1-ethyl- (CA INDEX NAME)




RN 720705-33-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopentylamino)-1-ethyl-, 2-acetylhydrazide (CA INDEX NAME)




RN 720705-34-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopentylamino)-1-ethyl-, 2-[(methylsulfonyl)acetyl]hydrazide (9CI) (CA INDEX NAME)



RN 720705-42-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(1,1-dimethylethoxy)carbonyl]hydrazide (CA INDEX NAME)




RN 720705-43-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, hydrazide, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


RN 720705-44-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-(cyclopropylcarbonyl)hydrazide (CA INDEX NAME)




RN 720705-35-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(4-fluorophenyl)amino]-, ethyl ester (CA INDEX NAME)




RN 720705-36-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopentylamino)-1-ethyl-, 1-methylhydrazide (CA INDEX NAME)



RN 720705-37-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopentylamino)-1-ethyl-, 2-(2-methyl-1-oxopropyl)hydrazide (CA INDEX NAME)




RN 720705-45-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-acetylhydrazide (CA INDEX NAME)




RN 720705-46-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-2-hydroxy-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720705-47-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-2-hydroxy-1-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720705-48-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S)-1-((hydroxymethyl)-2-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720705-49-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1R)-1-((hydroxymethyl)-2-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720705-50-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1S,2R)-2-hydroxy-1-phenylpropyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 720705-57-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(2,2-dimethyl-1-oxopropyl)hydrazide] (CA INDEX NAME)



RN 720705-58-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(1,1-dimethylethoxy)carbonyl]hydrazide (CA INDEX NAME)




RN 720705-59-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, hydrazide, monohydrochloride (9CI) (CA INDEX NAME)




RN 720705-51-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2R)-2-hydroxy-2-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720705-52-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2S)-2-hydroxy-2-phenylethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 720705-53-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-hydroxy-1,1-dimethylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




● HCl

RN 720705-60-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(tetrahydro-2H-pyran-4-yl)carbonyl]hydrazide (CA INDEX NAME)




RN 720705-61-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-(cyclobutylcarbonyl)hydrazide (CA INDEX NAME)




RN 720705-62-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-


L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
pyran-4-yl)amino]-, 2-[(5-oxo-2-pyrrolidinyl)carbonyl]hydrazide (CA INDEX NAME)



RN 720705-63-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(acetylmino)acetyl]hydrazide (9CI) (CA INDEX NAME)




RN 720705-64-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(1-methyl-2-piperidinyl)carbonyl]hydrazide (CA INDEX NAME)




RN 720705-65-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-


L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
pyran-4-yl)amino]-, 2-[(2-oxo-4-thiazolidinyl)carbonyl]hydrazide (CA INDEX NAME)



RN 720705-69-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(2,2-dimethylcyclopropyl)carbonyl]hydrazide (CA INDEX NAME)




RN 720705-70-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(acetylmino)acetyl]hydrazide (9CI) (CA INDEX NAME)




RN 720705-71-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-


L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
pyran-4-yl)amino]-, 2-[(4-methyl-1,2,5-oxadiazol-3-yl)acetyl]hydrazide (9CI) (CA INDEX NAME)



RN 720705-66-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(3-oxocyclopentyl)carbonyl]hydrazide (CA INDEX NAME)




RN 720705-67-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(tetrahydro-3-furanyl)carbonyl]hydrazide (CA INDEX NAME)




RN 720705-68-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-


L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
pyran-4-yl)amino]-, 2-[(tetrahydro-2H-pyran-4-yl)acetyl]hydrazide (9CI) (CA INDEX NAME)



RN 720705-72-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(1-methylcyclobutyl)carbonyl]hydrazide (CA INDEX NAME)




RN 720705-73-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(3-methyl-5-isoxazolyl)carbonyl]hydrazide (CA INDEX NAME)




RN 720705-74-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-


L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 pyran-4-yl)amino]-, 2-[(1-methyl-1H-pyrazol-5-yl)carbonyl]hydrazide (CA
 INDEX NAME)



RN 720705-75-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(1-acetyl-4-piperidinyl)carbonyl]hydrazide (CA
 INDEX NAME)




RN 720705-78-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, [bis(dimethylamino)methylene]hydrazide (9CI) (CA
 INDEX NAME)




RN 720705-79-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-


L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 pyran-4-yl)amino]-, 2-[(1H-1,2,3-triazol-1-ylacetyl)hydrazide (9CI) (CA
 INDEX NAME)



RN 720705-80-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(2,4-dimethyl-5-thiazolyl)acetyl]hydrazide (9CI)
 (CA INDEX NAME)




RN 720705-81-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(2-furanylacetyl)hydrazide (9CI) (CA INDEX NAME)




RN 720705-82-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(3-isoxazolylacetyl)hydrazide (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 720705-83-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(4-methoxyphenyl)acetyl]hydrazide (9CI) (CA INDEX
 NAME)




RN 720705-84-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(1H-tetrazol-1-ylacetyl)hydrazide (9CI) (CA INDEX
 NAME)




RN 720705-85-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(5-isothiazolylacetyl)hydrazide (9CI) (CA INDEX
 NAME)


L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 720705-86-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(3-methyl-5-isoxazolyl)acetyl]hydrazide (9CI) (CA
 INDEX NAME)




RN 720705-87-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[[4-(dimethylamino)phenyl]acetyl]hydrazide (9CI)
 (CA INDEX NAME)




RN 720705-88-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(2-methyl-4-thiazolyl)acetyl]hydrazide (9CI) (CA
 INDEX NAME)




RN 720705-89-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[[1-[(2-methylamino)-2-oxoethyl]cyclopentyl]acetyl]hydrazide (9CI) (CA INDEX NAME)




RN 720705-90-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(cyclopropylcarbonyl)amino]acetylhydrazide (9CI) (CA INDEX NAME)




RN 720705-91-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(5-methyl-3-isoxazolyl)carbonyl]hydrazide (CA INDEX NAME)




RN 720705-95-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(5-methyl-1H-1,2,4-triazol-3-yl)acetyl]hydrazide (9CI) (CA INDEX NAME)




RN 720705-96-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(3,5-dimethyl-4-isoxazolyl)acetyl]hydrazide (9CI) (CA INDEX NAME)




RN 720705-97-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(2-acetyl-1-oxopropyl)hydrazide (CA INDEX NAME)




RN 720705-92-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(5-methyl-3-isoxazolyl)acetyl]hydrazide (9CI) (CA INDEX NAME)




RN 720705-93-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(3-(4-methyl-5-thiazolyl)-1-oxopropyl)hydrazide (CA INDEX NAME)




RN 720705-94-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(6-oxo-2-piperidinyl)carbonyl]hydrazide (CA INDEX NAME)




RN 720705-98-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(1-acetyl-4-piperidinyl)acetyl]hydrazide (9CI) (CA INDEX NAME)




RN 720705-99-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(4-methylphenyl)acetyl]hydrazide (9CI) (CA INDEX NAME)




RN 720706-00-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-(4-methylbenzoyl)hydrazide (CA INDEX NAME)



RN 720706-01-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(2,4-dimethylbenzoyl)hydrazide] (CA INDEX NAME)



RN 720706-02-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(2,4-dimethylbenzoyl)hydrazide] (CA INDEX NAME)




RN 720706-03-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(2,4-dimethylbenzoyl)hydrazide] (9C1) (CA INDEX NAME)

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN


ACCESSION NUMBER: 2004:252512 CAPLUS
DOCUMENT NUMBER: 140:287376
TITLE: Preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase inhibitors for treatment of COPD, asthma, or allergic rhinitis
INVENTOR(S): Allen, David George; Coe, Diane Mary; Cook, Caroline Mary; Dowle, Michael Dennis; Edlin, Christopher David; Hamblin, Julie Nicolas; Johnson, Martin Redpath; Jones, Paul Spencer; Knowles, Richard Graham; Lindvall, Mika Kristian; Mitchell, Charlotte Jane; Redgrave, Alison Judith; Trivedi, Naimisha; Ward, Peter
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024728	A2	20040325	WO 2003-EP11814	20030912
WO 2004024728	A3	20041021		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RV: GB, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2497550	A1	20040325	CA 2003-2497550	20030912
AU 2003285300	A1	20040430	AU 2003-285300	20030912
EP 1539753	A2	20050615	EP 2003-778283	20030912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014392	A	20050712	BR 2003-14392	20030912
CN 1694882	A	20051109	CN 2003-825043	20030912
JP 2006503108	T	20060126	JP 2004-571743	20030912
NZ 538515	A	20070427	NZ 2003-538515	20030912
NO 2005008841	A	20050615	NO 2005-841	20050216
MX 2005PA02887	A	20050527	MX 2005-PA2887	20050315
IN 2005KN00473	A	20060609	IN 2005-KN473	20050321
US 2006089375	A1	20060427	US 2005-527866	20050927
PRIORITY APPL. INFO.:				
			GB 2002-21455	A 20020916
			GB 2002-30045	A 20021223
			GB 2003-6595	A 20030321
			GB 2003-8017	A 20030407
			GB 2003-19708	A 20030821
			GB 2003-21074	A 20030909
			WO 2003-EP11814	W 20030912
			WO 2003-GB11814	W 20030912


OTHER SOURCE(S): MARPAT 140:287376
GI



RN 720706-04-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, 2-[(4-bromophenyl)acetyl]hydrazide (9C1) (CA INDEX NAME)




RN 720706-19-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(tetrahydro-4-(hydroxymethyl)-2H-pyran-4-yl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. I [wherein R1 = (fluoro)alkyl, (CH2)2OH, (CH2)2CO2-alkyl; R2 = HMe, fluoroalkyl; R3 = (un)substituted cycloalkyl, cycloalkenyl, or heterocyclyl; R4 = NR5, OR5a; R5 = H, (fluoro)alkyl, (un)substituted cycloalkyl(alkyl), R5 = substituted alkyl, acyl(alkyl), carboxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), alkylsulfonoyl(alkyl), or cyano(alkyl); R5a = (fluoro)alkyl, cycloalkyl(alkyl), substituted Ph; and salts thereof] were prepared as phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. The invention also provides for the use of I or pharmaceutically acceptable salts thereof for the treatment and/or prophylaxis of an inflammatory and/or allergic disease, such as chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis. For example, 4-chloro-1-ethyl-N-[(4-fluorophenyl)1H-pyrazolo[3,4-b]pyridine-5-carboxamide (preparation given) was coupled with 4-aminotetrahydropyran in using TEA to give II. The latter inhibited human recombinant PDE 4B with a pIC50 of 7.9 and suppressed LPS-induced pulmonary neutrophilia in rats with an ED50 in the range of about 0.5 mg/kg to about 2 mg/kg. In the rat pica model of emesis, II exhibited pica response values (ED50 ranging from 4.8 mg/kg to 40 mg/kg) higher than the neutrophilia-inhibition doses and displayed a therapeutic index >2. Thus, II showed anti-inflammatory effects with low emetic side effects.

IT 675112-01-3P, Ethyl 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-05-7P, Ethyl (S)-1-ethyl-4-[(tetrahydrofuran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-07-9P, Ethyl (R)-1-ethyl-4-[(tetrahydrofuran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-09-1P, Ethyl 1-ethyl-4-[(tetrahydro-2H-thiopyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-11-5P, Ethyl 1-ethyl-4-[(tetrahydrothien-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-13-7P, Ethyl 4-(cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-15-9P, Ethyl 4-[(1,1-dioxido-2,3,4,5-tetrahydrothien-3-yl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-17-1P, Ethyl 4-[(1,1-dioxido-2,3,4,5-tetrahydro-2H-thiopyran-4-yl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-94-4P, Ethyl 4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-96-6P, Ethyl 4-[(1-acetyl)piperidin-4-yl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675113-00-5P, N-cyclopentyl-4-(cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-10-7P, 1-Ethyl-N-(pyridin-4-ylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-97-0P, tert-Butyl 4-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]piperidine-1-carboxylate 675114-08-6P, 1-Ethyl-N-(pyridin-3-ylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-51-9P, Ethyl 1-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675114-55-3P, Ethyl 1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675114-56-4P, Ethyl 4-(cyclohexylamino)-1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675114-63-3P, Ethyl 1-ethyl-4-[(4-hydroxycyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675114-64-4P, Ethyl 1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675115-08-9P, 4-[(1R,2R,4S)-Bicyclo[2.2.1]hept-2-yl)amino]-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-13-6P, N-[(2,4-Dimethylphenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-14-7P, N-[(3,4-Dimethylphenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-16-9P, 1-Ethyl-N-[(4-methyloxyphenyl)methyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-18-1P, N-[(4-(Dimethylamino)phenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-19-2P, N-[(4-[(Difluoromethyl)oxy]phenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-20-5P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[(4-(trifluoromethyl)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-75-0P, 1-Ethyl-N-(4-piperidinyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-05-9P, Methyl 3-[(1-ethyl-5-[(phenylmethyl)amino]carbonyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)amino]cyclohexanecarboxylate 675116-08-2P, N-Benzyl-1-ethyl-4-[(1-methoxy)acetyl]-4-piperidinylamino-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-20-1P, Methyl 3-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]benzoate 675117-21-2P, 4-(Cyclohexylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-22-3P, Methyl 4-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]benzoate 675117-72-3P, N-[(3,4-Dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-52-2P, Methyl 3-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]benzoate 675118-90-8P, Methyl 4-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]benzoate 675118-99-7P, 1-Ethyl-N-(2-pyridinylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-55-8P, Ethyl 1-ethyl-4-[(4-(hydroxymino)cyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675119-56-9P, 1-Ethyl-4-[(4-(hydroxymino)cyclohexyl)amino]-N-[(4-(methyloxy)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-68-3P, 675119-81-0P, N-[(3-Chloro-4-methylphenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-82-1P, N-[(4-Chloro-2-methylphenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-90-1P, Ethyl 1-ethyl-4-[(1-methoxy)acetyl]-4-piperidinylamino-1H-pyrazolo[3,4-b]pyridine-5-carboxylate


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(PDE4 inhibitor; prepn. of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic disease)

RN 675112-01-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 675112-11-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-3-thienyl)amino]-, ethyl ester (CA INDEX NAME)



RN 675112-13-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopropylamino)-1-ethyl-, ethyl ester (CA INDEX NAME)



RN 675112-15-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-1,1-dioxido-3-thienyl)amino]-, ethyl ester (CA INDEX NAME)


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 675112-05-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(3S)-tetrahydro-3-furanyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 675112-07-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(3R)-tetrahydro-3-furanyl]amino]-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 675112-09-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-thiopyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 675112-17-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)




RN 675112-94-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclohexylamino)-1-ethyl-, ethyl ester (CA INDEX NAME)




RN 675112-96-6 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-, ethyl ester (CA INDEX NAME)




RN 675113-00-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-cyclopentyl-4-(cyclopentylamino)-1-ethyl- (CA INDEX NAME)




RN 675113-10-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(4-(pyridinylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-97-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 675114-56-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclohexylamino)-1-ethyl-6-methyl-, ethyl ester (CA INDEX NAME)




RN 675114-63-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(4-hydroxycyclohexyl)amino]-, ethyl ester (CA INDEX NAME)




RN 675114-64-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(4-oxocyclohexyl)amino]-, ethyl ester (CA INDEX NAME)




RN 675114-08-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(3-pyridinylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675114-51-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)




RN 675114-55-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)




RN 675115-08-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 675115-13-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-dimethylphenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675115-14-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethylphenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675115-16-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-methoxyphenyl)methyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675115-18-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-(dimethylamino)phenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675115-19-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-(difluoromethoxy)phenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675115-20-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-[(4-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 675115-75-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-4-piperidinyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-05-9 CAPLUS
CN Cyclohexanecarboxylic acid, 3-[[[1-ethyl-5-[(phenylmethyl)amino]carbonyl]-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]-, methyl ester (CA INDEX NAME)




RN 675116-08-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(1-(methoxyacetyl)-4-piperidinyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 675117-20-1 CAPLUS
CN Benzoic acid, 3-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 675117-21-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl- (CA INDEX NAME)




RN 675117-22-3 CAPLUS
CN Benzoic acid, 4-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-




RN 675118-99-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-pyridinylmethyl)-4-
-[[tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675118-52-2 CAPLUS
CN Benzoic acid, 3-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 675119-55-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-, ethyl ester (CA INDEX NAME)




```

RN      675118-90-8  CAPLUS
CN      Benzoic acid, 4-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
        pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, methyl ester (CA
        INDEX NAME)

```




RN 675119-56-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 675119-68-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(1R,3S)-3-hydroxycyclohexylamino]-, ethyl ester, rel- (CA INDEX NAME)


Relative stereochemistry.




RN 675119-81-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 675119-90-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[[1-(methoxyacetyl)-4-piperidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IT 160034-53-7P, Ethyl-4-(cyclopentylamino)-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-92-2P, 1-Ethyl-4-(cyclopentylamino)-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-97-7P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-98-8P, N-Benzyl-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675112-99-9P, 1-Ethyl-N-(4-fluorophenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-01-6P, 4-(Cyclohexylamino)-N-cyclopentyl-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-02-7P, N-Cyclopentyl-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-03-8P, N-Cyclopentyl-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-04-9P, N-Cyclopentyl-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-07-2P, 4-(Cyclopentylamino)-1-ethyl-N-(pyridin-4-ylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-08-3P, 4-(Cyclohexylamino)-1-ethyl-N-(pyridin-4-ylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-12-9P,



RN 675119-02-1 CAPLUS

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
4-(Cyclopentylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-14-1P, 4-(Cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-
b]pyridine-5-carboxamide 675113-15-2P, 1-Ethyl-4-[(tetrahydro-2H-
pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-17-4P, N-Benzyl-4-(cyclopentylamino)-1-ethyl-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675113-19-6P,
N-Benzyl-4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-
carboxamide 675113-21-0P, 4-[(1-Acetyl)piperidin-4-yl]amino)-N-
benzyl-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-22-1P, 4-(Cyclopentylamino)-1-ethyl-N-(2-ethylbutyl)-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675113-24-3P,
4-(Cyclohexylamino)-1-ethyl-N-(2-ethylbutyl)-1H-pyrazolo[3,4-b]pyridine-5-
carboxamide 675113-26-5P, 1-Ethyl-N-(2-ethylbutyl)-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-27-6P, 1-Ethyl-N-(2-ethylbutyl)-4-[(1-methylpiperidin-4-
yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-29-8P,
4-[(1-Acetyl)piperidin-4-yl]amino)-1-ethyl-N-(2-ethylbutyl)-1H-pyrazolo[3,4-
b]pyridine-5-carboxamide 675113-30-1P, 4-(Cyclopentylamino)-1-
ethyl-N-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-31-2P, 4-(Cyclohexylamino)-1-ethyl-N-(4-fluorophenyl)-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675113-32-3P,
1-Ethyl-N-(4-fluorophenyl)-4-[(1-methylpiperidin-4-yl)amino]-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675113-33-4P,
4-[(1-Acetyl)piperidin-4-yl]amino)-1-ethyl-N-(4-fluorophenyl)-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675113-34-5P,
4-(Cyclopentylamino)-1-ethyl-N-propyl-1H-pyrazolo[3,4-b]pyridine-5-
carboxamide 675113-35-6P, 4-(Cyclohexylamino)-1-ethyl-N-propyl-
1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-36-7P,
1-Ethyl-N-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-
b]pyridine-5-carboxamide 675113-37-8P, 4-[(1-Acetyl)piperidin-4-
yl]amino)-1-ethyl-N-propyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-38-9P, 4-[(1-Acetyl)piperidin-4-yl]amino)-1-ethyl-N-
[(pyridin-4-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-39-0P, N-Benzyl-4-(cyclopentylamino)-1-methyl-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675113-40-3P,
N-Benzyl-4-(cyclohexylamino)-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-
carboxamide 675113-41-4P, N-Benzyl-1-methyl-4-[(tetrahydro-2H-
pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-42-5P, 4-(Cyclopentylamino)-N-(2-ethylbutyl)-1-methyl-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675113-43-6P,
4-(Cyclohexylamino)-N-(2-ethylbutyl)-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-
carboxamide 675113-44-7P, N-(2-Ethylbutyl)-1-methyl-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-45-8P, 4-(Cyclopentylamino)-N-(4-fluorophenyl)-1-methyl-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675113-46-9P,
4-(Cyclohexylamino)-N-(4-fluorophenyl)-1-methyl-1H-pyrazolo[3,4-b]pyridine-5-
carboxamide 675113-47-0P, N-(4-Fluorophenyl)-1-methyl-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-48-1P, 4-(Cyclopentylamino)-1-methyl-1H-pyrazolo[3,4-
b]pyridine-5-carboxamide 675113-49-2P, 4-(Cyclohexylamino)-1-
methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-50-3P,
4-[(1-Acetyl)piperidin-4-yl]amino)-N-benzyl-1-methyl-1H-pyrazolo[3,4-
b]pyridine-5-carboxamide 675113-51-6P, 1-Ethyl-N-methyl-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-54-9P, 1-Ethyl-N,N-dimethyl-4-[(tetrahydro-2H-pyran-4-
yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-56-1P,
1-Ethyl-N-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-
b]pyridine-5-carboxamide 675113-58-3P, 1-Ethyl-N-isopropyl-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-59-4P, (S)-N-Benzyl-1-ethyl-4-[(tetrahydrofuran-3-yl)amino]-

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-60-7P,
(R)-N-Benzyl-1-ethyl-4-[(tetrahydrofuran-3-yl)amino]-1H-pyrazolo[3,4-
b]pyridine-5-carboxamide 675113-61-8P, N-Benzyl-1-ethyl-4-
[(tetrahydrothien-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-62-9P, N-Benzyl-4-(cyclopropylamino)-1-ethyl-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675113-63-0P,
N-Benzyl-4-[(1,1-dioxido-2-tetrahydrothien-3-yl)amino]-1-ethyl-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675113-64-1P,
N-Benzyl-4-[(1,1-dioxido-2-tetrahydro-2H-thiopyran-4-yl)amino]-1-ethyl-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675113-65-2P,
N-Benzyl-1-ethyl-4-[(tetrahydro-2H-thiopyran-4-yl)amino]-1H-pyrazolo[3,4-
b]pyridine-5-carboxamide 675113-66-3P, (S)-1-Ethyl-N-(4-
fluorophenyl)-4-[(tetrahydrofuran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
carboxamide 675113-67-4P, (R)-1-Ethyl-N-(4-fluorophenyl)-4-
[(tetrahydrofuran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-68-5P, 1-Ethyl-N-(4-fluorophenyl)-4-[(tetrahydro-2H-
thiopyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-69-6P, 1-Ethyl-N-(4-fluorophenyl)-4-[(tetrahydrothien-3-
yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675113-70-9P,
4-(Cyclopropylamino)-1-ethyl-N-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-
5-carboxamide 675113-71-0P, 4-[(1,1-Dioxido-2-tetrahydrothien-3-
yl)amino]-1-ethyl-N-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-5-
carboxamide 675113-72-1P, 4-[(1,1-Dioxido-2-tetrahydro-2H-thiopyran-4-
yl)amino]-1-ethyl-N-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridine-5-
carboxamide 675113-73-2P, 1-Ethyl-N-(4-methylsulfonyl)benzyl)-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-74-3P, 1-Ethyl-N-[3-(methylsulfonyl)benzyl]-4-[(tetrahydro-
2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-76-5P, N-[(5-Chloropyridin-2-yl)methyl]-1-ethyl-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-77-6P, N-(4-Chlorobenzyl)-1-ethyl-N-isopropyl-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-78-7P, N-(3-Chlorobenzyl)-1-ethyl-N-(2-hydroxyethyl)-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-79-8P, 1-Ethyl-N-[(5-methyl-1-phenylisoxazol-4-yl)methyl]-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-80-1P, N-(2-tert-Butoxyethyl)-1-ethyl-4-[(tetrahydro-2H-
pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-81-2P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(1,3-
thiazol-2-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-82-3P, 1-Ethyl-N-(pyrimidin-4-ylmethyl)-4-[(tetrahydro-2H-
pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-83-4P, 1-Ethyl-N-(2-methyl-1,3-thiazol-4-yl)methyl)-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-84-5P, N-[3-(tert-Butoxymethyl)benzyl]-1-ethyl-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-85-6P, 1-Ethyl-N-[2-(methylsulfonyl)amino]ethyl)-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-86-7P, 1-Ethyl-N-(pyrazin-2-ylmethyl)-4-[(tetrahydro-2H-
pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-88-9P, N-(2-Chloro-6-Fluorobenzyl)-1-ethyl-4-[(tetrahydro-
2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-89-0P, 1-Ethyl-N-[(6-oxo-1,6-dihydro-2H-pyridin-3-yl)methyl]-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-90-3P, N-[3-(Aminocarbonyl)benzyl]-1-ethyl-4-[(tetrahydro-
2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-91-4P, 1-Ethyl-N-[4-[(methylamino)carbonyl]phenyl]-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-92-5P, 1-Ethyl-N-[2-(1-methyl-1H-imidazol-4-yl)ethyl]-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
675113-93-6P, N-[2-[(Anilino)carbonyl]amino]ethyl)-1-ethyl-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-94-7P, 1-Ethyl-N-(1H-tetrazol-5-ylmethyl)-4-[(tetrahydro-2H-
pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide hydrochloride
675113-95-8P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[2-(1H-
1,2,4-triazol-1-yl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-96-9P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[4-
(trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-98-1P, 1-Ethyl-N-[3-[(methylsulfonyl)amino]propyl]-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675113-99-2P, N-[2-(Dimethylamino)benzyl]-1-ethyl-4-[(tetrahydro-
2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-00-8P, 1-Ethyl-N-[(1-ethylpyrrolidin-2-yl)methyl]-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-01-9P, 1-Ethyl-N-(tetrahydrofuran-2-ylmethyl)-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-02-0P, 1-Ethyl-N-(tetrahydro-2H-pyran-4-yl)-4-[(tetrahydro-
2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-03-1P, N-[4-[(Dimethylamino)sulfonyl]benzyl]-1-ethyl-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-04-2P, 1-Ethyl-N-[3-[(methylsulfonyl)amino]benzyl]-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-05-3P, 1-Ethyl-N-(4-methoxyphenyl)-4-[(tetrahydro-2H-pyran-
4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-06-4P,
1-Ethyl-N-[2-(3-oxopropylidene-1-yl)propyl]-4-[(tetrahydro-2H-pyran-4-
yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-07-5P,
1-Ethyl-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-[(tetrahydro-2H-pyran-4-
yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-09-7P,
1-Ethyl-N-(1-methylpiperidin-4-yl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675114-10-0P,
1-Ethyl-N-(1-ethylpropyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675114-11-1P,
1-Ethyl-N-[2-(piperidin-1-yl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675114-12-2P,
1-Ethyl-N-[3-(morpholin-4-yl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-
1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-13-3P,
N-(3-Ethylpropyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675114-14-4P,
N-(Cyclohexylmethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675114-15-5P,
N-[3-(Dimethylamino)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675114-16-6P,
1-Ethyl-N-neopentyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-
b]pyridine-5-carboxamide 675114-17-7P, 1-Ethyl-N-4-
methoxybenzyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-
b]pyridine-5-carboxamide 675114-18-8P, 1-Ethyl-N-[2-
(phenylsulfonyl)amino]ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675114-19-9P,
N-[2-(Acetylaminomethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675114-20-2P,
1-Ethyl-N-[2-(methylsulfonyl)amino]ethyl)-4-[(tetrahydro-2H-pyran-4-
yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-21-3P,
1-Ethyl-N-[2-[(2-methoxyphenyl)methyl]amino]ethyl)-4-[(tetrahydro-2H-
pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-22-4P, 1-Ethyl-N-(2-oxo-2-phenylethyl)-4-[(tetrahydro-2H-
pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-23-5P, N-(2,5-Difluorobenzyl)-1-ethyl-4-[(tetrahydro-2H-
pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-24-6P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[4-
(trifluoromethyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
675114-25-7P, N-Benzyl-1-ethyl-N-propyl-4-[(tetrahydro-2H-pyran-4-
yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-26-8P,
N-Cyclopropyl-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-
b]pyridine-5-carboxamide 675114-27-9P, N-(2-Amino-2-oxoethyl)-1-
ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
carboxamide 675114-28-0P, 1-Ethyl-N-(3-methoxyphenyl)-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-29-1P, N-(3,4-Difluorobenzyl)-1-ethyl-4-[(tetrahydro-2H-
pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-30-2P, 1-Ethyl-4-[(1-ethyl-4-[(tetrahydro-2H-pyran-4-
yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-yl)carbonyl]amino]propanoate
675114-31-5P, N-(1-Benzylpiperidin-4-yl)-1-ethyl-4-[(tetrahydro-2H-
pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-33-7P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-(1,3,4-
thiadiazol-2-yl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-34-8P, N-(2,3-Dihydro-1H-inden-2-yl)-1-ethyl-4-[(tetrahydro-
2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-35-9P, 1-Ethyl-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-4-
[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-36-0P, N-(3,4-Dimethoxybenzyl)-1-ethyl-4-[(tetrahydro-2H-
pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-37-1P, N-(3-Chlorobenzyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-
yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-39-3P,
1-Ethyl-N-(2-hydroxyethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675114-41-7P,
N-[3-(Dimethylamino)-3-oxopropyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-
yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-42-8P,
1-Ethyl-N-[(1-methyl-1H-imidazol-5-yl)methyl]-4-[(tetrahydro-2H-pyran-4-
yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-43-9P,
1-Ethyl-N-4-[(methylamino)sulfonyl]phenyl)-4-[(tetrahydro-2H-pyran-4-
yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-44-0P,
N-(2-Cyanoethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675114-45-1P,
1-Ethyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-[(tetrahydro-2H-pyran-4-
yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-46-2P,
1-Ethyl-N-methyl-N-[(1-methyl-1H-imidazol-2-yl)methyl]-4-[(tetrahydro-2H-
pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-47-3P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[2-
(thien-2-yl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-48-4P, N-[2-(4-Chlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-
2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-49-5P, 1-Ethyl-N-[2-(2-methoxyphenyl)ethyl]-4-[(tetrahydro-
2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-50-6P, 1-Ethyl-4-(cyclohexylamino)-1-(3-thioxy-3-oxopropyl)-
1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675114-52-0P, 1-Ethyl-
1-(2-hydroxyethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-
b]pyridine-5-carboxylate 675114-53-1P, N-[4-
(Methylsulfonyl)benzyl]-1-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675114-54-2P,
N-(4-Fluorophenyl)-1-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675114-57-5P,
4-(Cyclohexylamino)-1-ethyl-6-methyl-N-[4-(methylsulfonyl)benzyl]-1H-
pyrazolo[3,4-b]pyridine-5-carboxamide 675114-58-6P,
N-Benzyl-4-(cyclohexylamino)-1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridine-5-
carboxamide 675114-59-7P, 4-(Cyclohexylamino)-1-ethyl-N-(4-
fluorophenyl)-6-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-60-0P, 4-(Cyclohexylamino)-1-ethyl-6-methyl-N-[4-
(trifluoromethyl)benzyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
675114-61-1P, 4-(Cyclohexylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-
ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 675114-62-2P, N-Benzyl-1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-65-5P, Ethyl 4-[(4-aminocyclohexyl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675114-66-6P, 1-Ethyl-N-[(1-oxido-3-pyridinyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-67-7P, 1-Ethyl-N-[(1-oxido-2-pyridinyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-68-8P, 1-Ethyl-N-[(1-oxido-4-pyridinyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-69-9P, 4-[(cis-4-Aminocyclohexyl)amino]-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-70-2P, 4-(Cyclobutylamino)-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-71-3P, 4-(Cycloheptylamino)-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-72-4P, 1-Ethyl-4-[(4-methylcyclohexyl)amino]-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-73-5P, N-Benzyl-1-ethyl-4-[(2-oxazepan-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-74-6P, N-Benzyl-1-ethyl-4-[(3-hydroxycyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-75-7P, N-Benzyl-1-ethyl-4-[(4-hydroxycyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-76-8P, N-Benzyl-1-ethyl-4-[(3-hydroxycyclopentyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-77-9P, N-Benzyl-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-78-0P, 1-Ethyl-N-(2-hydroxy-1-methylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-79-1P, Methyl (2S)-2-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-3-hydroxypropanoate 675114-80-4P, 1-Ethyl-4-[(3-methylcyclohexyl)amino]-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-81-5P, 1-Ethyl-4-[(1-methylcyclohexyl)amino]-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-82-6P, 4-[(1R,2R,4S)-Bicyclo[2.2.1]hept-2-yl)amino]-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-83-7P, 4-[(1R,2R,4S)-Bicyclo[2.2.1]hept-2-yl)amino]-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-84-8P, (S)-1-Ethyl-4-[(2-oxo-3-pyrrolidinyl)amino]-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-85-9P, 4-[(2,5-Dioxo-3-pyrrolidinyl)amino]-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-86-0P, 4-(1-Azabicyclo[2.2.2]oct-3-ylamino)-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-87-1P, 1-Ethyl-4-[(1-methylcyclohexyl)amino]-N-[(4-methyloxy)phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-88-2P, 4-(Cyclobutylamino)-1-ethyl-N-[(4-methyloxy)phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-89-3P, 4-(Cycloheptylamino)-1-ethyl-N-[(4-methyloxy)phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-90-6P, 4-[(1R,2R,4S)-Bicyclo[2.2.1]hept-2-yl)amino]-1-ethyl-N-[(4-methyloxy)phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-91-7P, 1-Ethyl-4-[(4-methylcyclohexyl)amino]-N-[(4-methyloxy)phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-92-8P, 1-Ethyl-4-[(3-methylcyclohexyl)amino]-N-[(4-methyloxy)phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-93-9P, 4-[(1R,2R,4S)-Bicyclo[2.2.1]hept-2-yl)amino]-1-ethyl-N-[(4-methyloxy)phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-94-0P, 4-[(cis-4-Aminocyclohexyl)amino]-1-ethyl-N-[(4-methyloxy)phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-95-1P, 4-(Cycloheptylamino)-1-ethyl-N-[(4-methylsulfonyl)amino]phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 carboxamide 675114-96-2P, 4-(Cyclobutylamino)-1-ethyl-N-[(4-methylsulfonyl)amino]phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-97-3P, 4-[(1R,2R,4S)-Bicyclo[2.2.1]hept-2-yl)amino]-1-ethyl-N-[(4-methylsulfonyl)amino]phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-98-4P, 4-[(1R,2S,4S)-Bicyclo[2.2.1]hept-2-yl)amino]-1-ethyl-N-[(4-methylsulfonyl)amino]phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675114-99-5P, 1-Ethyl-4-[(4-methylcyclohexyl)amino]-N-[(4-methylsulfonyl)amino]phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-00-1P, 1-Ethyl-4-[(3-methylcyclohexyl)amino]-N-[(4-methylsulfonyl)amino]phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-01-2P, 1-Ethyl-4-[(1-methylcyclohexyl)amino]-N-[(4-methylsulfonyl)amino]phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-02-3P, 4-[(cis-4-Aminocyclohexyl)amino]-1-ethyl-N-[(4-methylsulfonyl)amino]phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-03-4P, 4-(Cycloheptylamino)-1-ethyl-N-[(4-methylsulfonyl)amino]phenyl]methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-04-5P, 4-(Cycloheptylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-05-6P, 4-(Cyclobutylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-06-7P, N-(2,3-Dihydro-1H-inden-2-yl)-1-ethyl-4-[(3-methylcyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-07-8P, N-(2,3-Dihydro-1H-inden-2-yl)-1-ethyl-4-[(4-methylcyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-09-0P, 4-[(1R,2S,4S)-Bicyclo[2.2.1]hept-2-yl)amino]-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-10-3P, N-(2,3-Dihydro-1H-inden-2-yl)-1-ethyl-4-[(1-methylcyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-11-4P, 4-[(cis-4-Aminocyclohexyl)amino]-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-12-5P, 1-Ethyl-N-[(4-methylsulfonyl)amino]phenyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-15-8P, N-[(3,4-Dichlorophenyl)methyl]-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-17-0P, 1-Ethyl-N-[(4-methylsulfonyl)amino]phenyl]methyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-21-6P, 1-Ethyl-N-[(4-methylsulfonyl)amino]phenyl]methyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-22-7P, 1-Ethyl-N-(4-fluorophenyl)-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-24-9P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[(2-pyridinyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-25-0P, N-(2,3-Dihydro-1H-inden-2-yl)-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-26-1P, N-(1-Acetyl-4-piperidinyl)-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-27-2P, 1-Ethyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-28-3P, N-Ethyl-1-ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-29-4P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-N-[(1,3-thiazol-2-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-30-7P, 1-Ethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-31-8P, N-[(4-[(Di fluoromethyl)oxy]phenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-32-9P, 1-Ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]-N-[(4-(trifluoromethyl)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-33-0P, 1-Ethyl-N-[(4-methylsulfonyl)amino]phenyl]methyl-4-

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 [(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-34-1P, 1-Ethyl-N-[(4-methylsulfonyl)amino]phenyl]-4-[(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-35-2P, 1-Ethyl-N-(4-fluorophenyl)-4-[(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-37-4P, 1-Ethyl-N-(2-pyridinylmethyl)-4-[(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide trifluoroacetate 675115-38-5P, N-(2,3-Dihydro-1H-inden-2-yl)-1-ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-39-6P, N-(1-Acetyl-4-piperidinyl)-1-ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-40-9P, 1-Ethyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-[(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREF (Preparation); USES (Uses)
 (PDE4 inhibitor: prepn. of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic disease)
 RN 160034-53-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopentylamino)-1-ethyl-, ethyl ester (CA INDEX NAME)




RN 675112-92-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 675112-98-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675112-99-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(4-fluorophenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-01-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-cyclopentyl-1-ethyl- (CA INDEX NAME)




RN 675113-02-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-cyclopentyl-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-03-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-cyclopentyl-1-ethyl- (CA INDEX NAME)




RN 675113-07-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopentylamino)-1-ethyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 675113-15-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-17-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopentylamino)-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675113-19-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675113-08-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 675113-12-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopentylamino)-1-ethyl- (CA INDEX NAME)




RN 675113-14-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 675113-21-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675113-22-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopentylamino)-1-ethyl-N-(2-ethylbutyl)- (CA INDEX NAME)




RN 675113-24-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(2-ethylbutyl)- (CA INDEX NAME)




RN 675113-26-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-ethylbutyl)-4-((tetrahydro-2H-pyran-4-yl)amino)- (CA INDEX NAME)




RN 675113-27-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-ethylbutyl)-4-((1-methyl-4-piperidinyl)amino)- (CA INDEX NAME)




RN 675113-29-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-((1-acetyl-4-piperidinyl)amino)-1-ethyl-N-(2-ethylbutyl)- (CA INDEX NAME)




RN 675113-33-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-((1-acetyl-4-piperidinyl)amino)-1-ethyl-N-(4-fluorophenyl)- (CA INDEX NAME)




RN 675113-34-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopentylamino)-1-ethyl-N-propyl- (CA INDEX NAME)




RN 675113-35-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-propyl- (CA INDEX NAME)




RN 675113-30-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopentylamino)-1-ethyl-N-(4-fluorophenyl)- (CA INDEX NAME)




RN 675113-31-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(4-fluorophenyl)- (CA INDEX NAME)




RN 675113-32-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(4-fluorophenyl)-4-((1-methyl-4-piperidinyl)amino)- (CA INDEX NAME)




RN 675113-36-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-propyl-4-((tetrahydro-2H-pyran-4-yl)amino)- (CA INDEX NAME)




RN 675113-37-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-((1-acetyl-4-piperidinyl)amino)-1-ethyl-N-propyl- (CA INDEX NAME)




RN 675113-38-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-((1-acetyl-4-piperidinyl)amino)-1-ethyl-N-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 675113-39-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopentylamino)-1-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675113-40-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675113-41-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-methyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-45-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopentylamino)-N-(4-fluorophenyl)-1-methyl- (CA INDEX NAME)




RN 675113-46-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-(4-fluorophenyl)-1-methyl- (CA INDEX NAME)




RN 675113-47-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(4-fluorophenyl)-1-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-42-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopentylamino)-N-(2-ethylbutyl)-1-methyl- (CA INDEX NAME)




RN 675113-43-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-(2-ethylbutyl)-1-methyl- (CA INDEX NAME)




RN 675113-44-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2-ethylbutyl)-1-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-48-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopentylamino)-1-methyl-N-(4-fluorophenyl)- (CA INDEX NAME)




RN 675113-49-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-methyl-N-(4-fluorophenyl)- (CA INDEX NAME)




RN 675113-50-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-1-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675113-51-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-54-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N,N-dimethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-56-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N,1-diethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-61-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-3-thienyl)amino]- (CA INDEX NAME)




RN 675113-62-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopropylamino)-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)



RN 675113-63-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-1,1-dioxido-3-thienyl)amino]- (CA INDEX NAME)




RN 675113-58-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(1-methylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-59-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[(3S)-tetrahydro-3-furanyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 675113-60-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[(3R)-tetrahydro-3-furanyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 675113-64-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]- (CA INDEX NAME)



RN 675113-65-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-thiopyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-66-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(4-fluorophenyl)-4-[(3S)-tetrahydro-3-furanyl]amino]- (CA INDEX NAME)




RN 675113-67-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-((4-fluorophenyl)-4-
[[(3R)-tetrahydro-3-furanyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.




RN 675113-68-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-((4-fluorophenyl)-4-
[[(tetrahydro-2H-thiopyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-69-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-((4-fluorophenyl)-4-
[[(tetrahydro-3-thienyl)amino]- (CA INDEX NAME)




RN 675113-73-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-
(methylsulfonyl)phenyl]methyl]-4-[[(tetrahydro-2H-pyran-4-yl)amino]- (CA
INDEX NAME)




RN 675113-74-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[3-
(methylsulfonyl)phenyl]methyl]-4-[[(tetrahydro-2H-pyran-4-yl)amino]- (CA
INDEX NAME)




RN 675113-76-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[(5-chloro-2-pyridinyl)methyl]-
1-ethyl-4-[[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-70-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclopropylamino)-1-ethyl-N-
(4-fluorophenyl)- (CA INDEX NAME)




RN 675113-71-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-((4-fluorophenyl)-4-
[[(tetrahydro-1,1-dioxido-3-thienyl)amino]- (CA INDEX NAME)




RN 675113-72-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-((4-fluorophenyl)-4-
[[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-77-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[(4-chlorophenyl)methyl]-1-
ethyl-N-((1-methylethyl)-4-[[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX
NAME)




RN 675113-78-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[(3-chlorophenyl)methyl]-1-
ethyl-N-((2-hydroxyethyl)-4-[[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX
NAME)




RN 675113-79-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[(5-methyl-3-phenyl-4-
isoxazolyl)methyl]-4-[[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-80-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-[(1,1-dimethylethoxy)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-81-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-(2-thiazolylmethyl)- (CA INDEX NAME)




RN 675113-82-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(4-pyrimidinylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-86-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(pyrazinylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)




RN 675113-88-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-chloro-6-fluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-89-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-83-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2-methyl-4-thiazolyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-84-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-[(1,1-dimethylethoxy)methyl]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-85-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[2-(methyl(methylsulfonyl)amino)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-90-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-(aminocarbonyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-91-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[4-[(methylamino)carbonyl]phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-92-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[2-(1-methyl-1H-imidazol-4-yl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675113-93-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[2-[[phenylamino]carbonyl]amino]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-94-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-(1H-tetrazol-5-ylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 675113-95-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-(1H-tetrazol-5-ylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 675114-00-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-ethyl-2-pyrrolidindyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-01-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(tetrahydro-2-furanyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-02-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(tetrahydro-2H-pyran-4-yl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-96-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 675113-98-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[3-[(methylsulfonyl)amino]propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675113-99-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[2-(dimethylamino)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-03-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-[(dimethylamino)sulfonyl]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-04-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[3-[(methylsulfonyl)amino]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-05-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-methoxyphenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-06-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-07-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-09-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-methyl-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-13-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(3-ethoxypropyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-14-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(cyclohexylmethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-15-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[3-(dimethylamino)propyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-10-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-ethylpropyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-11-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[2-(1-piperidinyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-12-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[3-(4-morpholinyl)propyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-16-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,2-dimethylpropyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675114-17-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[4-(4-methoxyphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-18-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[2-[(phenylsulfonyl)amino]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-19-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(acetylamino)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-20-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[2-[(methylsulfonyl)amino]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-21-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[2-[(2-methoxyphenyl)methylamino]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-25-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N,1-diethyl-N-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-26-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-cyclopropyl-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-27-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2-amino-2-oxoethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-22-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-oxo-2-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-23-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,5-difluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-24-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(4-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 675114-28-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(3-methoxyphenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-29-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-difluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-30-4 CAPLUS


CN β-Alanine, N-[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]-, ethyl ester (CA INDEX NAME)




RN 675114-31-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-([1-(phenylmethyl)-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]) - (CA INDEX NAME)




RN 675114-33-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-1,3,4-thiadiazol-2-yl - (CA INDEX NAME)




RN 675114-34-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino] - (CA INDEX NAME)




RN 675114-39-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-hydroxyethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino] - (CA INDEX NAME)




RN 675114-41-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[3-(dimethylamino)-3-oxopropyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino] - (CA INDEX NAME)




RN 675114-42-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-methyl-1H-imidazol-5-yl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino] - (CA INDEX NAME)




RN 675114-35-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[2-(2-oxo-1-imidazolidinyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino] - (CA INDEX NAME)




RN 675114-36-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethoxyphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino] - (CA INDEX NAME)




RN 675114-37-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3-chlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino] - (CA INDEX NAME)




RN 675114-43-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[4-(methylamino)sulfonyl]phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino] - (CA INDEX NAME)




RN 675114-44-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2-cyanoethyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino] - (CA INDEX NAME)




RN 675114-45-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino] - (CA INDEX NAME)




RN 675114-46-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-methyl-N-[(1-methyl-1H-imidazol-2-yl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-47-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[2-(2-thienyl)ethyl]- (CA INDEX NAME)




RN 675114-48-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(4-chlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-53-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(methylsulfonyl)phenyl]methyl]-1-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-54-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(4-fluorophenyl)-1-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-57-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-6-methyl-N-[[4-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 675114-49-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[2-(2-methoxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-50-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclohexylamino)-5-(ethoxycarbonyl)-, ethyl ester (CA INDEX NAME)




RN 675114-52-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-hydroxyethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)




RN 675114-58-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-6-methyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-59-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(4-fluorophenyl)-6-methyl- (CA INDEX NAME)




RN 675114-60-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-6-methyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 675114-61-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-((cyclohexylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-6-methyl- (CA INDEX NAME)



RN 675114-62-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-6-methyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-65-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(4-aminocyclohexyl)amino]-1-ethyl-, ethyl ester (CA INDEX NAME)




RN 675114-69-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(cis-4-aminocyclohexyl)amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)


Relative stereochemistry.




RN 675114-70-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclobutylamino)-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-71-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cycloheptylamino)-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-66-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-oxido-3-pyridinyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-67-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-oxido-2-pyridinyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-68-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-oxido-4-pyridinyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-72-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-methylcyclohexyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-73-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(hexahydro-2-oxo-1H-azepin-3-yl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-74-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(3-hydroxycyclohexyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-75-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-hydroxycyclohexyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-76-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(3-hydroxycyclopentyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)



RN 675114-77-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-oxocyclohexyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-81-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(1-methylcyclohexyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-82-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 675114-83-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1R,2S,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 675114-78-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-hydroxy-1-methylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675114-79-1 CAPLUS
CN L-Serine, N-[(1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl)carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 675114-80-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(3-methylcyclohexyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-84-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(3S)-2-oxo-3-pyrrolidinylamino]-N-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 675114-85-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(2,5-dioxo-3-pyrrolidinyl)amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-86-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(1-azabicyclo[2.2.2]oct-3-ylamino)-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675114-87-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-methoxyphenyl)methyl]-4-[(1-methylcyclohexyl)amino]- (CA INDEX NAME)



RN 675114-88-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclobutylamino)-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 675114-89-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cycloheptylamino)-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 675114-93-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1R,2S,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 675114-94-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1R,2S,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 675114-95-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cycloheptylamino)-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 675114-90-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 675114-91-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-methoxyphenyl)methyl]-4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 675114-92-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-methoxyphenyl)methyl]-4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 675114-96-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclobutylamino)-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 675114-97-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 675114-98-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-ylamino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



RN 675114-99-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-methylcyclohexyl)amino]-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)




RN 675115-00-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(3-methylcyclohexyl)amino]-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)




RN 675115-01-2 CAPLUS


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cycloheptylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl- (CA INDEX NAME)



RN 675115-05-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclobutylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl- (CA INDEX NAME)




RN 675115-06-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-4-[(3-methylcyclohexyl)amino]- (CA INDEX NAME)




RN 675115-07-8 CAPLUS

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(1-methylcyclohexyl)amino]-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)




RN 675115-02-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(cis-4-aminocyclohexyl)amino]-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)

Relative stereochemistry.




RN 675115-03-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)




RN 675115-04-5 CAPLUS

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-4-[(1-methylcyclohexyl)amino]- (CA INDEX NAME)




RN 675115-09-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1R,2S,4S)-bicyclo[2.2.1]hept-2-ylamino]-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 675115-10-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-4-[(1-methylcyclohexyl)amino]- (CA INDEX NAME)




RN 675115-11-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(cis-4-aminocyclohexyl)amino]-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl- (CA INDEX NAME)


Relative stereochemistry.




RN 675115-12-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-(methylsulfonyl)methyl]phenyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 675115-15-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dichlorophenyl)methyl]-1-




RN 675115-22-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(4-fluorophenyl)-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675115-24-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-4-[(4-oxocyclohexyl)amino]-N-(2-pyridinylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CN 1


CRN 675115-23-8
CMF C21 H24 N6 O2



RN 675115-17-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-(methylsulfonyl)methyl]phenyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 675115-21-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-(methylsulfonyl)methyl]phenyl]-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




CN 2


CRN 76-05-1
CMF C2 H F3 O2




RN 675115-25-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675115-26-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(1-acetyl-4-piperidinyl)-1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)



RN 675115-27-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-((1-methyl-1H-pyrazol-4-yl)methyl)-4-((4-oxocyclohexyl)amino)- (CA INDEX NAME)




RN 675115-28-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N,1-diethyl-4-((4-oxocyclohexyl)amino)- (CA INDEX NAME)




RN 675115-29-4 CAPLUS


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-((tetrahydro-2H-pyran-3-yl)amino)-N-((4-(trifluoromethyl)phenyl)methyl)- (CA INDEX NAME)



RN 675115-33-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-((4-(methylsulfonyl)phenyl)methyl)-4-((tetrahydro-2H-pyran-3-yl)amino)- (CA INDEX NAME)




RN 675115-34-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-((4-(methylsulfonyl)methyl)phenyl)-4-((tetrahydro-2H-pyran-3-yl)amino)- (CA INDEX NAME)




RN 675115-35-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(4-fluorophenyl)-4-


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-((4-oxocyclohexyl)amino)-N-(2-thiazolylmethyl)- (CA INDEX NAME)



RN 675115-30-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-((tetrahydro-2H-pyran-3-yl)amino)- (CA INDEX NAME)




RN 675115-31-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-((4-(difluoromethoxy)phenyl)methyl)-1-ethyl-4-((tetrahydro-2H-pyran-3-yl)amino)- (CA INDEX NAME)



RN 675115-32-9 CAPLUS


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-((tetrahydro-2H-pyran-3-yl)amino)-N-((4-(trifluoromethyl)phenyl)methyl)- (CA INDEX NAME)



RN 675115-37-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-pyridinylmethyl)-4-((tetrahydro-2H-pyran-3-yl)amino)-, trifluoroacetate (9CI) (CA INDEX NAME)

CH 1

CRN 675115-36-3
CHF C20 H24 N6 O2




CH 2

CRN 76-05-1
CHF C2 H F3 O2




RN 675115-38-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-4-((tetrahydro-2H-pyran-3-yl)amino)- (CA INDEX NAME)




RN 675115-39-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1-acetyl-4-piperidinyl)-1-ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]- (CA INDEX NAME)



RN 675115-40-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-4-[(tetrahydro-2H-pyran-3-yl)amino]- (CA INDEX NAME)



IT 675115-41-0P, N-Ethyl-1-ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-42-1P, 1-Ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]-N-[(1,3-thiazol-2-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-43-2P, 4-[(4,4-difluorocyclohexyl)amino]-1-ethyl-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-44-3P, 1-Ethyl-4-[(4-fluoro-3-

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

carboxamide 675115-74-9P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(6-methoxyloxy)-3-pyridinyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-76-1P, 1-Ethyl-N-[(4-piperidinylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-77-2P, 1-Ethyl-N-[(1-ethylsulfonyl)-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-78-3P, 1-Ethyl-N-[(1-[(1-methyl-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-79-4P, N-[(1-Cyclopentylsulfonyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-80-7P, 1-Ethyl-N-[(1-methylsulfonyl)-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-81-8P, 1-Ethyl-N-[(1-phenylsulfonyl)-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-82-9P, 1-Ethyl-N-[(1-phenylsulfonyl)-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-83-0P, 1-Ethyl-N-[(1-propylsulfonyl)-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-84-1P, N-[(1-Cyclopropylcarbonyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-85-2P, 1-Ethyl-N-[(1-3-furanylcarbonyl)-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-86-3P, N-[(1-3,3-Dimethylbutanoyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-87-4P, 1-Ethyl-N-[(1-2-ethylbutanoyl)-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-88-5P, N-[(1-Cyclopentylacetyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-89-6P, 1-Ethyl-N-[(1-2-methylpropanoyl)-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-90-9P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(1-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-91-0P, 1-Ethyl-N-[(1-propanoyl)-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-92-1P, N-[(1-N-Acetylglucyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-93-2P, 1-Ethyl-N-[(1-4-morpholinylacetyl)-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-94-3P, 1-Ethyl-N-[(1-4-oxocyclohexyl)carbonyl]-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-95-4P, 1-Ethyl-N-[(1-[(1-oxocyclohexyl)acetyl]-4-piperidinyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-96-5P, 1-Ethyl-N-[(1-[(1-methyl-5-oxo-3-pyrrolidinyl)carbonyl]-4-piperidinyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-97-6P, 1-Ethyl-N-[(1-[(3-methyl-3-oxetanyl)carbonyl]-4-piperidinyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-98-7P, 1-Ethyl-N-[(1-[(4-fluorophenyl)acetyl]-4-piperidinyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-99-8P, N-[(1-3,3-Dimethylbutanoyl)-4-piperidinyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-00-4P, N-[(1-Cyclopentylacetyl)-4-piperidinyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-01-5P, N-[(1-Cyclopropylcarbonyl)-4-piperidinyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-02-6P, 1-Ethyl-N-[(1-[(4-oxocyclohexyl)carbonyl]-4-piperidinyl)methyl]-4-[(tetrahydro-2H-pyran-4-

cyclohexen-1-yl)amino]-N-(phenylmethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-45-4P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-46-5P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(3,4-dichlorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-47-6P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(3-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-48-7P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(3,4-difluorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-49-8P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(2,5-difluorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-50-1P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(3-(trifluoromethyl)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-51-2P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(4-(trifluoromethyl)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-52-3P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(2,6-difluorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-53-4P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(3-chlorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-54-5P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(4-(methyloxy)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-55-6P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(4-(methyloxy)phenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-56-7P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(4-[(dimethylamino)sulfonyl]phenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-57-8P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(1,2,3,4-tetrahydro-1-naphthalenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-58-9P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(2-(dimethylamino)phenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-59-0P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(2,4-dichlorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-60-3P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-61-4P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(2-chloro-6-fluorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-62-5P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(4-[(difluoromethyl)oxy]phenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-63-6P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(3-chloro-4-(methyloxy)phenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-64-7P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(5-chloro-2-pyridinyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-65-8P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(5-chloro-2,3-dihydro-1H-inden-2-yl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-66-9P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(1,3-thiazol-2-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-67-0P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(4-(methylsulfonyl)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-68-1P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(2,2-diphenylethyl)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-69-2P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(4-[(methylsulfonyl)amino]phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-70-3P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(4-[(methylamino)carbonyl]phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-71-4P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(4-(aminosulfonyl)phenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-72-7P, 4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-N-[(3-[(methylamino)carbonyl]phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675115-73-8P, 4-[(1-Acetyl-4-piperidinyl)amino]-N-[(4-(aminocarbonyl)phenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-03-7P, 1-Ethyl-N-[(1-[(4-fluorophenyl)acetyl]-4-piperidinyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-04-8P, 1-Ethyl-N-[(1-[(1-methyl-5-oxo-3-pyrrolidinyl)carbonyl]-4-piperidinyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-06-0P, 3-[(1-Ethyl-5-[(phenylmethyl)amino]carbonyl)-1H-pyrazolo[3,4-b]pyridine-4-yl)amino]cyclohexanecarboxylic acid 675116-07-1P, 1-Ethyl-N-(phenylmethyl)-4-[(4-piperidinylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-08-2P, 1-Ethyl-N-[(1-methyl-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-09-3P, 1-Ethyl-N-[(1-methyl-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-10-6P, 4-(Cyclohexylamino)-1-ethyl-N-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-11-7P, 1-Ethyl-N-[(4-fluorophenyl)-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-12-8P, 1-Ethyl-6-methyl-N-[(4-(methylsulfonyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-13-9P, N-[(2,3-Dihydro-1H-inden-2-yl)-1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-14-0P, 1-Ethyl-N-[(3-(1-piperidinylcarbonyl)phenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-15-1P, 1-Ethyl-N-[(4-(1-methyl-4-yl)amino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-16-2P, 1-Ethyl-N-[(2-fluorophenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-17-3P, N-[(3-[(Dimethylamino)carbonyl]phenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-18-4P, N-[(4-[(Difluoromethyl)oxy]phenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-19-5P, N-[(4-[Acetyl(methyl)amino]phenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-20-8P, 1-Ethyl-N-[(4-hydroxyphenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-21-9P, 1-Ethyl-N-[(4-(4-morpholinyl)-2-(trifluoromethyl)phenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-22-0P, 1-Ethyl-N-[(4-pyridinyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-23-1P, 1-Ethyl-N-[(4-[(4-methyl-1-piperazinyl)carbonyl]phenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-24-2P, 1-Ethyl-N-[(2-(2-oxo-1-pyrrolidinyl)phenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-25-3P, 1-Ethyl-N-[(3-(methylsulfonyl)phenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-26-4P, N-[(3-Acetyl(methyl)amino]phenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-27-5P, 1-Ethyl-N-[(3-(methylsulfonyl)amino]phenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-28-6P, 1-Ethyl-N-[(4-fluoro-2-hydroxyphenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-29-7P, N-[(4-Chlorophenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-30-0P, N-[(3-Chloro-2-cyanophenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-31-1P, 1-Ethyl-N-[(3-(1-piperidinylsulfonyl)phenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-32-2P, 1-Ethyl-N-[(2-(methylsulfonyl)phenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-33-3P, N-[(2-Acetyl(methyl)amino]phenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-34-4P, 1-Ethyl-N-[(3-(4-morpholinylcarbonyl)phenyl)-4-[(tetrahydro-2H-pyran-4-

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 y)-amino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-35-5P,
 N-(4-Chloro-3-cyanophenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675116-36-6P,
 1-Ethyl-N-(3-hydroxyphenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675116-37-7P,
 N-(3-Chlorophenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675116-38-8P,
 N-[3-(Acetylamino)methyl]-4-(methyloxy)phenyl]-1-ethyl-4-[(tetrahydro-2H-
 pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-39-9P, 1-Ethyl-N-(4-(1-piperidinylsulfonyl)phenyl)-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-40-2P, N-(3-[(Cyclohexyl(methyl)amino)carbonyl]phenyl)-1-
 ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675116-41-3P, 1-Ethyl-N-[2-(4-morpholinyl)phenyl]-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-42-4P, N-[3-(Acetylamino)sulfonyl]phenyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-43-5P, N-(3-Chloro-4-hydroxyphenyl)-1-ethyl-4-[(tetrahydro-
 2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-44-6P, 1-Ethyl-N-[4-(methyloxy)phenyl]-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-45-7P, 1-Ethyl-N-[3-(methylanino)carbonyl]phenyl]-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-46-8P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[3-
 (trifluoromethyl)phenyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-47-9P, 1-Ethyl-N-(3-pyridinyl)-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-48-0P,
 N-(3,4-Dichlorophenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675116-49-1P,
 N-(3-(Aminosulfonyl)-4-chlorophenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-50-4P,
 1-Ethyl-N-[3-(4-morpholinyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675116-51-5P,
 1-Ethyl-N-[4-(4-morpholinylsulfonyl)phenyl]-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-52-6P,
 1-Ethyl-N-[2-(4-methyl-1-piperazinyl)carbonyl]phenyl]-4-[(tetrahydro-2H-
 pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-53-7P, N-[2-(Dimethylamino)carbonyl]phenyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-54-8P, N-[2-Chloro-4-(trifluoromethyl)phenyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-55-9P, N-[2-(Acetylamino)methyl]phenyl]-1-ethyl-4-
 [(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-56-0P, N-(2-Chlorophenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-57-1P,
 N-(3-Chloro-2-fluorophenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675116-58-2P,
 1-Ethyl-N-(3-fluorophenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675116-59-3P,
 N-(2-Cyano-3-fluorophenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675116-60-6P,
 1-Ethyl-N-[4-(propylsulfonyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-
 1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-61-7P,
 N-[4-(Dimethylamino)carbonyl]phenyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-62-8P,
 1-Ethyl-N-[4-(methylsulfonyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-
 1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-63-9P,
 N-[4-(Acetylamino)methyl]phenyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-64-0P,
 1-Ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 carboxamide 675116-65-1P, N-(2-(Aminosulfonyl)ethyl)-4-
 (cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-66-2P, N-(2-Amino-2-oxoethyl)-4-(cyclohexylamino)-1-ethyl-
 1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-67-3P,
 4-(Cyclohexylamino)-1-ethyl-N-[2-[(methylsulfonyl)amino]ethyl]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675116-68-4P,
 4-(Cyclohexylamino)-1-ethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-
 b]pyridine-5-carboxamide 675116-69-5P, 4-(Cyclohexylamino)-1-
 ethyl-N-[(1-methyl-1H-pyrazolo-4-yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675116-70-6P, 4-(Cyclohexylamino)-1-ethyl-N-[3-
 (methylsulfonyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-71-9P, N-[(3-(Aminocarbonyl)phenyl)methyl]-4-
 (cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-72-0P, 4-(Cyclohexylamino)-1-ethyl-N-(tetrahydro-2-
 furanyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-73-1P, 4-(Cyclohexylamino)-N-[(4-
 [(dimethylamino)sulfonyl]phenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-
 5-carboxamide 675116-74-2P, N-[(5-Chloro-2-pyridinyl)methyl]-4-
 (cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-75-3P, 4-(Cyclohexylamino)-1-ethyl-N-[(4-
 (methylsulfonyl)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-76-4P, 4-(Cyclohexylamino)-1-ethyl-N-[(6-(methyloxy)-3-
 pyridinyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-77-5P, 4-(Cyclohexylamino)-1-ethyl-N-[4-
 [(methylamino)carbonyl]phenyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-78-6P, 4-(Cyclohexylamino)-1-ethyl-N-[3-
 [(methylamino)carbonyl]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675116-79-7P, N-[(4-(Aminocarbonyl)phenyl)methyl]-4-
 (cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-80-0P, 4-(Cyclohexylamino)-1-ethyl-N-[(4-
 hydroxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-81-1P, 4-(Cyclohexylamino)-1-ethyl-N-[(4-
 (methyloxy)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-82-2P, 4-(Cyclohexylamino)-N-[(3,4-difluorophenyl)methyl]-1-
 ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-83-3P,
 4-(Cyclohexylamino)-1-ethyl-N-[(4-(trifluoromethyl)phenyl)methyl]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675116-84-4P,
 4-(Cyclohexylamino)-1-ethyl-N-[(3-[(methylsulfonyl)amino]phenyl)methyl]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675116-85-5P,
 4-(Cyclohexylamino)-N-[(2,5-difluorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-
 b]pyridine-5-carboxamide 675116-86-6P, 4-(Cyclohexylamino)-1-
 ethyl-N-[(4-methylphenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-87-7P, 4-(Cyclohexylamino)-1-ethyl-N-[(2-
 [(methylsulfonyl)amino]phenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675116-88-8P, 4-(Cyclohexylamino)-1-ethyl-N-[(2-
 hydroxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-89-9P, 4-(Cyclohexylamino)-N-[(3,4-dichlorophenyl)methyl]-1-
 ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675116-90-2P,
 4-(Cyclohexylamino)-N-[(3,5-dichlorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-
 b]pyridine-5-carboxamide 675116-91-3P, 4-(Cyclohexylamino)-1-
 ethyl-N-(2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-92-4P, 4-(Cyclohexylamino)-1-ethyl-N-[(1,2,3,4-tetrahydro-1-
 naphthalenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-93-5P, 4-(Cyclohexylamino)-1-ethyl-N-[(2-
 (methylsulfinyl)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-94-6P, 4-(Cyclohexylamino)-1-ethyl-N-[(2-
 hydroxyphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-95-7P, N-[2-(4-(Aminosulfonyl)phenyl)ethyl]-4-
 (cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-96-8P, 4-(Cyclohexylamino)-1-ethyl-N-[2-


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 [(methylamino)carbonyl]phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675116-97-9P, 4-(Cyclohexylamino)-1-ethyl-N-[(2-
 (methylsulfonyl)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675116-98-0P, Methyl 2-[[[4-(cyclohexylamino)-1-ethyl-1H-
 pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]benzoate
 675116-99-1P, 4-(Cyclohexylamino)-1-ethyl-N-[2-(4-
 (methyloxy)phenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-00-7P, 4-(Cyclohexylamino)-N-[(2,3-dihydro-1H-inden-2-yl)-4-
 (cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-01-8P, 4-(Cyclohexylamino)-1-ethyl-N-[(2-fluoro-3-
 (trifluoromethyl)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-02-9P, 4-(Cyclohexylamino)-N-[(3,4-dimethylphenyl)methyl]-1-
 ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-03-0P,
 4-(Cyclohexylamino)-1-ethyl-N-[(2,4-fluorophenyl)ethyl]-1H-pyrazolo[3,4-
 b]pyridine-5-carboxamide 675117-04-1P, 4-(Cyclohexylamino)-1-
 ethyl-N-[2-(4-methylphenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-05-2P, 4-(Cyclohexylamino)-1-ethyl-N-[2-(4-
 (methyloxy)phenyl)ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-07-4P, 4-(Cyclohexylamino)-1-ethyl-N-(2-pyridinylmethyl)-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide trifluoroacetate
 675117-08-5P, 4-(Cyclohexylamino)-N-[(3,5-difluorophenyl)methyl]-1-
 ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-09-6P,
 4-(Cyclohexylamino)-N-(2,3-dihydro-1H-inden-1-yl)-1-ethyl-1H-pyrazolo[3,4-
 b]pyridine-5-carboxamide 675117-10-7P, 4-(Cyclohexylamino)-N-[(4-
 (dimethylamino)phenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide trifluoroacetate 675117-12-1P, 4-(Cyclohexylamino)-1-
 ethyl-N-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-13-2P, N-[(2,4-Bis(methyloxy)phenyl)methyl]-4-
 (cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-15-4P, N-[(6-Chloro-2-pyridinyl)methyl]-4-(cyclohexylamino)-
 1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide trifluoroacetate
 675117-17-6P, N-[(2-(Acetyl(methyl)amino)phenyl)methyl]-4-
 (cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 trifluoroacetate 675117-18-7P, 4-(Cyclohexylamino)-1-ethyl-N-[(4-
 fluoro-3-(trifluoromethyl)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675117-19-8P, 4-(Cyclohexylamino)-N-[(2,6-
 dichlorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-23-4P, 4-(Cyclohexylamino)-1-ethyl-N-(1H-tetrazol-5-
 yl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-24-5P,
 4-(Cyclohexylamino)-N-[(4-(difluoromethyl)oxy)phenyl)methyl]-1-ethyl-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675117-25-6P,
 4-(Cyclohexylamino)-1-ethyl-N-[(2-methyl-1,3-thiazol-4-yl)methyl]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675117-26-7P,
 N-[(2-Chloro-6-fluorophenyl)methyl]-4-(cyclohexylamino)-1-ethyl-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675117-27-8P,
 N-[(2-(Aminocarbonyl)phenyl)methyl]-4-(cyclohexylamino)-1-ethyl-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675117-28-9P,
 4-(Cyclohexylamino)-N-[(2-(dimethylamino)phenyl)methyl]-1-ethyl-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675117-29-0P,
 4-(Cyclohexylamino)-1-ethyl-N-[(4-fluorophenyl)methyl]-1H-pyrazolo[3,4-
 b]pyridine-5-carboxamide 675117-30-3P, 4-(Cyclohexylamino)-1-
 ethyl-N-[(3-(trifluoromethyl)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675117-31-4P, 4-(Cyclohexylamino)-N-[(2,6-
 difluorophenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-32-5P, 4-(Cyclohexylamino)-1-ethyl-N-[(3-
 fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-33-6P, 4-(Cyclohexylamino)-1-ethyl-N-[(2-
 (trifluoromethyl)phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-34-7P, N-(5-Chloro-2,3-dihydro-1H-inden-2-yl)-4-
 (cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 675117-35-8P, 4-(Cyclohexylamino)-1-ethyl-N-[(4-
 [(methylamino)carbonyl]phenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-
 carboxamide 675117-36-9P, 4-(Cyclohexylamino)-1-ethyl-N-[(4-
 (methyloxy)phenyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-37-0P, 4-(Cyclohexylamino)-1-ethyl-N-[(6-oxo-1,6-dihydro-3-
 pyridinyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 675117-38-1P, 4-(Cyclohexylamino)-1-ethyl-N-(3-pyridinylmethyl)-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675117-39-2P,
 4-[[[(4-(Cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-
 yl)carbonyl]amino]methyl]benzoic acid 675117-40-5P,
 3-[[[(4-(Cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-
 yl)carbonyl]amino]methyl]benzoic acid 675117-41-6P,
 4-(Cyclohexylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-1H-pyrazolo[3,4-
 b]pyridine-5-carboxamide hydrochloride (1:1) 675117-42-7P,
 4-(Cyclohexylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-1H-pyrazolo[3,4-
 b]pyridine-5-carboxamide methanesulfonate (1:1) 675117-44-9P,
 N-[[2-[(1,1-Dimethylethyl)oxy]-3-pyridinyl]methyl]-1-ethyl-4-[(tetrahydro-2H-
 pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 trifluoroacetate 675117-45-0P, N-[(3-Chloro-4-
 methylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-
 pyrazolo[3,4-b]pyridine-5-carboxamide 675117-46-1P,
 N-[(4-Chloro-2-methylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-
 yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-47-2P,
 N-[[2-[(Difluoromethyl)oxy]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-
 4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-48-3P,
 1-Ethyl-N-[(2-[(1-methylethyl)oxy]phenyl)methyl]-4-[(tetrahydro-2H-pyran-
 4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BROL (Biological study); PREP (Preparation); USES
 (Uses)

(PDE4 inhibitor; prepn. of pyrazolo[3,4-b]pyridines as PDE4 inhibitors
 for treatment of inflammatory and/or allergic disease)


RN 675115-41-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N,1-diethyl-4-[(tetrahydro-2H-
 pyran-3-yl)amino]- (CA INDEX NAME)




RN 675115-42-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-
 3-yl)amino]-N-(2-thiazolylmethyl)- (CA INDEX NAME)




RN 675115-43-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(4,4-difluorocyclohexyl)amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675115-44-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(4-fluoro-3-cyclohexen-1-yl)amino]-N-(phenylmethyl)- (CA INDEX NAME)




RN 675115-45-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl- (CA INDEX NAME)




RN 675115-48-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(3,4-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-49-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(2,5-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-46-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(3,4-dichlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-47-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(3-fluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-50-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(3-(trifluoromethyl)phenyl)methyl]-1-ethyl- (CA INDEX NAME)





RN 675115-51-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(4-(trifluoromethyl)phenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-52-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(2,6-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-53-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(3-chlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-57-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(1,2,3,4-tetrahydro-1-naphthalenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-58-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(2-(dimethylamino)phenyl)methyl]-1-ethyl- (CA INDEX NAME)



RN 675115-54-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(4-methoxyphenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-55-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(4-methoxyphenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-56-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[[4-[(dimethylamino)sulfonyl]phenyl]methyl]-1-ethyl- (CA INDEX NAME)


RN 675115-59-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(2,4-dichlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-60-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(2-fluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)





RN 675115-61-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(2-chloro-6-fluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-62-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(4-(difluoromethoxy)phenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-63-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(3-chloro-4-methoxyphenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-67-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(4-(methylsulfonyl)phenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-68-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(2,2-diphenylethyl)methyl]-1-ethyl- (CA INDEX NAME)



RN 675115-64-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(5-chloro-2-pyridinyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-65-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(5-chloro-2,3-dihydro-1H-inden-2-yl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-66-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(2-thiazolyl)methyl]-1-ethyl- (CA INDEX NAME)


RN 675115-69-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(4-[(methylsulfonyl)amino]phenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-70-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(4-[(methylamino)carbonyl]phenyl)methyl]-1-ethyl- (CA INDEX NAME)





RN 675115-71-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-N-[(4-[(aminosulfonyl)phenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675115-72-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1-acetyl-4-piperidinyl)amino]-1-ethyl-N-[[3-[(methylamino)carbonyl]phenyl)methyl]-(CA INDEX NAME)




RN 675115-73-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-acetyl-4-piperidinyl]amino]-N-[[4-(aminocarbonyl)phenyl]methyl]-1-ethyl- (CA INDEX NAME)



RN 675115-78-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-((1-methylethyl)sulfonyl)-4-piperidinyl)-4-[(tetrahydro-2H-pyran-4-yl)amino)]-(CA INDEX NAME)




RN 675115-79-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(cyclopentylsulfonyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675115-80-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(methylsulfonyl)-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


RN 675115-74-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1-(acetyl-4-piperidinyl)amino]-1-ethyl-N-[(6-methoxy-3-pyridinyl)methyl]- (CA INDEX)




RN 675115-76-1 CAPIUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(4-piperidinylmethyl)-
4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675115-77-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(ethylsulfonyl)-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675115-81-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-
[(phenylmethyl)sulfonyl]-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-
yl)amino]- (CA INDEX NAME)




RN 675115-82-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(phenylsulfonyl)-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675115-83-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(propylsulfonyl)-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675115-84-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(cyclopropylcarbonyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675115-85-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(3-furanylcabonyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675115-86-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(3,3-dimethyl-1-oxobutyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675115-90-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(1-oxopropyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675115-91-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(1-oxopropyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675115-92-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(1-oxopropyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675115-87-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(2-ethyl-1-oxobutyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675115-88-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[1-(cyclopentylacetyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)




RN 675115-89-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(2-methyl-1-oxopropyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675115-93-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-morpholinylacetyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)




RN 675115-94-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(4-oxocyclohexyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675115-95-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[1-(1-oxopropyl)-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 675115-96-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[1-[(1-methyl-5-oxo-3-pyrrolidinyl)carbonyl]-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)




RN 675115-96-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[1-[(1-methyl-5-oxo-3-pyrrolidinyl)carbonyl]-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675115-97-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[1-[(3-methyl-3-oxetanyl)carbonyl]-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 675116-01-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[1-[(cyclopropylcarbonyl)-4-piperidinylmethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-02-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[1-[(4-oxocyclohexyl)carbonyl]-4-piperidinylmethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-03-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[1-[(4-fluorophenyl)acetyl]-4-piperidinylmethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 675115-98-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[1-[(4-fluorophenyl)acetyl]-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)



RN 675115-99-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[1-[(3,3-dimethyl-1-oxobutyl)-4-piperidinylmethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-00-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[1-[(cyclopentylacetyl)-4-piperidinylmethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 675116-04-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[1-[(1-methyl-5-oxo-3-pyrrolidinyl)carbonyl]-4-piperidinylmethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675116-06-0 CAPLUS
 CN Cyclohexanecarboxylic acid, 3-[[1-ethyl-5-[(phenylmethyl)amino]carbonyl]-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]- (CA INDEX NAME)




RN 675116-07-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-4-[(4-piperidinylamino)- (CA INDEX NAME)




RN 675116-09-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-[(1-methylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]-, ethyl ester (CA INDEX NAME)




RN 675116-10-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-methyl- (CA INDEX NAME)




RN 675116-11-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(4-fluorophenyl)-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-12-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-6-methyl-N-[(4-

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methylethyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


RN 675116-16-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-fluorophenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-17-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[3-[(dimethylamino)carbonyl]phenyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-18-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[4-(difluoromethoxy)phenyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(methylsulfonyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


RN 675116-13-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675116-14-0 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[3-(1-piperidinylcarbonyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675116-15-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[4-(1-

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 675116-19-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[4-(acetylmethylamino)phenyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-20-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[4-(4-hydroxyphenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-21-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[4-(4-morpholinyl)-2-(trifluoromethyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-22-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-4-((4-methyl-1-piperazinyl)carbonyl)phenyl-4-((tetrahydro-2H-pyran-4-yl)amino)- (CA INDEX NAME)




RN 675116-23-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-4-((4-methyl-1-piperazinyl)carbonyl)phenyl-4-((tetrahydro-2H-pyran-4-yl)amino)- (CA INDEX NAME)




RN 675116-24-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-2-((2-oxo-1-pyrrolidinyl)phenyl)-4-((tetrahydro-2H-pyran-4-yl)amino)- (CA INDEX NAME)




RN 675116-28-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-4-((4-fluoro-2-hydroxyphenyl)carbonyl)phenyl-4-((tetrahydro-2H-pyran-4-yl)amino)- (CA INDEX NAME)




RN 675116-29-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(4-chlorophenyl)-1-ethyl-4-((tetrahydro-2H-pyran-4-yl)amino)- (CA INDEX NAME)




RN 675116-30-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(3-chloro-2-cyanophenyl)-1-ethyl-4-((tetrahydro-2H-pyran-4-yl)amino)- (CA INDEX NAME)




RN 675116-25-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-3-((methylsulfonyl)phenyl)-4-((tetrahydro-2H-pyran-4-yl)amino)- (CA INDEX NAME)




RN 675116-26-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[3-(acetylmethylamino)phenyl]-1-ethyl-4-((tetrahydro-2H-pyran-4-yl)amino)- (CA INDEX NAME)




RN 675116-27-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-3-((methylsulfonyl)amino)phenyl-4-((tetrahydro-2H-pyran-4-yl)amino)- (CA INDEX NAME)




RN 675116-31-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-3-((1-piperidinylsulfonyl)phenyl)-4-((tetrahydro-2H-pyran-4-yl)amino)- (CA INDEX NAME)




RN 675116-32-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-2-((methylsulfonyl)phenyl)-4-((tetrahydro-2H-pyran-4-yl)amino)- (CA INDEX NAME)




RN 675116-33-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(acetylmethylamino)phenyl]-1-ethyl-4-((tetrahydro-2H-pyran-4-yl)amino)- (CA INDEX NAME)




RN 675116-34-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[3-(4-morpholinylcarbonyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-35-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(4-chloro-3-cyanophenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-36-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(3-hydroxyphenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-40-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[3-(cyclohexylmethylamino)carbonyl]phenyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-41-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[2-(4-morpholinyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-42-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[3-[(acetylaminosulfonyl)phenyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-37-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(3-chlorophenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-38-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[3-[(acetylaminomethyl)-4-methoxyphenyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-39-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[4-(1-piperidinylsulfonyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-43-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(3-chloro-4-hydroxyphenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-44-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[4-[(methylsulfonyl)amino]phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-45-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[3-[(methylamino)carbonyl]phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-46-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 675116-47-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-3-pyridinyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-48-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(3,4-dichlorophenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-52-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[2-((4-methyl-1-piperazinyl)carbonyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-53-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-((dimethylamino)carbonyl)phenyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-54-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2-chloro-4-(trifluoromethyl)phenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-49-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[3-(aminosulfonyl)-4-chlorophenyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-50-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[3-(4-morpholinyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-51-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[4-(4-morpholinylsulfonyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-55-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-((acetylamino)methyl)phenyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-56-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2-chlorophenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-57-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(3-chloro-2-fluorophenyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-58-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(3-fluorophenyl)-4-
[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-59-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2-cyano-3-fluorophenyl)-1-
ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675116-60-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(4-
(propylsulfonyl)phenyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX
NAME)




RN 675116-64-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-
3-yl)amino]- (CA INDEX NAME)




RN 675116-65-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(aminosulfonyl)ethyl]-4-
(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 675116-66-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2-amino-2-oxoethyl)-4-
(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 675116-61-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[4-
[(dimethylamino)carbonyl]phenyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-
yl)amino]- (CA INDEX NAME)




RN 675116-62-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[4-
(methylsulfonyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX
NAME)




RN 675116-63-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[4-
[(acetylaminomethyl)phenyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-
(CA INDEX NAME)




RN 675116-67-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[2-
(methylsulfonyl)amino]ethyl]- (CA INDEX NAME)




RN 675116-68-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-
(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 675116-69-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-
[(1-methyl-1H-pyrazol-4-yl)methyl]- (CA INDEX NAME)




RN 675116-70-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[3-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 675116-71-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-(aminocarbonyl)phenyl]methyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 675116-72-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[4-(tetrahydro-2-furanyl)methyl]methyl]- (CA INDEX NAME)




RN 675116-76-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[4-(methoxy-3-pyridinyl)methyl]methyl]- (CA INDEX NAME)




RN 675116-77-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[4-(methylamino)carbonyl]phenyl]methyl]- (CA INDEX NAME)




RN 675116-78-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[4-(hydroxyphenyl)methyl]methyl]- (CA INDEX NAME)




RN 675116-73-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[[4-(dimethylamino)sulfonyl]phenyl]methyl]-1-ethyl- (CA INDEX NAME)




RN 675116-74-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[5-(5-chloro-2-pyridinyl)methyl]methyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 675116-75-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)




RN 675116-79-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(aminocarbonyl)phenyl]methyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 675116-80-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[4-(4-hydroxyphenyl)methyl]methyl]- (CA INDEX NAME)




RN 675116-81-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[4-(methoxyphenyl)methyl]methyl]- (CA INDEX NAME)




RN 675116-82-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(3,4-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675116-83-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[4-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 675116-84-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[3-{(methylsulfonyl)amino}phenyl)methyl]- (CA INDEX NAME)




RN 675116-85-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(2,5-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675116-86-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[4-methylphenyl)methyl]- (CA INDEX NAME)




RN 675116-87-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[2-{4-[(methylsulfonyl)amino]phenyl}ethyl]- (CA INDEX NAME)




RN 675116-88-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(2-hydroxyphenyl)methyl]- (CA INDEX NAME)




RN 675116-89-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(3,4-dichlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675116-90-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(3,5-dichlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675116-91-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(2-phenylethyl)- (CA INDEX NAME)




RN 675116-92-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(1,2,3,4-tetrahydro-1-naphthalenyl)methyl]- (CA INDEX NAME)




RN 675116-93-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[2-{(methylsulfonyl)amino}phenyl)methyl]- (CA INDEX NAME)




RN 675116-94-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-([2-(4-hydroxyphenyl)ethyl]- (CA INDEX NAME)




RN 675116-95-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-([4-(aminosulfonyl)phenyl]ethyl)-4-(cyclohexylamino)-1-ethyl]- (CA INDEX NAME)




RN 675116-96-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-([2-[(methylamino)carbonyl]phenyl]methyl)- (CA INDEX NAME)




RN 675117-00-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-(2,3-dihydro-4,5-dimethoxy-1H-inden-2-yl)-1-ethyl- (CA INDEX NAME)




RN 675117-01-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-([2-fluoro-3-(trifluoromethyl)phenyl]methyl)- (CA INDEX NAME)




RN 675117-02-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-([3,4-dimethylphenyl]methyl)-1-ethyl- (CA INDEX NAME)




RN 675116-97-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-([2-(methylsulfonyl)phenyl]methyl)- (CA INDEX NAME)




RN 675116-98-0 CAPLUS
CN Benzoic acid, 2-([4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl)amino]methyl]-, methyl ester (CA INDEX NAME)




RN 675116-99-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-([2-(methylsulfonyl)phenyl]ethyl)- (CA INDEX NAME)




RN 675117-03-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-([2-(4-fluorophenyl)ethyl]- (CA INDEX NAME)



RN 675117-04-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-([2-(4-methylphenyl)ethyl]- (CA INDEX NAME)




RN 675117-05-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-([2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)



RN 675117-07-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(2-pyridinylmethyl)-, trifluoroacetate (9C1) (CA INDEX NAME)

CM 1

CRN 675117-06-3
CMF C21 H26 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 675117-08-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(3,5-difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)


•

CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 675117-12-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[(2-fluorophenyl)methyl]- (CA INDEX NAME)




RN 675117-13-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(2,4-dimethoxyphenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675117-15-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(6-chloro-2-pyridinyl)methyl]-4-(cyclohexylamino)-1-ethyl-, trifluoroacetate (9C1) (CA INDEX NAME)

CM 1

CRN 675117-14-3




RN 675117-09-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-(2,3-dihydro-1H-inden-1-yl)-1-ethyl- (CA INDEX NAME)




RN 675117-11-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(4-(dimethylamino)phenyl)methyl]-1-ethyl-, trifluoroacetate (9C1) (CA INDEX NAME)

CM 1

CRN 675117-10-9
CMF C24 H32 N6 O



CMF C21 H25 Cl N6 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 675117-17-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-(acetymethylamino)phenyl)methyl]-4-(cyclohexylamino)-1-ethyl-, trifluoroacetate (9C1) (CA INDEX NAME)

CM 1

CRN 675117-16-5
CMF C25 H32 N6 O2




CM 2


CRN 76-05-1




RN 675117-18-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-
[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 675117-19-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(2,6-
dichlorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675117-23-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-
(1H-tetrazol-5-ylmethyl)- (9CI) (CA INDEX NAME)




RN 675117-24-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(4-
(difluoromethoxy)phenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675117-25-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-
[(2-methyl-4-thiazolyl)methyl]- (CA INDEX NAME)




RN 675117-26-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-chloro-6-
fluorophenyl)methyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 675117-27-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-
(aminocarbonyl)phenyl)methyl]-4-(cyclohexylamino)-1-ethyl- (CA INDEX
NAME)




RN 675117-28-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(2-
(dimethylamino)phenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675117-29-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-
[(4-fluorophenyl)methyl]- (CA INDEX NAME)




RN 675117-30-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-
[(3-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 675117-31-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(2,6-
difluorophenyl)methyl]-1-ethyl- (CA INDEX NAME)




RN 675117-32-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-
[(3-fluorophenyl)methyl]- (CA INDEX NAME)




RN 675117-33-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 675117-34-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(5-chloro-2,3-dihydro-1H-inden-2-yl)-4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)




RN 675117-35-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-[[4-[(methylamino)carbonyl]phenyl]methyl]- (CA INDEX NAME)




RN 675117-39-2 CAPLUS
CN Benzoic acid, 4-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 675117-40-5 CAPLUS
CN Benzoic acid, 3-[[[4-(cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 675117-41-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 675117-36-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(4-methoxyphenyl)- (CA INDEX NAME)



RN 675117-37-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-1-ethyl- (CA INDEX NAME)



RN 675117-38-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-1-ethyl-N-(3-pyridinylmethyl)- (CA INDEX NAME)




● HCl

RN 675117-42-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-(cyclohexylamino)-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl-, monomethanesulfonate (9CI) (CA INDEX NAME)

CH 1

CRN 675117-21-2
CMF C24 H29 N5 O



CH 2

CRN 75-75-2
CMF C H4 O3 S




L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 675117-44-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[2-(1,1-dimethylethoxy)-3-pyridinyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 675117-43-8
CMF C24 H32 N6 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 675117-45-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-46-1 CAPLUS

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-50-7P, N-[[3-[(difluoromethyl)oxy]phenyl]methyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-51-8P, 1-Ethyl-N-[[4-(hydroxy-3-(methyloxy)phenyl)methyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-52-9P, N-[(5-Acetyl-2-hydroxyphenyl)methyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-53-0P, 1-Ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-N-[[2-[(trifluoromethyl)oxy]phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-54-1P, N-[[4-(Acetylaminophenyl)methyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-55-2P, 1-Ethyl-N-[[2-(3-hydroxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-56-3P, N-[[2-(3-Chlorophenyl)ethyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-57-4P, 1-Ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-N-[[2-[[4-[[trifluoromethyl]oxy]phenyl]ethyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-58-5P, 1-Ethyl-N-[[2-[[3-(methyloxy)phenyl]ethyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-59-6P, N-[[2-(4-Acetylphenyl)ethyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-60-9P, N-[[2-(3,4-Dichlorophenyl)ethyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-61-0P, N-[[2-[[3-(Aminosulfonyl)phenyl]ethyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-62-1P, N-[[2-[[3-Bis(methyloxy)phenyl]ethyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-63-2P, N-[[2-[[2,3-Dichlorophenyl]ethyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-64-3P, N-[[2-[[3,5-Bis(methyloxy)phenyl]ethyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-65-4P, 1-Ethyl-N-[[2-[[3-methyl-4-(methyloxy)phenyl]ethyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-66-5P, N-[[2-[[2,6-Difluorophenyl]ethyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-67-6P, N-[[2-[[2,6-Bis(methyloxy)phenyl]ethyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-70-1P, 1-Ethyl-N-[[2-(2-methylphenyl)ethyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-74-5P, N-[[4,5-Bis(methyloxy)-2,3-dihydro-1H-inden-2-yl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-76-7P, N-[[2-[[4-(Aminosulfonyl)phenyl]ethyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-78-9P, 1-Ethyl-N-[[2-(2-methylsulfinyl)phenyl]methyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-80-3P, 1-Ethyl-N-[[2-phenylethyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-82-5P, N-[[4-(Dimethylamino)phenyl]methyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-84-7P, 1-Ethyl-N-[[2-(4-fluorophenyl)ethyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-86-9P, 1-Ethyl-N-[[2-(4-methylphenyl)ethyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-88-1P, N-[[3-(Aminosulfonyl)phenyl]methyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-90-5P, 1-Ethyl-N-[[4-(methylphenyl)methyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675117-92-7P, 1-Ethyl-N-[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(chloro-2-methylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-47-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[2-(difluoromethoxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675117-48-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[2-(1-methylethoxy)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



IT 675117-49-4P, 1-Ethyl-N-[[3-[(1-methylethyl)oxy]phenyl]methyl]-4-


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Methyl 2-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate]methyl]benzoate 675117-97-2P, N-[[6-Chloro-2-pyridinyl]methyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide trifluoroacetate 675117-99-4P, N-[[2,3-Dihydro-1H-inden-1-yl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-01-1P, N-[[2-(Acetyl(methyl)amino)phenyl]methyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-05-5P, 1-Ethyl-N-[[phenylmethyl]-N-propyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-08-8P, N-[[2-(Dimethylamino)ethyl]-1-ethyl-N-[[phenylmethyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-11-3P, N-Butyl-1-ethyl-N-[[phenylmethyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-14-6P, N-Ethyl-1-ethyl-N-[[phenylmethyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-17-9P, 1-Ethyl-N-[[1-phenyl-4-piperidinyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-20-4P, 1-Ethyl-N-[[1-[(ethylamino)carbonyl]-4-piperidinyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-24-8P, Formic acid 1-ethyl-N-[[1-methyl-2-(4-methyl-1-piperazinyl)ethyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-27-1P, Methyl 2-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-yl]carbonyl]amino]-1-piperidinyl]acetate 675118-31-7P, 1-Ethyl-N-[[4-(4-morpholinylmethyl)phenyl]methyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide trifluoroacetate 675118-35-1P, 1-Ethyl-N-[[3-[[4-methyl-1-piperazinyl]methyl]phenyl]methyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide trifluoroacetate 675118-39-5P, N-[[5-(Aminocarbonyl)-3-pyridinyl]methyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide trifluoroacetate 675118-41-9P, 1-Ethyl-N-[[4-(1-methylethyl)phenyl]methyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-43-1P, N-[[3-(Cyclopentyl)oxy]methyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-46-4P, 1-Ethyl-N-[[4-(4-methyl-1-piperazinyl)methyl]phenyl]methyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide trifluoroacetate 675118-48-6P, N-[[2,4-Dichlorophenyl]methyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-49-7P, N-[[2,4-Difluorophenyl]methyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-50-0P, N-[[2-Chloro-4-fluorophenyl]methyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-51-1P, N-[[2-[[2-Chloro-3-(methyloxy)phenyl]ethyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-54-4P, 1-Ethyl-N-[[3-[[1-pyrrolidinylmethyl]phenyl]methyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide trifluoroacetate 675118-55-5P, 1-Ethyl-N-[[2-[[4-[[methylsulfonyl]amino]phenyl]ethyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-56-5P, N-[[2,5-Bis(methyloxy)phenyl]methyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-57-7P, N-[[2,6-Bis(methyloxy)phenyl]methyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-58-8P, 1-Ethyl-N-[[2-(2-fluorophenyl)methyl]-4-[[tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-59-9P, N-[[3,5-Difluorophenyl]methyl]-1-ethyl-4-[[tetrahydro-2H-pyran-4-yl)amino]-


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-60-2P,
N-[[4-(Chlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-61-3P,
N-Cyclohexyl-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-62-4P, 1-Ethyl-N-[2-[[4-(methylsulfonyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-63-5P,
1-Ethyl-N-[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-64-6P, N-[[4-[(Cyclopropylamino)carbonyl]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-65-7P, 1-Ethyl-N-[[4-(4-methyl-1-piperazinyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-66-8P,
1-Ethyl-N-[[4-(1-pyrrolidinylmethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-67-9P, 1-Ethyl-N-[[6-(methoxyloxy)-1-oxo-2,3-dihydro-1H-inden-2-yl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-68-0P, N-[[2,5-Dichlorophenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-69-1P, N-[[3,5-Dimethylphenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-70-4P, N-[[2,3-Difluorophenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-71-5P, 1-Ethyl-N-[[2-(methylsulfonyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-72-6P, 1-Ethyl-N-[[3-(hydroxyphenyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-73-7P, N-[[3,5-Bis(methoxyloxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-74-8P, 1-Ethyl-N-[[2-(4-hydroxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-75-9P, N-[[3,5-Dichlorophenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-76-0P, N-[[2,4-Bis(methoxyloxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-77-1P, 1-Ethyl-N-[[2-(methoxyloxy)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-78-2P, N-[[2,4-Dimethylphenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-79-3P, 1-Ethyl-N-[[2-[(methoxyloxy)carbonyl]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-80-6P, 1-Ethyl-N-[[2-[(methoxyloxy)phenyl]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-82-8P, N-[[2-(Chlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-84-0P, 1-Ethyl-N-[[2-(hydroxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-86-2P, N-[[1,3-Benzodioxol-5-yl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-88-4P, 1-Ethyl-N-[[1,2,3,4-tetrahydro-1-naphthalenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-92-0P, N-[[3,4-Dichlorophenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-94-2P, N-[[4-(Aminocarbonyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-96-4P, N-[[2,6-Difluorophenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675118-97-5P, 1-Ethyl-N-[[4-(hydroxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-33-2P, 1-Ethyl-N-[[4-(iodophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-34-3P, N-[[4-[(1,1-Dimethylethyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-35-4P, N-[[3-Cyanophenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-36-5P, N-[[2,6-Dichlorophenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-37-6P, N-[[5-(Chloro-2-methylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-38-7P, N-[[3,5-Dibromophenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-39-8P, 1-Ethyl-N-[[4-(ethylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-40-1P, 1-Ethyl-N-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-41-2P, 1-Ethyl-N-[[2-(iodophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-42-3P, N-[[2-Bromophenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-43-4P, 1-Ethyl-N-[[4-(hydroxymethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-44-5P, 1-Ethyl-N-[[3-(hydroxymethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-45-6P, 1-Ethyl-N-[[3-(hydroxymethyl)-2-methylphenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-46-7P, N-[[2,3-Dichloro-6-(hydroxymethyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-47-8P, N-[[2,4-Dichloro-6-methylphenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-48-9P, 1-Ethyl-N-[[4-(2-methylpropyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-49-0P, N-[[2,5-Dimethylphenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-50-3P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[[2,4,5-trifluorophenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-51-4P, 1-Ethyl-N-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-52-5P, N-[[2-Chloro-6-methylphenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-53-6P, 4-[[[1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-yl]carbonyl]amino]methyl]benzoic acid sodium salt 675119-54-7P, 3-[[[1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-yl]carbonyl]amino]methyl]benzoic acid 675119-57-0P, N-[[4-(Dimethylamino)phenyl]methyl]-1-ethyl-4-[[4-(hydroxymino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-58-1P, 1-Ethyl-4-[[4-[(ethoxycarbonyl)amino]cyclohexyl]amino]-N-[[4-(methylthio)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-59-2P, 1-Ethyl-4-[[4-[(methylthio)amino]cyclohexyl]amino]-N-[[4-(methylthio)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-60-5P, 4-[[4-[[[1,1-Dimethylethyl]oxy]imino]cyclohexyl]amino]-1-ethyl-N-[[4-(methylthio)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-61-6P, 1-Ethyl-N-[[4-(methoxyloxy)phenyl]methyl]-4-[[7-oxoheptahydro-1H-azepin-4-yl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-62-7P, Ethyl 1-ethyl-4-[[7-oxoheptahydro-1H-azepin-4-yl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675119-63-8P, 4-[[cis-4-(Butylamino)cyclohexyl]amino]-N-[[2,3-dihydro-1H-inden-2-yl]-1-ethyl-1H-

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
pyrazolo[3,4-b]pyridine-5-carboxamide 675118-98-6P,
1-Ethyl-N-[[6-(methoxyloxy)-3-pyridinyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-00-3P,
1-Ethyl-4-[[tetrahydro-2H-pyran-4-yl]amino]-N-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-02-5P, N-[[4-(2-Amino-2-oxoethyl)phenyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-04-7P, 1-Ethyl-N-[[4-(methoxyloxy)carbonyl]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-06-9P, 1-Ethyl-N-[[4-(2-methylamino)-2-oxoethyl]phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-07-0P, 1-Ethyl-N-[[3-(fluorophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-09-2P, 1-Ethyl-N-[[4-(methylsulfonyl)amino]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-11-6P, N-[[4-(Aminocarbonyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-12-7P, N-[[2-(Aminocarbonyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-13-8P, N-[[4-[(Difluoromethyl)oxy]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-14-9P, N-[[3-[(Dimethylamino)ethyl]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-15-0P, N-[[3-Chloro-4-(methoxyloxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-16-1P, N-[[1-Acetyl-4-piperidinyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-17-2P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[[2-(trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-18-3P, N-[[5-Chloro-2,3-dihydro-1H-inden-2-yl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-19-4P, N-[[3-[(Acetylthio)phenyl]methyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-20-7P, 1-Ethyl-N-[[4-(fluorophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-21-8P, 1-Ethyl-N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-22-9P, 1-Ethyl-N-[[2-(ethylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-23-0P, 1-Ethyl-N-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-24-1P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[[2,3,4-trifluorophenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-25-2P, N-[[4-Chloro-2-fluorophenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-26-3P, N-[[4-Bromo-2-fluorophenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-27-4P, N-[[3,5-Dimethylphenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-28-5P, N-[[2,3-Dimethylphenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-29-6P, N-[[2,3-Dichlorophenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-30-9P, N-[[4-Cyanophenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-31-0P, N-[[4-Bromophenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-32-1P, 1-Ethyl-N-[[5-fluoro-2-(trifluoromethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
pyrazolo[3,4-b]pyridine-5-carboxamide 675119-64-9P,
4-[[trans-4-Aminocyclohexyl]amino]-1-ethyl-N-[[phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-65-0P,
4-[[trans-2-Aminocyclohexyl]amino]-1-ethyl-N-[[phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-66-1P, 4-[[cis-2-Aminocyclohexyl]amino]-1-ethyl-N-[[phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-67-2P, 4-[[3-Aminocyclohexyl]amino]-1-ethyl-N-[[phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-68-3P, 675119-70-7P 675119-71-8P 675119-72-9P 675119-73-0P 675119-74-1P 675119-75-2P 675119-76-3P 675119-77-4P 675119-78-5P 675119-79-6P 675119-80-9P, N-[[2,3-Dichlorophenyl]methyl]-1-ethyl-4-[[4-oxocyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-83-2P, N-[[2,4-Dimethylphenyl]methyl]-1-ethyl-4-[[4-(hydroxymino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-84-3P, N-[[3,4-Dimethylphenyl]methyl]-1-ethyl-4-[[4-(hydroxymino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-85-4P, N-[[2,3-Dichlorophenyl]methyl]-1-ethyl-4-[[4-(hydroxymino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-86-5P, N-[[3-Chloro-4-methylphenyl]methyl]-1-ethyl-4-[[4-(hydroxymino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-87-6P, N-[[4-Chloro-2-methylphenyl]methyl]-1-ethyl-4-[[4-(hydroxymino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-88-7P, N-[[4-[(Difluoromethyl)oxy]phenyl]methyl]-1-ethyl-4-[[4-(hydroxymino)cyclohexyl]amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-89-8P, 1-Ethyl-4-[[4-(hydroxymino)cyclohexyl]amino]-N-[[4-(trifluoromethyl)phenyl]methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675119-93-4P, N-[[3,4-Dimethylphenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide hydrochloride (1:1) 675119-94-5P, 1-Ethyl-N-[[H-tetrazol-5-yl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675123-04-3P, (R)-N-[[2,3-Dihydro-1H-inden-1-yl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675123-05-4P, (S)-N-[[2,3-Dihydro-1H-inden-1-yl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PDE4 inhibitor; prepn. of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic disease)
RN 675119-49-4 CAPLUS
CN 1H-pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[3-(1-methylethoxy)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-50-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-(difluoromethoxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-51-8 CAPLW5
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-hydroxy-3-methoxyphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX




RN 675117-52-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(5-acetyl-2-hydroxyphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-56-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(3-chlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-57-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[2-[4-(trifluoromethoxy)phenyl]ethyl]- (CA INDEX NAME)




RN 675117-58-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-(3-methoxyphenyl)ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-53-0 CAPIUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[2-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 675117-54-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-{{4-(acetylamino)phenyl)methyl}-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]}-(CA INDEX NAME)




RN 675117-55-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-(3-hydroxyphenyl)ethyl)-4-((tetrahydro-2H-pyran-4-yl)amino)- (CA INDEX NAME)




RN 675117-59-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(4-acetylphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-60-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(3,4-dichlorophenyl)ethyl]-
1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-61-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-[3-(aminosulfonyl)phenyl]ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-
(CA INDEX NAME)




RN 675117-62-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-63-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(2,3-dichlorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-64-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(3,5-dimethoxyphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-70-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[2-(2-methylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-74-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,3-dihydro-4,5-dimethoxy-1H-inden-2-yl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-76-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-(aminosulfonyl)phenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-65-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[2-(4-methoxy-3-methylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-66-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(2,6-difluorophenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-68-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(2,6-dimethoxyphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-78-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[2-(methylsulfinyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-80-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(2-phenylethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-82-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-(dimethylamino)phenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-84-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-([2-(4-fluorophenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675117-86-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-([2-(4-methylphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-88-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-(aminosulfonyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675117-97-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(6-chloro-2-pyridinyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CH 1

CRN 675117-96-1
CHF C20 H23 Cl N6 O2




CH 2


CRN 76-05-1
CHF C2 H F3 O2




RN 675117-99-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,3-dihydro-1H-inden-1-yl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-90-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-methylphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-92-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-fluoro-3-(trifluoromethyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675117-94-9 CAPLUS
CN Benzoic acid, 2-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 675118-01-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[2-(acetylmethylamino)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-05-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(phenylmethyl)-N-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-08-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(dimethylamino)ethyl]-1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675118-11-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-butyl-1-ethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675118-14-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N,1-diethyl-N-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-17-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(1-phenyl-4-piperidinyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

CH 2

CRN 64-18-6
CHF C H2 O2

$\text{CH}=\text{OH}$


RN 675118-27-1 CAPLUS
CN 1-Piperidineacetic acid, 4-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 675118-31-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-(4-morpholinylmethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)


CH 1

CRN 675118-30-6
CHF C26 H34 N6 O3




CH 2

CRN 76-05-1




RN 675118-20-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[1-[(ethylamino)carbonyl]-4-piperidinyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675118-24-8 CAPLUS
CN Formic acid, compd. with 1-ethyl-N-[[1-methyl-2-(4-methyl-1-piperazinyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxamide (9CI) (CA INDEX NAME)

CH 1

CRN 675118-23-7
CHF C22 H35 N7 O2




CHF C2 H F3 O2



RN 675118-35-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CH 1

CRN 675118-34-0
CHF C27 H37 N7 O2



CH 2


CRN 76-05-1
CHF C2 H F3 O2



RN 675118-39-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[5-(aminocarbonyl)-3-pyridinyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CH 1

CRN 675118-38-4
CHF C21 H25 N7 O3




CH 2


CRN 76-05-1
CMP C2 H F3 O2




RN 675118-41-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-{{[4-(1-methylethyl)phenyl]methyl}-4-[(tetrahydro-2H-pyran-4-yl)amino]}- (CA INDEX NAME)




RN 675118-43-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-(cyclopentyloxy)-4-methoxyphenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-49-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-difluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675118-50-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-chloro-4-fluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675118-51-1 CARLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(2-chloro-3-methoxyphenyl)ethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-46-4 CAPLUS

1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

OK 1

CRN 675118-45-3
OMF C27 H37 N7 O2




CH 2

CRN 76-05-1
CMF C2 H F3 02



RN 675118-48-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-dichlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-54-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[3-(1-pyrrolidinylmethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CH 1

CRN 675118-53-3
CHF C26 H34 N6 O2




9 2

CRN 76-05-1
CMF C2 H F3 02




RN 675118-55-5 CAPLUS


1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[2-[4-(methylsulfonyl)amino]phenyl]ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]-
(CA INDEX NAME)




RN 675118-56-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,5-dimethoxyphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-57-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,6-dimethoxyphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-58-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2-fluorophenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-62-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2-(4-methylsulfonylphenyl)ethyl)amino]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-63-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2-fluoro-3-(trifluoromethyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-64-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-(cyclopropylamino)carbonyl)phenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-59-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,5-difluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-60-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-61-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-cyclohexyl-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-65-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-(4-methyl-1-piperazinyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675118-66-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-(1-pyrrolidinylmethyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-67-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,3-dihydro-6-methoxy-1-oxo-1H-inden-2-yl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-68-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,5-dichlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-69-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,5-diethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-70-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,3-difluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-74-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2-(4-hydroxyphenyl)ethyl)-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-75-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,5-dichlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-76-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-dimethoxyphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-71-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2-(methylsulfonyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-72-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(3-hydroxyphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-73-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,5-dimethoxyphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-77-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2-methoxyphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-78-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-79-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2-(methylamino)carbonyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-80-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-([2-(4-methoxyphenyl)ethyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-82-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-chlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-84-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-([2-(2-chlorophenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-94-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-([4-(aminocarbonyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-96-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-([2,6-difluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-97-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-([4-(2-amino-2-oxoethyl)phenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-86-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-([1,3-benzodioxol-5-ylmethyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-88-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-([1,2,3,4-tetrahydro-1-naphthalenyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-92-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-([3,4-dichlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675118-98-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-([6-methoxy-3-pyridinyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-00-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-([3-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 675119-02-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-([4-(2-amino-2-oxoethyl)phenyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-04-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-[(methylamino)carbonyl]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-06-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-[2-(methylamino)-2-oxoethyl]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-07-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-(3-fluorophenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-13-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(difluoromethoxy)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-14-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-[(dimethylamino)methyl]phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-15-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-chloro-4-methoxyphenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-09-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-11-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(aminosulfonyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-12-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[2-(aminocarbonyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-16-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1-acetyl-4-piperidyl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-17-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 675119-18-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(5-chloro-2,3-dihydro-1H-inden-2-yl)-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-19-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-((acetylamino)methyl)phenyl]methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-20-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-fluorophenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-21-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-fluoro-2-(trifluoromethyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-25-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-chloro-2-fluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-26-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-bromo-2-fluorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-27-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,5-dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-22-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2-ethylphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-23-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2-fluoro-5-(trifluoromethyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-24-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(2,3,4-trifluorophenyl)methyl]- (CA INDEX NAME)




RN 675119-28-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,3-dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-29-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,3-dichlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-30-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-cyanophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-31-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-bromophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-32-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(5-fluoro-2-(trifluoromethyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-33-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-iodophenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-37-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(5-chloro-2-methylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-38-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,5-dibromophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-39-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-ethylphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-34-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-{1,1-dimethylethyl}phenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-35-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3-cyanophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-36-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,6-dichlorophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-40-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(3-fluoro-4-(trifluoromethyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-41-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(2-iodophenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-42-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-bromophenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-43-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-(hydroxymethyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-44-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(3-(hydroxymethyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-45-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(3-(hydroxymethyl)-2-methylphenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-49-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,5-dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-50-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-[(2,4,5-trifluorophenyl)methyl]- (CA INDEX NAME)




RN 675119-51-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-46-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,3-dichloro-6-(hydroxymethyl)phenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-47-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-dichloro-6-methylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-48-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-(2-methylpropyl)phenyl)methyl]-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675119-52-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-chloro-6-(trifluoromethyl)phenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675119-53-6 CAPLUS
CN Benzoic acid, 4-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, monosodium salt (9CI) (CA INDEX NAME)




● Na

RN 675119-54-7 CAPLUS

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Benzoic acid, 3-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]- (CA INDEX NAME)




RN 675119-57-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[[4-(dimethylamino)phenyl]methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 675119-58-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[4-(ethoxyimino)cyclohexyl]amino]-1-ethyl-N-[[4-methoxyphenyl]methyl]- (CA INDEX NAME)


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 675119-59-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[[4-(methoxyimino)cyclohexyl]amino]-N-[[4-methoxyphenyl]methyl]- (CA INDEX NAME)




RN 675119-60-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[4-[(1,1-dimethylethoxy)imino]cyclohexyl]amino]-1-ethyl-N-[[4-methoxyphenyl]methyl]- (CA INDEX NAME)




L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 675119-61-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[[hexahydro-7-oxo-1H-azepin-4-yl]amino]-N-[[4-methoxyphenyl]methyl]- (CA INDEX NAME)




RN 675119-62-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[[[hexahydro-7-oxo-1H-azepin-4-yl]amino]-, ethyl ester (CA INDEX NAME)



RN 675119-63-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[cis-4-(butylamino)cyclohexyl]amino]-N-(2,3-dihydro-1H-inden-2-yl)-1-ethyl- (CA INDEX NAME)


Relative stereochemistry.

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 675119-64-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[trans-4-aminocyclohexyl]amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)

Relative stereochemistry.




RN 675119-65-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[1R,2R)-2-aminocyclohexyl]amino]-1-ethyl-N-(phenylmethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 675119-66-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[1R,2S)-2-aminocyclohexyl]amino]-1-ethyl-N-(phenylmethyl)-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 675119-67-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(3-aminocyclohexyl)amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 675119-69-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N,1-diethyl-4-[(1R,3S)-3-hydroxycyclohexyl]amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 675119-70-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-(4-fluorophenyl)-4-


Relative stereochemistry.



RN 675119-74-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethoxyphenyl)methyl]-1-ethyl-4-[(1R,3S)-3-hydroxycyclohexyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.

Relative stereochemistry.



RN 675119-71-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(1R,3S)-3-hydroxycyclohexyl]amino]-N-(2-thiazolylmethyl)-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 675119-72-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-N-[(4-fluorophenyl)methyl]-4-[(1R,3S)-3-hydroxycyclohexyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.

Relative stereochemistry.




RN 675119-76-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(1R,3S)-3-hydroxycyclohexyl]amino]-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 675119-77-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethylphenyl)methyl]-1-ethyl-4-[[{(1R,3S)-3-hydroxycyclohexyl}amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 675119-78-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[{(1R,3S)-3-hydroxycyclohexyl}amino]-N-[(4-methoxyphenyl)methyl]-, rel- (CA INDEX NAME)


Relative stereochemistry.




RN 675119-79-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-dimethylphenyl)methyl]-1-ethyl-4-[[{(1R,3S)-3-hydroxycyclohexyl}amino]-, rel- (CA INDEX NAME)

Relative stereochemistry.


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 675119-80-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,3-dichlorophenyl)methyl]-1-ethyl-4-[[4-(oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675119-83-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,4-dimethylphenyl)methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 675119-84-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethylphenyl)methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)


L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 675119-85-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,3-dichlorophenyl)methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 675119-86-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3-chloro-4-methylphenyl)methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 675119-87-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(4-chloro-2-methylphenyl)methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)



RN 675119-88-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-(difluoromethoxy)phenyl]methyl]-1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]- (CA INDEX NAME)




RN 675119-89-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[4-(hydroxyimino)cyclohexyl]amino]-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 675119-93-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-dimethylphenyl)methyl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 675119-94-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-N-(1H-tetrazol-5-ylmethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

4-[(1-Acetyl-4-piperidinyl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-64-8P, 1-Ethyl-4-(4-piperidinylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-65-9P, 4-(Cyclohexylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-75-1P, N-Benzyl-4-[(1-[(1,1-dimethylethyl)oxy]carbonyl]-4-piperidinyl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide 675112-87-5P

RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate: prepn. of pyrazolo[3,4-b]pyridines as PDE4 inhibitors for treatment of inflammatory and/or allergic disease)

RN 675112-03-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)



RN 675112-19-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(3S)-tetrahydro-3-furanyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 675112-21-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-thiopyran-4-yl)amino]- (CA INDEX NAME)

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 675123-04-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1R)-2,3-dihydro-1H-inden-1-yl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 675123-05-4 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1S)-2,3-dihydro-1H-inden-1-yl]-1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




IT 675112-03-5P, 1-Ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-19-3P, (5S)-1-Ethyl-4-[(tetrahydrofuran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-21-7P, 1-Ethyl-4-[(tetrahydro-2H-thiopyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-23-9P, 1-Ethyl-4-[(tetrahydrothien-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-25-1P, 4-(Cyclopropylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-27-3P, 4-[(1,1-Dioxidotetrahydrothien-3-yl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-29-5P, 4-[(1,1-Dioxidotetrahydro-2H-thiopyran-4-yl)amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-33-1P, 1-Propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-36-4P, 4-(Cyclohexylamino)-1-ethyl-6-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-38-6P, 1-Ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-42-2P 675112-54-6P, 1-Ethyl-4-[(4-oxocyclohexyl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-56-8P, Ethyl 1-ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 675112-60-4P, 1-Ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 675112-62-6P,

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 675112-23-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-3-thienyl)amino]- (CA INDEX NAME)




RN 675112-25-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopropylamino)-1-ethyl- (CA INDEX NAME)




RN 675112-27-3 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-1,1-dioxido-3-thienyl)amino]- (CA INDEX NAME)




RN 675112-29-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]- (CA INDEX NAME)




RN 675112-33-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-propyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675112-36-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclohexylamino)-1-ethyl-6-methyl- (CA INDEX NAME)




RN 675112-56-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]-, ethyl ester (CA INDEX NAME)




RN 675112-60-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(tetrahydro-2H-pyran-3-yl)amino]- (CA INDEX NAME)



RN 675112-62-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[[1-acetyl-4-piperidinyl]amino]-1-ethyl- (CA INDEX NAME)




RN 675112-38-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-6-methyl-4-[(tetrahydro-2H-pyran-4-yl)amino]- (CA INDEX NAME)




RN 675112-42-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(1R,3S)-3-hydroxycyclohexyl]amino]-, rel- (CA INDEX NAME)


Relative stereochemistry.




RN 675112-54-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(4-oxocyclohexyl)amino]- (CA INDEX NAME)




RN 675112-64-8 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-(4-piperidinylamino)- (CA INDEX NAME)




RN 675112-65-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclohexylamino)-1-ethyl- (CA INDEX NAME)



RN 675112-75-1 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-ethyl-5-[(phenylmethyl)amino]carbonyl]-1H-pyrazolo[3,4-b]pyridin-4-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 675112-87-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-ethyl-4-[(tetrahydro-2H-pyran-4-yl)amino]-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




ACCESSION NUMBER: 2002:720128 CAPLUS
DOCUMENT NUMBER: 137:379680
TITLE: Synthesis, Molecular Modeling Studies, and Pharmacological Activity of Selective A1 Receptor Antagonists
AUTHOR(S): Bondavalli, Francesco; Botta, Maurizio; Bruno, Olga; Ciacci, Andrea; Corelli, Federico; Fossa, Paola; Lucacchini, Antonio; Manelli, Fabrizio; Martini, Claudia; Menozzi, Giulio; Mosti, Luisa; Ranise, Angelo; Schenone, Silvia; Tafi, Andrea; Trincavelli, Maria Letizia
CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Università degli Studi di Genova, Genoa, I-16132, Italy
SOURCE: Journal of Medicinal Chemistry (2002), 45(22), 4875-4887
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:379680


AB We present a combined computational study aimed at identifying the three-dimensional structural properties required for different classes of compounds to show antagonistic activity toward the A1 adenosine receptor (AR). Particularly, an approach combining pharmacophore mapping, mol. alignment, and pseudoreceptor generation was applied to derive a hypothesis of the interaction pathway between a set of A1 AR antagonists taken from the literature and a model of the putative A1 receptor. The pharmacophore model consists of seven features and represents an improvement of the N6-C8 model, generally reported as the most probable pharmacophore model for A1 AR agonists and antagonists. It was used to build up a pseudoreceptor model able to rationalize the relationships between structural properties and biol. data of, and external to, the training set. In fact, to further assess its statistical significance and predictive power, the pseudoreceptor was employed to predict the free energy of binding associated with compounds constituting a test set. While part of these mols. was also taken from the literature, the remaining compounds were designed and synthesized by our research group. All of the new compounds were tested for their affinity toward A1, A2a, and A3 AR, showing interesting antagonistic activity and A1 selectivity.
IT 383911-67-9P 383911-73-7P 476006-34-5P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis, mol. modeling studies, and pharmacol. activity of selective A1 receptor antagonists)
RN 383911-67-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclopropylamino)-, ethyl ester (CA INDEX NAME)




RN 383911-73-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(phenylamino)-, ethyl ester (CA INDEX NAME)




RN 476006-34-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclohexylamino)-, ethyl ester (CA INDEX NAME)



IT 476006-35-6P 476006-38-9P 476006-44-7P
476006-47-0P
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis, mol. modeling studies, and pharmacol. activity of selective A1 receptor antagonists)
RN 476006-35-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclopropylamino)-, ethyl ester (CA INDEX NAME)




RN 476006-38-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclohexylamino)-, ethyl ester (CA INDEX NAME)




RN 476006-44-7 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopropylamino)-1-[(1E)-2-phenylethenyl]-, ethyl ester (CA INDEX NAME)

Double bond geometry as shown.



RN 476006-47-0 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclohexylamino)-1-[(1E)-2-phenylethenyl]-, ethyl ester (CA INDEX NAME)


Double bond geometry as shown.



REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2002:63503 CAPLUS
 DOCUMENT NUMBER: 136:102381
 TITLE: Preparation of pyrazolopyridines as phosphodiesterase 4 (PDE4) inhibitors for treatment of diseases
 INVENTOR(S): Nakai, Hisao; Kishikawa, Katsuya
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 37 pp.
 CODEN: JKKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002020386	A	20020123	JP 2000-206030	20000707
PRIORITY APPL. INFO.: OTHER SOURCE(S):	MARPAT 136:102381 JP 2000-206030 20000707			




AB Pyrazolopyridines I [R1 = OH, C1-8 alkoxy, SH, C1-8 alkylthio, C2-8 alkynyl, NO2, cyano, Ph, etc.; R2 = H, C1-8 alkoxy; R3 = H, C1-8 alkyl; R4 = H, C1-8 alkyl, C3-7 cycloalkyl, (un)substituted Ph, heterocyclyl, etc.; R5 = H, C1-8 alkyl, (un)substituted Ph, etc.] or their nontoxic salts are prepared. The compds. are useful for prophylactic and therapeutic treatment of inflammation, diabetes, allergy, autoimmune disease, osteoporosis, obesity, etc. Thus, refluxing 1,3-dimethyl-4-chloropyrazolo[5,4-b]pyridine-5-carboxamide with 3-methoxyaniline for 6 h gave 1 (R1 = OMe, R2 = R3 = H, R4 = R5 = Me), which inhibited PDE4 with IC50 value of 0.004 μ M.

IT 389058-31-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolopyridines as phosphodiesterase 4 inhibitors for treatment of diseases)

RN 389058-31-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(3-methoxyphenyl)amino]-1-methyl- (CA INDEX NAME)




L4 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2001:651020 CAPLUS
 DOCUMENT NUMBER: 136:69767
 TITLE: Synthesis and biological data of 4-amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl esters, a new series of A1-adenosine receptor (A1AR) ligands
 AUTHOR(S): Schenone, S.; Bruno, O.; Fossa, P.; Ranise, A.; Menozzi, G.; Mosti, L.; Bondavalli, F.; Martini, C.; Trincavelli, L.
 CORPORATE SOURCE: Dipartimento di Scienze Farmaceutiche, Facolta di Farmacia dell'Universita degli Studi di Genova, Genova, 16132, Italy
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(18), 2529-2531
 CODEN: BMCLEB; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 136:69767

AB The synthesis of a new family of A1-adenosine receptor (A1AR) ligands has been performed in a straightforward way. Affinity data at A1AR, A2AAR and A3AR in bovine membranes show that these new compds. bind the A1AR in a selective way over A2AAR and A3AR and one of them presents a very high affinity, probably due to the phenethylamine substituent at C-4.

IT 383911-67-9P 383911-73-7P
 RL: BCP (Biochemical process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
 (preparation and activity of 4-amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate derivs. as A1-adenosine receptor ligands)


RN 383911-67-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(cyclopropylamino)-, ethyl ester (CA INDEX NAME)




RN 383911-73-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-(2-chloro-2-phenylethyl)-4-(phenylamino)-, ethyl ester (CA INDEX NAME)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1998:101345 CAPLUS
DOCUMENT NUMBER: 128:238965
TITLE: Pyrazolopyridines: effect of structural alterations on activity at adenosine- and GABAA-receptors
AUTHOR(S): Shi, Dan; Padgett, William L.; Hutchinson, Kira D.; Moore, Stacey P.; Daly, John W.
CORPORATE SOURCE: Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA
SOURCE: Drug Development Research (1997), 42(1), 41-56
CODEN: DDREDX; ISSN: 0272-4391
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of 4-substituted 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid derivs. related in structure to the putative anxiolytics cartazolate, tracazolate, and etazolate were assessed for affinity at A1- and A2A-adenosine receptors and at GABA-, benzodiazepine-, and picrotoxinin-binding sites of the GABAA-receptor-channel. None of the derivs. had markedly greater affinity at A1-receptors than cartazolate (K_i 0.5 μM), but many had markedly lower affinity than cartazolate (K_i 1.5 μM) at A2A-receptors. At the benzodiazepine-binding site of GABAA-receptors some of the derivs. enhanced [3H]diazepam binding, as did cartazolate and GABA, some had no effect and some inhibited binding. Most of the derivs. inhibited binding of the benzodiazepine-antagonist [3H]Ro 15-1788. At the GABA-binding site, only a few of the derivs. inhibited binding of the antagonist [3H]SR-95531, as did GABA. At the picrotoxinin-binding site, many inhibited binding of [35S]TBPS, but none were as potent as cartazolate or GABA. Anal. of the interactions indicates that stimulation of [3H]diazepam binding is allosteric and results from binding of the pyrazolopyridine at the GABA site or a subdomain of that site, while inhibition of [3H]Ro 15-1788 binding is competitive and due to binding at the benzodiazepine site. Inhibition of [35S]TBPS binding at the picrotoxinin-channel site appears to be allosteric through the GABA site and/or by direct competition at the channel site. Alterations in structure markedly alter the affinities of pyrazolopyridines at such sites on the GABAA-receptor-channel.
IT 160034-50-4 160034-53-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(pyrazolopyridines structural alterations effect on activity at adenosine- and GABAA-receptors)
RN 160034-50-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-methyl-4-(phenylamino)-, ethyl ester (CA INDEX NAME)




RN 160034-53-7 CAPLUS

L4 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopentylamino)-1-methyl-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1996:109105 CAPLUS
DOCUMENT NUMBER: 124:249637
TITLE: A survey of nonxanthine derivatives as adenosine receptor ligands
AUTHOR(S): Siddiqi, Suhail M.; Ji, Xiao-duo; Melman, Nelli; Olah, Mark E.; Jain, Rahul; Evans, Patricia; Glashofer, Marc; Padgett, William L.; Cohen, Louis A.; et al.
CORPORATE SOURCE: Molecular Recognition Section, National Institutes of Health, Bethesda, MD, 20892, USA
SOURCE: Nucleosides & Nucleotides (1996), 15(1-3), 693-717
CODEN: NUNUDS; ISSN: 0732-8311
PUBLISHER: Dekker
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The binding affinities at rat A1, A2a, and A3 adenosine receptors of a wide range of heterocyclic derivs. have been determined. Mono-, bi-, tricyclic and macrocyclic compds. were screened in binding assays, using either [3H]PIA or [3H]CGS 21680 in rat brain membranes or [125I]AB-MECA in CHO cells stably transfected with rat A3 receptors. Several new classes of adenosine antagonists (e.g. 5-oxoimidazopyrimidines and a pyrazoloquinazoline) were identified. Various sulfonylpiperazines, 11-hydroxytetrahydrocarbazolenine, 4H-pyrido[1,2-a]pyrimidinone, folic acid, and cytochalasin H and J bound to A3 receptors selectively. Moreover, cytochalasin A, which bound to A1 adenosine receptors with K_i value of 1.9 μM, inhibited adenylyl cyclase in rat adipocytes, but not via reversible A1 receptor binding.
IT 160034-50-4, Ethyl 4-phenylamino-1-methylpyrazolo[3,4-b]pyridine-5-carboxylate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonxanthine derivs. as adenosine receptor ligands)
RN 160034-50-4 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-methyl-4-(phenylamino)-, ethyl ester (CA INDEX NAME)



ACCESSION NUMBER: 1995:214970 CAPLUS

DOCUMENT NUMBER: 122:45666

TITLE: 1-Methyl-4-substituted-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid derivatives: effect of structural alterations on activity at A1 and A2 adenosine receptors

AUTHOR(S): Daly, John W.; Hutchinson, Kira D.; Secunda, Sherrie I.; Shi, Dan; Padgett, William L.; Shamin, Mah T.

CORPORATE SOURCE: Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 20892, USA

SOURCE: Medicinal Chemistry Research (1994), 4(5), 293-306

CODEN: MCRREB; ISSN: 1054-2523

PUBLISHER: Birkhaeuser

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of Et 1-methyl-4-substituted-1H-pyrazolo[3,4-b]pyridine-5-carboxylates related in structure to cartazolate (Et 1-ethyl-4-n-butylamino-1H-pyrazolo[3,4-b]pyridine-5-carboxylate) were prepared. Both cartazolate and its 1-Me analog had affinities for A1- and A2-adenosine receptors of 1 to 2 μ M. Affinity for adenosine receptors in the 1-Me series requires a 4-NHR moiety; 4-NR2, 4-OR, 4-NHNR2 analogs are much less active. The most potent of the 4-NHR analogs is the 4-cyclopentylamino analog with affinities of 0.3 and 0.5 μ M for A1- and A2-adenosine receptors, resp. Replacement of the 5-carboxy group with a 5-carboxamido moiety has little effect on affinity of the 4-n-butylamino analog for adenosine receptors, while replacement with a 5-carboxylic acid greatly reduces affinity. Although no selective agonists were obtained, a range of relatively potent adenosine antagonists have been defined.


160034-50-4P 160034-53-7P

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(pyrazolopyridinecarboxylic acid derivs. preparation and effect of structural alterations on binding of A1 and A2 adenosine receptors)


RN 160034-50-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-methyl-4-(phenylamino)-, ethyl ester (CA INDEX NAME)



RN 160034-53-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-(cyclopentylamino)-1-methyl-, ethyl ester (CA INDEX NAME)



ACCESSION NUMBER: 1976:421450 CAPLUS

DOCUMENT NUMBER: 85:21450

ORIGINAL REFERENCE NO.: 85:3513a, 3516a

TITLE: 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acids and esters

INVENTOR(S): Hoehn, Hans; Denzel, Theodor

PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc., USA

SOURCE: U.S., 13 pp. Division of U.S. 3,755,340.

CODEN: USXXAM

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3925309	A	19751209	US 1973-368561	19730611
US 3755340	A	19730828	US 1971-169536	19710805
US 3833594	A	19740903	US 1973-368562	19730611
US 3856799	A	19741224	US 1973-368802	19730611
CA 997352	A2	19760921	CA 1974-211343	19741015
PRIORITY APPLN. INFO.:			US 1970-41568	A2 19700528
			US 1971-169536	A3 19710805
			CA 1972-147053	A3 19720713

GI



AB Pyrazolopyridinecarboxylic acids and esters I (R = H, Et, (CH₂)₈Me; R1 = alkyl, PhCH₂, Ph, H, 4-ClC₆H₄CO; R2 = H, Me, Ph; R3 = H, alkyl, 3-F₃CC₆H₄, (CH₂)_nNEt₂ (n = 2, 3), Ph(CH₂)_n (n = 2, 3), 2,3-xyllyl, 2-HO₂CC₆H₄, Ac, 4-ClC₆H₄CO, Ph, tosyl; R4 = H, Et, CH₂CH₂OH; NR3R4 = hexahydromethylidiazepino, dimethylpyrazolyl, morpholino, 1-pyrrolidinyl, piperazino and 4-Me derivative, piperidino, dimethylpyrazino; R5 = H, Me)

(62 compds.) useful as tranquilizers, inflammation inhibitors, analgesics, and central nervous system depressants (no data), were prepared, e.g., by stirring 1-ethyl-5-aminopyrazole with EtOCH₂C(CO₂Et) 2 hr at 120° (84% yield), cyclizing the malonate II by heating at 235-50° for 1-2 hr (92% yield), refluxing the hydroxypyrazolopyridine III (R7 = OH, R = R1 = Et, R2 = H) with POCl₃ 4 hr, and treating the chloro compound III (R7 = Cl, other R's as above) with BuNH₂ to give 91.5% I (R = R1 = Et, R2 = R4 = R5 = H, R3 = Bu). Aminolysis of III (R7 = EtO) also gave I. I (R = Et, R1 = Me, R2 = R4 = R5 = H, R3 = Bu) (IV) was prepared in 7 steps from 3-methyl-5-aminoisoxazole via Et 3-acetyl-4-(butylamino)-2-hydroxy-5-pyridinecarboxylate (V). IV was also prepared by chlorinating V to give the 2-Cl analog which was cyclized with N₂H₄ by refluxing 5 hr in EtOH. I (R5 = H) were prepared by cyclizing the appropriate 5-aminopyrazole with AcCH₂(CO₂Et)₂ with polyphosphorous acid at 120°/3 hr, chlorinating the III (R7 = OH) so formed, and treating the Cl compound with BuNH₂.

34966-35-3P 34966-36-4P 34966-37-5P


34966-42-2P 34966-43-3P 53064-94-1P

59444-08-5P 59444-09-6P

RI: SPN (Synthetic preparation); PREP (Preparation)


RN 34966-35-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(2,3-dimethylphenyl)amino]-1-ethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 34966-36-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(2,3-dimethylphenyl)amino]-1-ethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 34966-37-5 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(2-carboxyphenyl)amino]-1-ethyl-, 5-ethyl ester (9CI) (CA INDEX NAME)



RN 34966-42-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(phenylamino)-, ethyl ester (9CI) (CA INDEX NAME)



RN 34966-43-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(phenylamino)-, ethyl ester (9CI) (CA INDEX NAME)



RN 53064-94-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(2-aminophenyl)amino]-1-ethyl-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1975:16871 CAPLUS
DOCUMENT NUMBER: 82:16871
ORIGINAL REFERENCE NO.: 82:2709a,2712a
TITLE: Diazepiones
INVENTOR(S): Denzel, Theodor; Hoeft, Hans; Schulze, Ernst
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.
SOURCE: Fr. Demande, 30 pp.
CODEN: FROXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2200003	A1	19740419	FR 1973-33998	19730921
FR 2200003	B1	19770311		
US 4012373	A	19770315	US 1972-291503	19720922
CA 1013349	A1	19770705	CA 1973-178721	19730813
GB 1450452	A	19760922	GB 1973-39325	19730820
JP 49069700	A	19740705	JP 1973-107409	19730820
			US 1972-291503	A 19720922


PRIORITY APPL. INFO.:

GI For diagram(s), see printed CA issue.
AB Tranquilizing (no data) pyrazolopyrido-benzodiazepinones I [R-R2 = H, R3 = Me, Et, (CH2)3NMe2, CH2CH2NMe2, CHMeCH2NMe2, CH2CH2NMe2, 3-piperidinopropyl, Bu; R = Et, R1 = R2 = H, R3 = Me; R = R3 = Et, R1 = R2 = H, R1 = Cl, R2 = H, R1 = H, R2 = Cl; R = R1 = R3 = H, R2 = Cl; R = (CH2)3NMe2, R1 = R2 = H, R3 = Me, Et; R = R3 = Me, (CH2)3NMe, CH2Ph, Bu] were prepared by several methods from 1-ethyl-5-aminopyrazole.


IT 53064-94-1P 53064-99-6P 53065-03-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cyclization of)


RN 53064-94-1 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(2-aminophenyl)amino]-1-ethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 53064-99-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(2-aminophenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 59444-09-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(3-fluorophenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 59444-09-6 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(3-fluorophenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 53065-03-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(2-amino-4-chlorophenyl)amino]-1-ethyl-, ethyl ester (9CI) (CA INDEX NAME)




IT 53064-98-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and hydrolysis of)

RN 53064-98-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(2-aminophenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




IT 53065-02-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reduction of)
 RN 53065-02-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(4-chloro-2-nitrophenyl)amino]-1-ethyl-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1974:463691 CAPLUS
 DOCUMENT NUMBER: 81:63691
 ORIGINAL REFERENCE NO.: 81:10153a,10156a
 TITLE: Pyrazolopyridobenzodiazepinones
 INVENTOR(S): Denzel, Theodor; Hoehn, Hans; Schulze, Ernst
 PATENT ASSIGNEE(S): Chemische Fabrik von Heyden G.m.b.H.
 SOURCE: Ger. Offen., 32 pp.
 CODEN: GWXEXX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2346466	A1	19740411	DE 1973-2346466	19730914
US 4012373	A	19770315	US 1972-291503	19720922
CA 1013349	A1	19770705	CA 1973-178721	19730813
GB 1450452	A	19760922	GB 1973-39325	19730820
JP 49069700	A	19740705	JP 1973-107409	19730922
PRIORITY APPLN. INFO.:			US 1972-291503	A 19720922


GI For diagram(s), see printed CA Issue.
 AB Twenty pyrazolo-pyridobenzodiazepinones I (R = H, Cl-10 alkyl, CH₂Ph, or (CH₂)₃Me₂; R₁ = H, 6-Cl, or 7-Cl; R₂ = e.g. Cl-10 alkyl, CH₂Ph, (CH₂)₂NEt₂, 3-piperidinopropyl, or (CH₂)₃NMe₃ iodide) were prepared and useful as anxiolytics, inflammation inhibitors, tranquilizers, and drugs in the treatment of asthma. Thus, the ester II was refluxed in o-xylene in the presence of Me₃COK to give 71% I (R = R₁ = R₂ = H) (III). Reaction of III with NaH and Cl(CH₂)₃NMe₂ in dioxane gave 77% I (R = R₁ = H, R₂ = (CH₂)₃NMe₂). The anilide IV was refluxed in DMF to give 65% I (R = R₂ = H, R₁ = 6-Cl), which on reaction with NaH and EtI in dioxane gave 81% I (R = R₂ = Et, R₁ = 6-Cl).
 IT 53064-94-1P 53064-98-5P 53064-99-6P
 53065-02-4P 53065-03-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 53064-94-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(2-aminophenyl)amino]-1-ethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 53064-98-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(2-ethylamino)phenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 53064-99-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[(2-ethylamino)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 53065-02-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(4-chloro-2-nitrophenyl)amino]-1-ethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 53065-03-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(2-amino-4-




L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1972:448325 CAPLUS
 DOCUMENT NUMBER: 77:48325
 ORIGINAL REFERENCE NO.: 77:8015a,8018a
 TITLE: 1H-pyrazolo[3,4-b]pyridines
 AUTHOR(S): Hoehn, H.; Denzel, Th.; Janssen, W.
 CORPORATE SOURCE: Chem. Fabrik von Heyden G.m.b.H., Regensburg, Fed. Rep. Ger.
 SOURCE: Journal of Heterocyclic Chemistry (1972), 9(2), 235-53
 CODEN: JHCTAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 77:48325

GI For diagram(s), see printed CA Issue.
 AB Aminopyrazoles were condensed with ROCH: C(CO₂Et)₂ to give the pyrazoles (I), which were cyclized by heating in Ph₂O or by treatment with POCl₃ to give the pyrazolo[3,4-b]pyridines (II, R₃ = OH (III), Cl (IV), resp.). About 100 II (R = Me, Et, Me₂CH, Bu, Ph, PhCH₂, R₁ = H, Me, Ph, R₂ = MeO, EtO, PhCH₂O, CH₂tpibond, OCH₂O, BuO, NENH₂, NENH₂, NEN:OMe₂, PhNDSH, (HOCH₂)₂C:NH, (5-nitrofurfurylidene)hydrazino, BuNH₂, NH₂, PhCH₂NH, Me₃CNH, 1-pyrrolidinyl, PhNH, N₃, etc., R₃ = H, Et, Bu) were prepared from III and IV.


IT 34966-22-8P 34966-23-9P 34966-35-3P
 34966-36-4P 34966-37-5P 34966-42-2P
 34966-43-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 34966-22-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[[3-(trifluoromethyl)phenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 34966-23-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)


L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 34966-35-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(2,3-dimethylphenyl)amino]-1-ethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 34966-36-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(2,3-dimethylphenyl)amino]-1-ethyl- (9CI) (CA INDEX NAME)




RN 34966-37-5 CAPLUS


L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(2-carboxyphenyl)amino]-1-ethyl-, 5-ethyl ester (9CI) (CA INDEX NAME)



RN 34966-42-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-(phenylamino)-, ethyl ester (9CI) (CA INDEX NAME)



RN 34966-43-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-(phenylamino)- (9CI) (CA INDEX NAME)




L4 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1972:59619 CAPLUS
 DOCUMENT NUMBER: 76:59619
 ORIGINAL REFERENCE NO.: 76:9609a,9612a
 TITLE: 4-Amino-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid derivatives
 INVENTOR(S): Hoehn, Hans; Denzel, Theodor
 PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc.
 SOURCE: Ger. Offen., 20 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2123318	A	19711209	DE 1971-2123318	19710511
DE 2123318	C2	19840503		
ZA 7101710	A	19711229	ZA 1971-1710	19710316
ES 390163	A1	19730701	ES 1971-390163	19710414
HU 163173	B	19730628	HU 1971-SU614	19710421
CH 527208	A	19720831	CH 1971-527208	19710503
JP 55004105	B	19800129	JP 1971-31475	19710511
NL 7106688	A	19711130	NL 1971-6688	19710514
NL 172657	B	19830502		
NL 172657	C	19831003		
FR 2100698	A5	19720324	FR 1971-19340	19710527
FR 2100698	B1	19740823		
SE 367202	B	19740520	SE 1971-6895	19710527
BE 767842	A1	19711129	BE 1971-104025	19710528
			US 1970-41568	A 19700528


PRIORITY APPLN. INFO.:
 GI For diagram(s), see printed CA Issue.
 AB The tranquilizing, ataractic, intracellular cyclic AMP-increasing, antinflammatory, and analgesic title compds. [I, R=Et, Me, PhCH₂, Bu or Ph; R₁=H or Me; X=NR₂R₃ with R₂ or R₃=H, Et, (CH₂)₂NEt₂, or Bu, or X=4-methylpiperidino or morpholino; R₄=H or Et] were prepared by amination of I (X=OEt or Cl), which were prepared from II by cyclization and etherification or chlorination, resp. Thus, II (R=Et, R₁=H), prepared in 84% yield from 1-ethyl-5-aminopyrazole and EtOCH: C(CO₂Et)₂, was heated in Ph₂O for 1-2 hr at 235-50° to give 92% I (R=R₄=Et, R₁=H, X=OH), which (259 g) on treatment with EtI and K₂CO₃ in DMF gave 165 g I (R=R₄=Et, R₁=H, X=OEt) (III). III was treated with NH₃-EtOH for 15 hr in an autoclave to give 90% I (R=R₄=Et, R₁=H, X=NH₂). Similarly prepared were approx. 40 other I.

IT 34966-22-8P 34966-23-9P 34966-35-3P
 34966-36-4P 34966-37-5P 34966-42-2P
 34966-43-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 34966-22-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[[3-(trifluoromethyl)phenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)





RN 34966-23-9 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-[[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 34966-35-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(2,3-dimethylphenyl)amino]-1-ethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 34966-36-4 CAPLUS



RN 34966-37-5 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 4-[(2-carboxyphenyl)amino]-1-ethyl-, 5-ethyl ester (9CI) (CA INDEX NAME)



RN 34966-42-2 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-(phenylamino)-, ethyl ester (9CI) (CA INDEX NAME)



RN 34966-43-3 CAPLUS
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxylic acid, 1-ethyl-4-(phenylamino)- (9CI) (CA INDEX NAME)

=> d his

(FILE 'HOME' ENTERED AT 17:32:32 ON 05 DEC 2007)

FILE 'REGISTRY' ENTERED AT 17:32:45 ON 05 DEC 2007
L1 STRUCTURE UPLOADED
L2 50 S L1
L3 1359 S L1 FULL

FILE 'CAPLUS' ENTERED AT 17:38:08 ON 05 DEC 2007
L4 30 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
162.33	338.24

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-23.40	-23.40

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 17:43:23 ON 05 DEC 2007